Abstract
Although it is widely considered, in many cases, to involve two separable stages (poor placentation followed by oxidative stress/inflammation), the precise originating causes of preeclampsia (PE) remain elusive. We have previously brought together some of the considerable evidence that a (dormant) microbial component is commonly a significant part of its etiology. However, apart from recognizing, consistent with this view, that the many inflammatory markers of PE are also increased in infection, we had little to say about immunity, whether innate or adaptive. In addition, we focused on the gut, oral and female urinary tract microbiomes as the main sources of the infection. We here marshall further evidence for an infectious component in PE, focusing on the immunological tolerance characteristic of pregnancy, and the well-established fact that increased exposure to the father’s semen assists this immunological tolerance. As well as these benefits, however, semen is not sterile, microbial tolerance mechanisms may exist, and we also review the evidence that semen may be responsible for inoculating the developing conceptus (and maybe the placenta) with microbes, not all of which are benign. It is suggested that when they are not, this may be a significant cause of PE. A variety of epidemiological and other evidence is entirely consistent with this, not least correlations between semen infection, infertility and PE. Our view also leads to a series of other, testable predictions. Overall, we argue for a significant paternal role in the development of PE through microbial infection of the mother via insemination.
Keywords: preeclampsia, immunology, microbes, dormancy, semen, infection
“In one of the last articles which he wrote, the late Professor F.J. Browne (1958) expressed the opinion that all the essential facts about pregnancy toxemia are now available and that all that is required to solve the problem is to fit them together in the right order, like the pieces of a jigsaw puzzle. (1)”
“It appears astonishing how little attention has been given in reproductive medicine to the maternal immune system over the last few decades. (2)”
Introduction
Preeclampsia (PE) is a multifactorial disease of pregnancy, in which the chief manifestations are hypertension and proteinuria (3–11). It is commonest in primigravidae, where it affects some 3–5% of such pregnancies worldwide (10, 12, 13), and is associated (if untreated) with high morbidity and mortality (14–18). The incidence can be even greater in some geographical locations (19, 20). There is much literature on accompanying features, and, notwithstanding possible disease subdivisions (21, 22), the development of PE is typically seen as a “two-stage” process [e.g., Ref. (23–29)], in which in a first stage incomplete remodeling of spiral arteries leads to poor placentation. In a second stage, the resulting stress, especially hypoxia-induced oxidative stress (30–36) (and possibly hypoxia-reperfusion injury), then leads to the symptoms typical of later-pregnancy PE. However, the various actual originating causes of either of these two stages remain obscure. Many theories have been proposed [albeit a unitary explanation is unlikely (21)], and indeed, PE has been referred to as a “disease of theories” (1, 37–39). The only effective “cure” is delivery (40, 41), which often occurs significantly preterm, with its attendant complications for both the neonate and in later life (42, 43). Consequently, it would be highly desirable to improve our understanding of the ultimate causes of PE, so that better prevention or treatments might be possible.
The “two-stage” theory is well established, and nothing we have to say changes it. However, none of this serves to explain what “initiating” or “external” factors are typically responsible for the poor placentation, inflammation, and other observable features of PE (44).
Microbes are ubiquitous in the environment, and one potential external or initiating factor is low-level microbial infection. In a recent review (44), we developed the idea (and summarized extensive evidence for it) that a significant contributor to PE might be a [largely dormant (45–48) and non-replicating] microbiome within the placenta and related tissues, also detectable in blood and urine. Others [e.g., Ref. (49–56)] have drawn similar conclusions. Interestingly, recent analyses (21, 57) of placental gene expression in PE implicate changes in the expression of triggering receptor on myeloid cells-1 and the metalloprotease INHA, and in one case (21) also lactotransferrin, that also occur during infection (58–61). Although we highlighted the role of antibiotics as potentially preventative of PE (44), and summarized the significant evidence for that, we had relatively little to say about immunology, and ignored another well-known antidote to infectious organisms in the form of vaccines. There is certainly also an immune component to PE [e.g., Ref. (26, 62–70) and below]. One of the main theories of (at least part of the explanation of) PE is that of “immune maladaptation” (62, 64, 66, 71). Thus, the main focus of the present analysis is to assess the extent to which there is any immunological evidence for a role of infectious agents (and the utility of immunotolerance to or immunosuppression of them) in PE. Figure 1 summarizes our review in the form of a “mind map” (72). We begin with the broad question of immunotolerance, before turning to an epidemiological analysis. A preprint has been lodged in bioRxiv (73).
Figure 1.
A “mind map” (72) of the review. Start at “midnight” and read clockwise.
Immune Tolerance in Pregnancy
Much of the original thinking on this dates back to Sir Peter Medawar (74–79), who recognized that the paternal origin of potentially half the antigens of the fetus (80) created an immunological conundrum: it should normally be expected that the fetus’s alloantigens would cause it to be attacked by the maternal immune system as “foreign.” There would therefore have to be an “immune tolerance” (79, 81–83). Historically it was believed that the fetus is largely “walled off” from the mother (84); however, we now appreciate (85–88) that significant trafficking of fetal material across the placenta into the maternal circulation and vice versa occurs throughout pregnancy. Indeed, this is the basis for the development of non-invasive prenatal testing. In line with this, grams of trophoblast alloantigens are secreted daily into the maternal circulation during the third trimester (Figure 2), and this is related to the prevalence of PE (89–95). Consequently, both the concept and the issue of immune tolerance are certainly both real and important. At all events, the immunobiology of the fetus has been treated in theory largely in the way that a transplanted graft is treated, and uteroplacental dysfunction [leading to PET and intrauterine growth restriction (IUGR)] has in some cases been regarded as a graft rejection [e.g., Ref. (70, 96–102)]. Clearly there are relationships between the immunogenicity of the foreign agent and the responsiveness of the host; to this end, Zelante et al. (103) recognize the interesting similarities between tolerance to paternal alloantigens (as in pregnancy) and the tolerance observed in chronic fungal infections. This said, the host–graft analogy is increasingly seen as somewhat naive (104–106).
Figure 2.
Effective lowering of the normal immunological response to fetal cell trafficking [sometimes referred to as “suppressed” but in fact a highly dynamic state (104, 106)] leads to a normal pregnancy, while its failure can lead to preeclampsia. We note too that other Thelper populations may play roles in the physiologic and pathologic immune interactions between mother and offspring.
The Clinical Course of Automimmune Disease during Pregnancy: An Inconsistent Effect
The seminal observation by Philip Hench that the symptoms of the rheumatoid arthritis (RA) were frequently and dramatically ameliorated by several conditions, including pregnancy (107), led to the discovery of cortisone (108) and gave unique insights into the complex interaction between the maternal immune system and the developing fetal/placental unit. Contemporary data suggests that the improvement in RA is not ubiquitous as first thought. Amongst all pregnant women about 25% of women have no improvement in their symptoms at any stage in pregnancy and in a small number of cases the disease may actually worsen (109). The process by which pregnancy affects disease activity in RA is not completely understood and several putative mechanisms have been proposed. Of interest, although plasma cortisol rises during pregnancy and was initially thought to be key in the amelioration of symptoms, there is actually no correlation between cortisol concentrations and disease state (110). It has also been reported that the degree of maternal and paternal MHC mismatch has been shown to correlate with the effect of the RA remission during pregnancy (111), leading to the hypothesis that the early immunological events in pregnancy that establish tolerance to the fetal allograft contribute to RA remission. Clearly, this may also account for the disparity in response to pregnancy. RA is not unique in being the only autoimmune disease to be profoundly altered by pregnancy. Although less well studied, non-infectious uveitis tends to improve during pregnancy from the second trimester onward, with the third trimester being associated with the lowest disease activity (112). Again, the mechanism underlying this phenomenon is not completely elucidated.
It is now generally accepted (113) that, notwithstanding the sweeping generalization, autoimmune diseases with a strong cellular (innate) pathophysiology (RA, multiple sclerosis) improve, whereas diseases characterized by autoantibody production such as systemic lupus erythematous and Grave’s disease tend toward increased severity in pregnancy.
We have previously reported an association between pregnancy and the risk of subsequent maternal autoimmune disease which was also related to the mode and gestation of delivery. There was an increased risk of autoimmune disease after cesarean section may be explained by amplified fetal cell traffic at delivery, while decreased risks after abortion may be due to the transfer of more primitive fetal stem cells (114).
Mechanisms of Immune Tolerance during Pregnancy
Following the recognition of maternal immunotolerance, a chief discovery was the choice of HLA-G, a gene with few alleles, for the antigens used at the placental interface. Thus, the idea that placental HLA-G proteins facilitate semiallogeneic pregnancy by inhibiting maternal immune responses to foreign (paternal) antigens via these actions on immune cells is now well established (115–120).
It is also well established that regulatory T cells (Tregs) play an indispensable role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host (121). Consequently, much of present thinking seems to involve a crucial role for Tregs in maintaining immunological tolerance during pregnancy (70, 77, 122–132), with the result that effector T cells cannot accumulate within the decidua (the specialized stromal tissue encapsulating the fetus and placenta) (133).
In an excellent review, Williams et al. (134) remark “Regulatory T cells (Tregs) are a subset of inhibitory CD4+ helper T cells that function to curb the immune response to infection, inflammation, and autoimmunity.” “There are two developmental pathways of Tregs: thymic (tTreg) and extrathymic or peripheral (pTreg). tTregs appear to suppress autoimmunity, whereas pTregs may restrain immune responses to foreign antigens, such as those from diet, commensal bacteria, and allergens.” Their differential production is controlled by a transcription factor called Foxp3.
Further, “a Foxp3 enhancer, conserved noncoding sequence 1 (CNS1), essential for pTreg but dispensable for tTreg cell generation, is present only in placental mammals. It is suggested that during evolution, a CNS1-dependent mechanism of extrathymic differentiation of Treg cells emerged in placental animals to enforce maternal–fetal tolerance” (135).
Williams et al. conclude that “These findings indicate that maternal–fetal tolerance to paternal alloantigens is an active process in which pTregs specifically respond to paternal antigens to induce tolerance. Thus, therapies should aim not to suppress the maternal immune system but rather to enhance tolerance. These findings are consistent with an increase in the percentage of Tregs during pregnancy and with no such increase in women with recurrent pregnancy loss (136)” (134). Thus maternal tolerance is based on exposure to the paternal alloantigens, although mechanisms such as the haem oxygenase detoxification of haem from degrading erythrocytes (137) are also important. Note too that pregnancy loss is often caused by automimmune activity (138) (and see later).
Additionally, Treg cells have several important roles in the control of infection [e.g., Ref. (139–144)]. These include moderating the otherwise potentially dangerous response to infection and being exploited by certain parasites to induce immunotolerance.
Finally, here, it is also recognized that the placenta does allow maternal IgG antibodies to pass to the fetus to protect it against infections. Also, foreign fetal cells persist in the maternal circulation (145) [as does fetal DNA (146, 147), nowadays used in prenatal diagnosis]. One cause of PE is clearly an abnormal immune response toward the placenta. There is substantial evidence for exposure to partner’s semen as prevention for PE, largely due to the absorption of several immune modulating factors present in seminal fluid (148). We discuss this in detail below.
Innate and Adaptive Immunity
Although they are not entirely independent (149, 150), and both respond to infection, it is usual to discriminate (the faster) innate and (the more leisurely) adaptive immune responses [e.g., Ref. (151–155)]. As is well known [reviewed recently (156)], the innate immune system is responsible for the recognition of foreign organisms such as microbes. It would be particularly convenient if something in the immune response did actually indicate an infection rather than simply any alloantigen, but unfortunately—especially because of the lengthy timescale over which PE develops—innate responses tend to morph into adaptive ones. This means (i) that there may be specific signals from early innate events that may be more or less specific to innate responses and (ii) that it also does not exclude the use of particular patterns of immune responsive elements (157–159) to characterize disease states.
An alteration of the immune system is widely recognized as an accompaniment to normal pregnancy (77, 104–106, 127, 160–162), and especially in PE (63–65, 67, 69–71, 163–170), and it is worth looking at it a little more closely.
The innate immune system responds to microbial components such as lipopolysaccharide (LPS) via cell membrane receptors. Innate immune cells express a series of evolutionarily conserved receptors known as pattern-recognition receptors (PRRs). PRRs recognize and bind conserved sequences known as pathogen-associated molecular patterns (PAMPs). Bacterial LPS and peptidoglycan, and double stranded viral RNA are unique to microbes and act as canonical PAMPs, while the main family of PRRs is represented by the Toll-like receptors (TLRs) (171, 172). Downstream events, as with many others (173, 174) converge on the NF-κB system and/or interferon, leading to the release of a series of inflammatory cytokines such as IL-2, IL-6, IL-8, TNF-α, and especially IL-1β.
Matzinger’s “danger model” (175–180) [and see Ref. (79) and Figure 3] suggested that activation of the immune system could be evoked by danger signals from endogenous molecules expelled from injured/damaged tissues, rather than simply from the recognition of non-self (although of course in the case of pregnancy some of these antigens are paternal alloantigens). Such endogenous molecules are referred to as damage-associated molecular patterns (DAMPs), but are not our focus here, albeit they likely have a role in at least some elements of PE (181). We shall see later, however, that Matzinger’s theory is entirely consistent with the kinds of microbial (and disease) tolerance that do seem to be an important part of pregnancy and PE [and see Ref. (182)].
Figure 3.
Matzinger’s “danger model” vs. the classical theory of self vs. self-nonself. Based on and redrawn from Ref. (178).
The maternal innate immune system plays an important role both in normal pregnancy and in particular in hypertensive disorders of pregnancy including preeclampsia (PE) (167, 183–189). One persuasive and widely accepted view is that normal pregnancy is characterized by a low-grade systemic inflammatory response and specific metabolic changes, and that virtually all of the features of normal pregnancy are simply exaggerated in PE (44, 183, 190, 191). Certainly it is long established that “Normal pregnancy and PE both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis” (183), and there are innate immune defenses in the uterus during pregnancy (160). Normal pregnancy has been considered to be a Th2 type immunological state that favors immune tolerance in order to prevent fetal rejection (137). However, normal pregnancy actually fluctuates between pro- (implantation and placentation; parturition) and anti-inflammatory (fetal growth) phases (105, 106). By contrast, PE has been classically described as a Th1/Th2 imbalance (125, 164, 192–194), but as mentioned above [and before (44)], recent studies have highlighted the role of Tregs as part of a Th1/Th2/Th17 paradigm (167, 168). This leads to the question of whether there is some kind of trade-off between the responses to paternal alloantigens and those of microbes.
A Trade-Off for Mating and Immune Defense against Infection
Certainly there is some evidence for a trade-off between mating and immune defense against infection (195–197). Consistent with this (albeit with much else) is the fact (198–200) that pregnancy is associated with an increased severity of at least some infectious diseases. There is evidence (201, 202) that “adaptive immune responses are weakened, potentially explaining reduced viral clearance. Evidence also suggests a boosted innate response, which may represent a compensatory immune mechanism to protect the pregnant mother and the fetus and which may imply decreased susceptibility to initial infection” (199).
The Role(S) of Complement in PE
Complement, or more accurately the complement cascade, is an important part of the innate immune system that responds to infection. Later (downstream) elements also respond to the adaptive immune system. Our previous review (44) listed many proteins whose concentrations are changed in both infection and PE. Since we regard low-level infection as a major cause of the inflammation observed in PE, one would predict that the complement system is activated in PE, and this observation is amply borne out (203–217). Some of the details are mentioned in Table 1.
Table 1.
Changes in the complement system during PE and related pregnancy disorders.
| Complement element | Details | Reference |
|---|---|---|
| Bb | Raised in PE, OR 2.1 (CI 1.4–3.1, P < 0.0003). | (205) |
| Bb | Adjustment for risk factors did not attenuate the association between an elevated Bb and preeclampsia [adjusted odds ratio (aOR) 3.8, 95% CI 1.6–9, P < 0.002] in the cohort. After removing women with plasma obtained before 10 weeks, the adjusted OR of Bb in the top decile for preeclampsia was 6.1 (95% CI 2.2–17, P < 0.0005) | (204) |
| Bb | Median Bb levels were higher in the maternal plasma of severe PE subjects (n = 24) than in controls (n = 20), 1.45 ± 1.03 versus 0.65 ± 0.23 µg/mL, P < 0.001 | (214) |
| Bb | Preterm birth. Women with Bb in the top quartile were 4.7 times more likely to have an SPTB less than 34 weeks’ gestation as compared with women who had levels of Bb in the lower 3 quartiles (CI 1.5–14, P < 0.003) | (203) |
| Bb | Maternal Bb levels were significantly higher in the preeclamptic group than in the nonpreeclamptic group (P < 0.003 in all studied, P < 0.007 in African Americans) | (218) |
| Bb | Pyelonephritis. Pregnant women with pyelonephritis had a higher median plasma concentration of fragment Bb than those with a normal pregnancy (1.3 mg/ml, IQR: 1.1–1.9 vs. 0.8 mg/ml, IQR: 0.7–0.9; P < 0.001). No significant differences were observed in the median maternal plasma concentration of fragment Bb between pregnant women with pyelonephritis who had a positive blood culture and those with a negative blood culture | (219) |
| Bb | Median amniotic fluid Bb levels were also significantly higher (P = 0.03) in preeclamptic women than in normal pregnant women (1,127 versus 749 ng/mL). The alternative complement pathway is principally involved | (215) |
| Bb, C3a, C5a, and MAC | Increased significantly in EOSPE (all P < 0.01) and LOSPE (P-value: 0.027, <0.001, 0.001, and <0.001, respectively) compared with Early/Late control | (216). See also (220) |
| Bb or C3a | Women who were obese with levels of Bb or C3a in the top quartile were 10.0 (95% confidence interval, 3.3–30) and 8.8 (95% confidence interval, 3–24) times, respectively, more likely to develop preeclampsia compared with the referent group at 20 weeks gestation | (221) |
| C1q and C4d | Increased significantly in LOSPE (P-value: 0.003 and.014, respectively) compared with L-control | (216). See also (220) |
| C3a | Adjusted for parity and prepregnancy body mass index, women with levels of C3a in the upper quartile in early pregnancy were three times more likely to have an adverse outcome later in pregnancy compared with women in the lowest quartile (95% confidence interval, 1.8–4.8; P < 0.001). This was especially the case for preterm birth (P < 0004). Elevated C3a as early as the first trimester of pregnancy is an independent predictive factor for adverse pregnancy outcomes, suggesting that complement-related inflammatory events in pregnancy contribute to the subsequent development of poor outcomes at later stages of pregnancy | (208) |
| C3a | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. | (211) |
| C3a | Women who developed early-onset preeclampsia as compared with the term pregnant controls had significantly higher (P = 0.04) median amniotic fluid C3a levels (318.7 versus 254.5 ng/mL) | (215) |
| C3a | 751.6 (194.6–1,660) vs. 1,358 (854.8–2,142) ng/mL, P < 0.05 preeclamptic vs. healthy pregnant | (222) |
| C3a, C3a_desArg, and C5a | Elevated at term in PE but not earlier (P < 0.05) | (223, 224) |
| C3a, C5a, and AT1-AA | Levels in serum from the severe preeclampsia group were significantly higher than in controls (P < 0.05) | (225) |
| C4 | C4 was lowered (P < 0.001) in serum of term preeclamptics | (226) |
| C4d | Placental immunochemistry showed that C4d was rarely present in placentas from healthy controls (3%), whereas it was observed in 50% of placentas obtained from preeclamptic women (P = 0.001) | (210) |
| C5a | The mean cord plasma C5a concentration was higher in patients with PE (8.3 ± 1.71 ng/ml) than normal women (3.2 ± 0.35 ng/ml) P < 0.01 | (212) |
| C5b-9 | Severe preeclampsia was associated with marked elevations in urinary C5b-9 [median and interquartile range, 4.3 (1.2–15.1) ng/mL] relative to subjects with chronic hypertension and healthy controls (P < 0.0001) | (227) |
| C6 | Novel evidence that genetic variations in complement genes C6 and MASP1 were associated with preeclampsia risk | (217) |
The complement cascade may be activated in three main ways (Figure 4), known as classical, alternative or lectin pathways (150, 206, 208, 228, 229). Complement activation by the classical, alternative or lectin pathway results in the generation of split products C3a, C4a, and C5a with proinflammatory properties.
Figure 4.
The complement system [based on figures in Ref. (155, 208)].
Because both innate and adaptive immunity can activate elements of the downstream complement system, it is hard to be definitive, but there is some evidence that elements such as Ba and Bb [the latter of known structure (230)] are selectively released during infection, very much upstream and in the alternative pathway (208, 228, 229, 231–233). Most importantly (Table 1), while probably not a specific serum marker, there is considerable evidence that Bb levels are increased in PE, arguably providing further evidence for a role of infectious agents in the etiology of PE.
We might also note that C1q−/− mice shows features of PE (234), consistent with the view that lowering levels of anti-infection response elements of the complement system leads to PE, consistent again with an infectious component to PE.
Induction of Tolerance by Exposure to Antigens and Our Main Hypothesis: Roles of Semen and Seminal Plasma
A number of groups [e.g., Ref. (118, 148, 235–240)] have argued for a crucial role of semen in inducing maternal immunological protection, and this is an important part of our own hypothesis here. The second component, however, is a corollary of it. If it is accepted that semen can have beneficial effects, it may also be that in certain cases it can also have harmful effects. Specifically, we rehearse the fact that semen is not sterile, and that it can be a crucial source of the microbes that may, over time, be responsible for the development of PE (and indeed other disorders of pregnancy, some of which we rehearse).
Semen consists essentially of the sperm cells suspended in a fluid known as seminal plasma (241). Seminal plasma contains many components (242, 243), such as transforming growth factor β (TGF-β) (236, 244–248), and there is much evidence that a number of them are both protective and responsible for inducing the immune tolerance observed in pregnancy. Thus, in a key article on the issue, Robertson et al. state, “TGF-β has potent immune-deviating effects and is likely to be the key agent in skewing the immune response against a Type-1 bias. Prior exposure to semen in the context of TGF-β can be shown to be associated with enhanced fetal/placental development late in gestation. In this article, we review the experimental basis for these claims and propose the hypothesis that, in women, the partner-specific protective effect of insemination in PE might be explained by induction of immunological hyporesponsiveness conferring tolerance to histocompatibility antigens present in the ejaculate and shared by the conceptus” (148).
Transforming growth factor-β and prostaglandin E [also prevalent in seminal fluid (249)] are potent Treg cell-inducing agents, and coitus is one key factor involved in expanding the pool of inducible Treg cells that react with paternal alloantigens shared by conceptus tissues (250–253).
Both in humans and in agricultural practice, semen may be stored with or without the seminal fluid (in the latter cases, the sperm have been removed from it and they alone are used in the insemination). However, a number of articles have shown very clearly that it is the seminal fluid itself that contains many protective factors, not least in improving the likelihood of avoiding adverse pregnancy outcomes (148, 197, 254, 255). Thus semen is the preferred substrate for inducing immunotolerance and hence protection against PE.
Evidence from Epidemiology—Semen Can be Protective Against PE
As well as those [such as preexisting diseases such as hypertension and diabetes (256, 257), that we covered previously (44)], there are several large-scale risk (or antirisk) factors that correlate with the incidence of PE. They are consistent with the idea that a woman’s immune system adapts slowly to (semen) proteins from a specific male partner (148, 235, 236), and that the content of semen thus has major phenotypic effects well beyond its donation of (epi)genetic material. We believe that our hypothesis about the importance of semen in PE has the merit of being able to explain each of them in a simple and natural way:
The first pregnancy with any given partner means an increased susceptibility to PE (5, 258, 259).
Conception early in a new relationship means an increased susceptibility to PE (260–262).
Conception after using barrier contraceptives means an increased susceptibility to PE (261, 263, 264).
Conception after using non-barrier methods or after a long period of cohabitation means a decreased susceptibility to PE (235, 261).
Donor egg pregnancies have a hugely inflated chance of PE (259, 265–267).
PE in a first pregnancy increases its likelihood in subsequent pregnancies (268).
Oral sex with the father is protective against PE in a subsequent pregnancy (269, 270).
Donor sperm pregnancies (artificial insemination) are much more likely to lead to PE (270, 276–279).
We consider each in turn (Figure 5).
Figure 5.
Some epidemiological risk factors for preeclampsia.
The First Pregnancy with Any Given Partner Means an Increased Susceptibility to PE
This is extremely well established [e.g., Ref. (5, 67, 163, 256, 258, 259, 280–288)]. Thus, Duckitt and Harrington (256) showed nulliparity to have a risk ratio (over pregnant women with previous pregnancies) of 2.91 (95% CI 1.28–6.61). Luo et al. (283) find an odds ratio (OR) of 2.42 (95% CI 2.16–2.71) for PE in primiparous vs. multiparous women, while Deis et al. found the OR to be 2.06 (CI 1.63–2.60), P = 0.0021. Dildy et al. (289) summarize several studies, including a very large one by Conde-Agudelo and Belizán (290) (RR 2.38; 95% CI 2.28–2.49), while the meta-analysis of English et al. (287) gives a risk ratio for nulliparity of 2.91 (CI 1.28–6.61). The consistency of each of these studies allows one to state with considerable confidence that there is a two- to threefold greater chance of PE with a first baby.
However, an additional and key clue here is not simply (and maybe even not mainly) that it is just being nulliparous (i.e., one’s first pregnancy) but that it is primipaternity—one’s first pregnancy with a given father—that leads to an increased susceptibility to PE (19, 204, 291–303) [cf. (304)]. Changing partners effectively “resets the clock” such that the risk with a new father is essentially as for first pregnancies. Thus, Lie et al. (305) noted that if a woman becomes pregnant by a man who has already fathered a pre-eclamptic pregnancy in a different woman her increased risk of developing pre-eclampsia is 1.8-fold (CI 1.2–2.6). This is far greater than the typical incidence of PE, even for nulliparous women. The equivalent figure in the study of Lynch et al. (204) was RR = 5.1, 95% CI 1.6–15. The strong implication of all of this is that the father can have bad effects but that some kind of “familiarity” with the partner is protective (301), the obvious version—and that more or less universally accepted—being an immunological familiarity (i.e., tolerance). Note, however, that this is when the pregnancy goes to term: a prior birth confers a strong protective effect against PE, whereas a prior abortion confers only a weaker protective effect (259).
Conception Early in a New Relationship Means an Increased Susceptibility to PE
The idea that conception early in a new relationship means an increased susceptibility to PE follows immediately from the above. The landmark studies here are those of Robillard et al. (19, 260, 296), of Einarsson et al. (261), and of Saftlas et al. (262).
Robillard et al. (260) studied 1,011 consecutive mothers in an obstetrics unit. The incidence of pregnancy-induced hypertension (PIH) was 11.9% among primigravidae, 4.7% among same-paternity multigravidae, and 24.0% among new-paternity multigravidae. For both primigravidae and multigravidae, the length of (sexual) cohabitation before conception was inversely related to the incidence of PIH (P < 0.0001).
Einarsson et al. (261) studied both the use of barrier methods and the extent of cohabitation prior to pregnancy. For those (allegedly, etc.) using barrier methods before insemination, the OR for PE when prior cohabitation was only 0–4 months versus the OR for PE: normotensive was 17.1 (CI 2.9–150.6) versus 1.2 (CI 0.1–11.5) when the period of cohabitation was 8–12 months, and 1.0 for periods of cohabitation exceeding 1 year.
Saftlas et al. (262) recognized that parous women who change partners before a subsequent pregnancy appear to lose the protective effect of a prior birth. In a large study (mainly based around calcium supplementation), they noted that women with a history of abortion who conceived again with the same partner had nearly half the risk of PE [adjusted odds ratio (aOR) = 0.54, 95% confidence interval: 0.31–0.97]. In contrast, women with an abortion history who conceived with a new partner had the same risk of PE as women without a history of abortion (aOR = 1.03, 95% confidence interval: 0.72–1.47). Thus, the protective effect of a prior abortion operated only among women who conceived again with the same partner.
Conception after Using Barrier Contraceptives Means an Increased Susceptibility to PE
A prediction that follows immediately from the idea that paternal antigens in semen (or seminal fluid) are protective is that the regular use of barrier methods will lower maternal exposure to them, and hence increase the likelihood of PE. This too is borne out (261, 263, 264). Thus Klonoff-Cohen et al. found a 2.37-fold (CI 1.01–5.58) increased risk of PE for users of contraceptives that prevent exposure to sperm. A dose-response gradient was observed, with increasing risk of PE for those with fewer episodes of sperm exposure. Similarly, Hernández-Valencia et al. (264) found that the OR for PE indicated a 2.52-fold (CI 1.17–5.44, P < 0.05), increased risk of PE for users of barrier contraceptives compared with women using nonbarrier contraceptive methods.
Conception after Using Non-Barrier Methods or after a Long Period of Cohabitation Means a Decreased Susceptibility to PE
This is the flip side of the studies given above [e.g., Ref. (260–262)]. It is clear that maternal–fetal HLA sharing is associated with the risk of PE, and the benefits of long-term exposure to the father’s semen, while complex (306), seem to be cumulative (307). Thus, short duration of sexual relationship was more common in women with PE compared with uncomplicated pregnancies [≤6 months 14.5 versus 6.9%, aOR 1.88, 95% CI 1.05–3.36; ≤ 3 months 6.9% versus 2.5%, aOR 2.32, 95% CI 1.03–5.25 (308)]. Oral contraceptives are somewhat confounding here, in that they may either be protective or a risk factor depending on the duration of their use and the mother’s physiological reaction to them (309).
Donor Egg Pregnancies Have a Hugely Inflated Chance of PE
If an immunological component is important to PE (as it evidently is), it is to be predicted that donor egg pregnancies are likely to be at much great risk of PE, and they are [e.g., Ref. (259, 265–267, 310–314)] [and also of preterm birth (PTB) (315)]. Thus, Letur et al. (265, 266) found that PE was some fourfold more prevalent using donated eggs (11.2 vs. 2.8%, P < 0.001), while Tandberg et al. (259) found that various “assisted reproductive technologies” had risk ratios of 1.3 (1.1–1.6) and 1.8 (1.2–2.8) in second and third pregnancies, respectively. Pecks et al. studied PIH (not just PE) and found that the calculated OR for PIH after oocyte donation, compared to conventional reproductive therapy, was 2.57 (CI 1.91–3.47), while the calculated OR for PIH after oocyte donation, compared to other women in the control group, was 6.60 (CI 4.55–9.57). Stoop et al. (316) found a Risk Ratio of 1.502 (CI 1.024–2.204) for PIH. In a study by Levron et al. (317), adjustment for maternal age, gravidity, parity, and chronic hypertension revealed that oocyte donation was independently associated with a higher rate of hypertensive diseases of pregnancy (P < 0.01). In a twins study, Fox et al. (318) found, on adjusted analysis, that the egg donation independently associated with PE (aOR 2.409, CI 1.051–5.524). The meta-anaysis of Thomopoulos et al. (319) gave a risk ratio for egg donation of 3.60 (CI 2.56–5.05) over controls, a value similar to that of Blázquez et al. (320). Finally, a recent meta-analysis by Masoudian et al. (313) found that that the risk of PE is considerably higher in oocyte-donation pregnancies compared to other methods of assisted reproductive technology (OR, 2.54; CI 1.98–3.24; P < 0.0001) or to natural conception (OR, 4.34; CI 3.10–6.06; P < 0.0001). The incidence of gestational hypertension and PE was significantly higher in ovum donor recipients compared with women undergoing autologous IVF [24.7% compared with 7.4%, P < 0.01, and 16.9% compared with 4.9%, P < 0.02 (321)]. All of these are entirely consistent with an immune component being a significant contributor to PE. Given our suggestion that many of these disorders of pregnancy have a microbial component, one obvious question pertains to whether the use of antibiotics assists the successful progression of IVF. Unfortunately this question has been little researched in humans (322).
PE in a First Pregnancy Increases Its Likelihood in Subsequent Pregnancies
This too is well established: a woman who has had PE has an increased risk of PE in subsequent pregnancies (288, 323), especially if suffering from hypertension (324). This may be seen as relatively unsurprising, and of course bears many explanations, and the increased risks can be very substantial (268). In the overall analysis of English et al. (287), the risk ratio was 7.19 (CI 5.85–8.83). Other examples give the recurrence risk, overall, as some 15–18% (288). The risk of recurrent PE is inversely related to gestational age at the first delivery, and in the study of Mostello et al. (325) was 38.6% for 28 weeks’ gestation or earlier, 29.1% for 29–32 weeks, 21.9% for 33–36 weeks, and 12.9% for 37 weeks or more. Low birthweight in the first pregnancy is an independent predictor of PE in the second: birth weight below the tenth percentile in the first delivery accounted for 10% of the total cases of PE in the second pregnancy and 30% of recurrent cases (326). From the perspective developed here, the suggestion is that whatever is responsible for PE in one pregnancy can “live on” in the mother and afflict subsequent ones. One thing that can “live on” is a dormant microbial community. We discussed at length in the previous review (44), and develop in more detail later (in the section “host tolerance to microbial pathogens”) the evidence that dormant microbes (such as Helicobacter pylori and Mycobacterium tuberculosis) can live within their host for decades.
Oral Sex with the Father Is Protective against PE in a Subsequent Pregnancy
Oral sex (with the father of one’s baby) protects against PE (269, 270) (P = 0.0003), arguably because exposure to the paternal antigens in the seminal fluid have a greater exposure to the blood stream via the buccal mucosa than they would via the vagina. This is a particularly interesting (and probably unexpected) finding, that is relatively easily understood from an immunological point of view, and it is hard to conceive of alternative explanations. [Note, however, that in the index study (269), the correlation or otherwise of oral and vaginal sex was not reported, so it is not entirely excluded that more oral sex also meant more vaginal sex.]
Age Is a Risk Factor for PE
Age is a well known risk factor for PE (271–275), and of course age is a risk factor for many other diseases, so we do not regard this as particularly strong evidence for our ideas. However, we have included it in order to note that age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction (327).
Donor Sperm Pregnancies (Artificial Insemination) Are Much More Likely to Lead to PE
Finally, here, turning again to the father, it has been recognized that certain fathers can simply be “dangerous” in terms of their ability to induce PE in those who they inseminate (302, 328). By contrast, if immunotolerance to a father builds up slowly as a result of cohabitation and unprotected sex, a crucial prediction is that donor sperm pregnancies will not have this property, and should lead to a much greater incidence of PE. This is precisely what is observed (270, 276–279, 310).
In an early study (276), Need et al. observed that the overall incidence of PE was high (9.3%) in pregnancies involving artificial insemination by donor (AID) compared with the expected incidence of 0.5–5.0%. The expected protective effect of a previous pregnancy was not seen, with a 47-fold increase in PE (observed versus expected) in AID pregnancies after a previous full-term pregnancy. That is a truly massive risk ratio.
Smith et al. (277) compared the frequency of PE when AI was via washed sperm from a partner or a donor, finding a relative risk for PE of 1.85 (95% CI 1.20–2.85) for the latter, and implying that the relevant factor was attached to (in or on) the sperm themselves.
In a similar kind of study, Hoy et al. found (278), after adjusting for maternal age, multiple birth, parity and presentation, that “donor sperm” pregnancies were more likely to develop PE (OR 1.4, 95% CI 1.2–1.8).
Salha et al. (310) found that the incidence of PE in pregnancies resulting from donated spermatozoa was 18.2% (6/33) compared with 0% in the age- and parity-matched partner insemination group (P < 0.05).
Wang et al. (329) found that the risk of PE tripled in those never exposed to their partner’s sperm, i.e., those treated with intracytoplasmatic sperm injection done with surgically obtained sperm.
In a study of older women, Le Ray et al. (330) noted that the PE rate differed significantly between various groups using assisted reproductive technology (3.8% after no IVF, 10.0% after IVF only, and 19.2% after IVF with oocyte donation, P < 0.001).
Davis and Gallup reviewed what was known in 2006 (279), particularly from an evolutionary point of view, concluding that one interpretation of PE was that it was the mother’s way of removing “unsuitable” fetuses. This does not sit easily with the considerable mortality and morbidity associated with PE predelivery, especially in the absence of treatment. However, Davis and Gallup (279) did recognize that “pregnancies and children that result from unfamiliar semen have a lower probability of receiving sufficient paternal investment than do pregnancies and children that result from familiar semen,” and that is fully consistent with our general thinking here. Bonney draws a similar view (182), based on the “danger” model (176, 178), that takes a different view from that of the “allograft” or “self-nonself discrimination” model. In the “danger model,” the decision to initiate an immune response is based not on discrimination between self and non-self, but instead is based on the recognition of “danger” (abnormal cell death, injury, or stress). One such recognition is the well-established recognition of microbes as something likely to be causative of undesirable outcomes.
In the study of González-Comadran et al. (331), conception using donor sperm was again associated with an increased risk of PE (OR 1.63, 95% CI 1.36–1.95).
Thomopoulos et al. carried out two detailed and systematic reviews (319, 332); the latter (319) covered 7,038,029 pregnancies (203,375 following any invasive ART) and determined that the risk of PE was increased by 75% (95% CI 50–103%).
Overall, these studies highlight very strongly indeed that the use of unfamiliar male sperm is highly conducive to PE relative to that of partner’s sperm, especially when exposure is over a long period. We next turn to the question of why, in spite of this, we also see PE even in partner-inseminated semen, as well as more generally.
Evidence from Epidemiology—Semen Can be Harmful and Can Contribute Strongly to PE
In our previous review (44), we rehearsed the evidence for a considerable placental and vaginal microbiome [see also (333–335)], but did not discuss the semen microbiome at all. To repeat, therefore, the particular, and essentially novel, part of our hypothesis here is that if it is accepted that semen (and seminal plasma) can have beneficial effects, it should also be recognized that in certain cases it can also have harmful effects. In particular, we shall be focusing on its microbial content [we ignore any epigenetic effects (336)]. We note that this idea would fit easily with the recognition that as well as inducing tolerance to paternal antigens, exposures to the father’s semen can build tolerance (immunity) to its microbes, thereby decreasing the risk of PE. However, microbes and their associated PAMPs are well known to be highly inflammatory, whether or not they are reproducing, and we consider that it is this that is likely the particular driver of the sequelae observable in PE.
Microbes Associated with PE
The female’s urogenital microbiome is important in a number of pregnancy disorders (56, 337–339). Specifically, we previously found many examples in which microbes are associated with PE, and we here update the CC-BY-licensed Table 2 thereof (44).
Table 2.
Many studies have identified a much greater prevalence of infectious agents in the blood or urine or gums of those exhibiting PE than in matched controls.
| Microbes | Comments | Reference |
|---|---|---|
| Chlamydia pneumoniae | IgG seroprevalence and gDNA associated with PE (P < 0.0001) | (340) |
| IgG (but not IgA or IgM) associated with PE, OR = 3.1 | (341) | |
| Significantly greater numbers with PE, and reversion under antichlamydial treatment | (342) | |
| Much greater incidence (P < 0.006) | (343) | |
| OR 4.1; P < 0.02 for association with PE (15/48 cases vs. 3/30 controls) | (344) | |
| Chlamydia trachomatis | Increased risk of PE, OR = 7.2 or 1.6 based on serology | (345, 346) |
| Cytomegalovirus | RR for PE 1.5 if infected with CMV | (347) [see also (348)] |
| Helicobacter pylori | Seropositivity or DNA. OR = 2.7, or 26 if CagA seropositivity | (349) and editorial (350) |
| IgG seropositivity 54% PE vs. 21% controls | (343) | |
| Anti-CagA antibodies cross-react with trophoblasts and could inhibit placentation | (351) | |
| 2.8× greater seropositivity in PE group | (352) | |
| OR = 2.86 for seropositivity in PE, correlated with high malondialdehyde levels | (353) | |
| Wide-ranging review of many studies showing PE more prevalent after Hp infection | (354) | |
| Seropositivity PE:control = 84%:32% (P < 0.001) | (355) | |
| OR for seropositivity 1.83 (P < 0.001) | (356) | |
| Seropositivity PE:control 86:43% (P < 0.001) | (357) | |
| Massive increase in seropositivity in women with PE | (358) | |
| Seroprevalence (57%) > controls (33.%) (P < 0.001). Seropositivity for CagA-positive strains 45.2% in preeclamptic women vs. 13.7% in controls (P < 0.001). Infection associated with abnormalities of uterine arteries | (55) | |
| Much greater incidence of antibodies to H. pylori | P < 0.0001 | |
| Human immunodeficiency virus (HIV) | OR 3.52, 95% CI 2.51–4.94, some ascribable to therapy | (359) |
| Human papillomavirus (HPV) | High-risk human papillomavirus (HR-HPV) presence implies an OR of 2.18 for PE | (360) |
| Meta-analyses | Incidence of PE 19% with asymptomatic bacteriuria, vs. 3% (primigravid) or 6% (multigravid) controls (P < 0.005) | (361) |
| UTI more than twice as likely in severe preeclamptics than in controls | (362) | |
| OR of 1.6 for PE if UTI present | (363) | |
| Increased risk of PE OR 1.57 for UTI, 1.76 for periodontal disease | (52) | |
| Early application of antibiotics in infection reduced PE by 52% | (49) | |
| Any overt infection led to an RR of 2 for PE | (54) | |
| UTI has OR of 3.2 for PE; OR = 4.3 if in third trimester | (364) | |
| UTI has OR of 1.3 for mild/moderate and 1.8 for severe PE | (365) | |
| Increased risk of PE with UTI (OR 1.22) or antibiotic prescription (OR 1.28) | (366) | |
| OR of 6.8 for symptomatic bacteriuria in PE vs. controls | (367) | |
| OR 1.3–1.8 of mild or severe PE if exposed to UTI | (368) | |
| OR 1.4 for PE following UTI | (369) | |
| OR 1.3 for PE after UTI | (370) | |
| Meta-analyses showing associations between PD and PE | (53, 371, 372) | |
| High frequency of neutropenia and sepsis in preeclamptic mothers | (373) | |
| OR 2.79, CI 2.01–3.01, P < 0.0001 for periodontal disease associating with PE | (374) | |
| Periodontitis at enrollment (OR = 5.78, 95% CI 2.41–13.89) and within 48 h of delivery (OR = 20.15, 95% CI 4.55–89.29) is associated with an increased risk of preeclampsia | (375) | |
| Periodontitis associated with PE: OR 7.48 (CI 2.72–22.42) | (376) | |
| Review | (333) | |
| Placental microbiome and PE | Many organisms in 13% of PE placentas vs. none in controls (P < 0.006) | (377) |
| Plasmodium falciparum (malaria) | Indications that infection with malaria is associated with PE | (378) |
| 1.5 RR for PE if malarial | (379) | |
| Seasonality: 5.4-fold increase in eclampsia during malaria season | (380) | |
| Preeclampsia was significantly associated with malaria infection during pregnancy (P < 0.03) and 69.7% of cases of preeclampsia with infected placenta might be attributable to malaria infection | (381) | |
In addition, we recognize the considerable evidence for a role of viruses in various disorders of pregnancy (106, 382, 383).
Microbiology of Semen
Semen itself is very far from being sterile, even in normal individuals, with infection usually being defined as 103 organisms/mL semen (384). Of course the mere existence of sexually transmitted diseases implies strongly that there is a seminal fluid (or semen) microbiome that can vary substantially between individuals, and that can contribute to infection [e.g., Ref. (385–387)], fertility (385) (and see below), and any other aspect of pregnancy (388), or even health in later life (389).
It is logical to start here with the observation that semen is a source of microbes from the fact that there are a great many sexually transmitted infectious diseases for which it is the vehicle. Table 3 summarizes some of these.
Table 3.
Organisms of well-known sexually transmitted diseases that have been associated with semen.
| Organism (disease) | Comments | Reference |
|---|---|---|
| Chlamydia trachomatis | Effects on fertility | (390) |
| 32% prevalence in infertile couples | (391) | |
| Human Immunodeficiency Virus (AIDS) | Many examples of seminal transmission via unprotected sex | (392–397) |
| Neissseria gonorrhoeae (gonorrhea) | Gonorrhea actually means “flow of semen” | (398) |
| Survives being frozen in semen used for artificial insemination | (399) | |
| Many antigonococcal antibodies also present | (400) | |
| Same strains in urine and semen; likely origin in urethra | (401) | |
| Treponema pallidum (syphilis) | Infectivity of semen | (402) |
| More than half (12 out of 20) of the women classified as proved and probably syphilitic had mild to moderate PE | (403) | |
| Coinfection of syphilis and HIV in men having sex with men | (404) | |
Notwithstanding the difficulties of measurement (405), there is, in particular, a considerable literature on fertility (406), since infertile males tend to donate sperm for assay in fertility clinics, and infection is a common cause of infertility [e.g., Ref. (384) and Table 4]. Note that “infertility” is not always an absolute term: pregnancies result in 27% of cases of treated “infertile” couples followed up after trying to conceive for 2 years, and with oligozoospermia as the primary cause of infertility (407). Most studies involve bacteria (bacteriospermia). Articles on this and other microbial properties of semen beyond STDs include those in Table 4.
Table 4.
Some examples of the semen microbiome and reproductive biology.
| Study | Organisms | Reference |
|---|---|---|
| Complementarity between partners | Many. Gardnerella vaginalis in female partners was significantly related to inflammation in male genital tracts | (408) |
| Fertility | Many microbiological changes as a function of fertility (more microbes correlate with lower fertility) | (384, 388, 407, 409–453) |
| General microbiology | 552 different microbes in 182 samples out of 201 tested, simply plating 10 µL of semen | (454) |
| Microbes in 36/37 samples | ||
| Review | (455) | |
| 35% of samples had microbes | (456) | |
| (457) | ||
| IVF | No positive antibiotic effect | (458) |
| LPS and protection by probiotic lactobacilli | (purified LPS) | (459) |
| Review | Many microbes | (445, 460, 461) |
| Semen quality | Ralstonia increased in low-quality sperm | (462) |
| Viral infection | Ebola virus | (463–466) |
| HIV | ||
| Zika virus | (467) | |
| (468–470) | ||
We deliberately avoid discussing mechanisms in any real detail here, since our purpose is merely to show that semen is commonly infected with microbes, whose presence might well lead to PE. However, we were very struck by the ability of Escherichia coli and other organisms (440, 448, 471) actually to immobilize sperm [e.g., Ref. (472–475)]. As with amyloidogenic blood clotting (476, 477), bacterial LPS (156) may be a chief culprit (459). The Gram-positive equivalent, lipoteichoic acid (LTA), is just as potent in the fibrinogen-clotting amyloidogen assay (478), but while Gram-positives can also immobilize sperm (479, 480), the influence of purified LTA on sperm seems not to have been tested.
Another prediction from this analysis is that since infection is a significant cause of both infertility and PE [and it may account for 15% of infertile cases (384, 473)], we might expect to see some correlations between them. Although one might argue that anything seen as imperfect “background” health or subfecundity might impinge on the incidence of PE [such as endocrine disruption (481) or DNA damage of whatever cause (482)], the risk ratio for PE in couples whose infertility had an unknown basis was 5.61 (CI 3.3–9.3) in one study in Aberdeen (483) and 1.29 (CI 1.05–1.60) in another in Norway (484). Time to pregnancy in couples may be used (in part) as a surrogate for (in)fertility and is associated with a variety of poor pregnancy outcomes (485); in this case, the risk ratio for PE for TTP exceeding 6 months was 2.47 (CI 1.3–4.69) (486). Given the prevalence of infection in infertile sperm (Table 4), and the frequency of infertility [10% in the Danish study (485), which defined it as couples taking a year or more to conceive], it seems reasonable to suggest that microbiological testing of semen should be done on a more routine basis. It would also help to light up any relationships between the microbiological properties of sperm and the potentially causal consequence of increased PE risk.
We also note, as thoughtfully and importantly suggested by referee 1, that the microbes in the semen may already induce inflammation in the endometrium a few days before the conceptus implants. This may itself constitute a hostile “environment” that can contribute to the process of defective implantation, rather than working via the fetus itself.
More quantitatively, and importantly intellectually, if infection is seen as a major cause of PE, as we argue here, and it is known that infection is a cause of infertility, then one should suppose that infertility, and infertility caused by infection, should be at least as common, and probably more common than is PE, and this is the case, adding some considerable weight to the argument. Indeed, if PE was much more common than infertility or even infection, it would be much harder to argue that the latter was a major cause of the former. In European countries ~10–15% of couples are afflicted by infertility (384, 485), and in some 60% of cases infection or a male factor is implicated (384). In some countries, the frequency of male infertility is 13–15% http://bionumbers.hms.harvard.edu/bionumber.aspx?id=113483&ver=0 or higher (487), and the percentage of females with impaired fecundity has been given as 12.3% https://www.cdc.gov/nchs/fastats/infertility.htm. These kinds of numbers would imply that 6–9% of couples experience infection- or male-based infertility, and this exceeds the 3–5% incidence of PE.
In a similar vein, antibiotics, provided they can get through the relevant membranes (488–490), should also have benefits on sperm parameters or fertility if a lack of it is caused by infection, and this has indeed been observed [e.g., Ref. (436, 452, 491)].
Roles of the Prostate and Testes
In the previous review, we focused on the gut, periodontitis, and the urinary tract of the mother as the main source of organisms that might lead to PE. Here we focus on the male, specifically the prostate and the testes, given the evidence for how common infection is in semen. The main function of the prostate gland is to secrete prostate fluid, one of the components of semen. Thus, although it is unlikely that measurements have regularly been done to assess any relationship between this and any adverse effects of pregnancy, it was of interest to establish whether it too is likely to harbor microbes. Indeed, such “male accessory gland infection” is common (492–496). In some cases, the origin is probably periodontal (497). Recent studies have implicated microbial PRRs, especially TLRs, as well as inflammatory cytokines and their signaling pathways, in testicular function, implying an important link between infection/inflammation and testicular dysfunction (498). The testes are a common and important site of infection in the male (499, 500), and even bacterial LPS can cause testitis (501). Similarly, infection (especially urinary tract infection) is a common cause of prostatitis (502–512). Finally, prostatitis is also a major cause of infertility (492, 493, 495). Such data contribute strongly to the recognition that semen is not normally going to be sterile, consistent with the view that it is likely to be a major originating cause of the infections characteristic of PE.
Microbial Infections in Spontaneous Abortions, Miscarriages, and PTB
Our logic would also imply a role for (potentially male-derived) microbes in miscarriages and spontaneous abortions. A microbial component to these seems well established for both miscarriages (513–515) and spontaneous abortions (516–521). Of course the ability of Brucella abortus to induce abortions in domesticated livestock, especially cattle (and occasionally in humans), is well known (522–524); indeed, bacteriospermia is inimical to fertilization success (525), and nowadays it is well controlled in livestock by the use of vaccines (526) or antimicrobials (525). Indeed, stored semen is so widely used for the artificial insemination of livestock in modern agriculture that the recognition that semen is not sterile has led to the routine use of antibiotics in semen “extenders” [e.g., Ref. (527–530)].
The same general logic is true for infection as a common precursor to PTB in the absence of PE, where it is much better established [e.g., Ref. (531–565)]. It arguably has the same basic origins in semen.
Although recurrent pregnancy loss is usually treated separately from infertility (where the role of infection is reasonably well established) it is possible that in many cases it is, like PE, partly just a worsened form of an immune reaction, with both sharing similar causes (including the microbial infection of semen). There is in fact considerable evidence for this [e.g., Ref. (138, 443, 566–580)]. Of course it is not unreasonable that poor sperm quality, that may be just sufficient to initiate a pregnancy, may ultimately contribute to its premature termination or other disorders of pregnancy, so this association might really be expected. It does, however, add considerable weight to the view that a more common screening of the male than presently done might be of value (581) in assessing a range of pregnancy disorders besides PE. In particular, it seems that infection affects motility (see above), and that this in turn is well correlated (573) with sperm DNA fragmentation and ultimate loss of reproductive quality.
Amyloids in semen are known to enhance human immunodeficiency virus infectivity (582). According to our own recent experimental analyzes, they may be caused by bacterial LPS (476, 477) or LTA (478). We note too that the sperm metabolome also influences offspring, e.g., from obese parents (583), and that many other variables are related to sperm quality, including oxidative stress (584–591). Thus it is entirely reasonable to see semen as a cause of problems as well as benefits to an ensuing pregnancy.
Microbial Effects on Immunotolerance
If our thesis is sound, one may expect to find evidence for the effects of microbes on the loss of immunotolerance in other settings. One such is tolerance to dietary antigens, of which gluten, a cause of celiac disease, is preeminent. Recently, evidence has come forward that shows a substantial effect of a reovirus in lowering the immunotolerance to gluten in a mouse model of celiac disease, and thereby causing inflammation (592, 593). Interestingly, pregnancies in women with celiac disease were considerably more susceptible to PTB and other complications than were controls (594–601), especially when mothers were not on a gluten-free diet. Similarly, preeclamptic pregnancies led to a much (4-fold) higher likelihood of allergic sensitization in the offspring (602) The roles of hygiene, the microbiome and disease are a matter of considerable current interest [e.g., Ref. (603)].
It was consequently logical to see if intolerance to peanut antigen was also predictive of PE, but we could find no evidence for this. Again, however, in a study (604) in which PE had roughly its normal prevalence, mothers experiencing it were significantly more likely to give birth to children with increased risk of asthma, eczema, and aeroallergen and food allergy.
Effects of Vaccination on Pregnancy Outcomes, Including PE
We noted above (and again below) that the evidence for a role of microbes in PTB is overwhelming [also reviewed in Ref. (44)]. From an immunological point of view, there seems to be a hugely beneficial outcome of vaccination against influenza in terms of lowering PTB (605–610) [cf. (611)] or stillbirth (612). PE was not studied, save in Ref. (613) where the risk ratio of vaccination (0.484, CI 0.18–1.34) implied a marginal benefit. There do not seem to be any safety issues, either for influenza vaccine (612–633) or for other vaccines (625) such as those against pertussis (634–636) or human papillomavirus (637).
As well as miscarriage and PTB, other adverse pregnancy outcomes studied in relation to vaccine exposure (638) include IUGR. IUGR frequently presents as the fetal phenotype of PE, sharing a common etiology in terms of poor placentation in early pregnancy (639). These other adverse events have been scored more frequently than has been PE, and Table 5 summarizes the evidence for a protective effect of vaccines, though it is recognized that there is the potential for considerable confounding effects [e.g., Ref. (632, 640)]. While Table 5 does not have examples from PE this is because the tests have seemingly not been done; because the effects on related disorders of pregnancy are clear, we think these should be sufficient to encourage people to look at the effects on PE (indeed readers may already have unpublished data).
Table 5.
Protective events of vaccines against various adverse pregnancy outcomes.
| Adverse event | Risk or odds ratio (95% confidence interval) of vaccinated:unvaccinated | Reference |
|---|---|---|
| Preterm birth | OR = 0.39 (0.18–0.83) | (606) |
| 0.56 (0.45–0.70) | (608) | |
| 0.60 0.38–0.94 | (605) | |
| 0.28 (0.11–0.74) during epidemic | ||
| 0.63 (0.47–0.84) | (607) | |
| IUGR | 0.15 (0.02–0.94) | (606) |
| 0.36 (0.17–0.78) | (624) | |
| 0.31 (0.13–0.75) | (605) | |
| 0.63 (0.4–1.0) | (641) | |
| Stillbirth | 0.73 (0.55–0.96) | (612) |
There are no apparent benefits of vaccine-based immunization vs. recurrent miscarriage (642, 643).
Unrelated to the present question, but very interesting, is the fact that the risk of RA for men was higher among men who fathered their first child at a young age (P for trend <0.001) (644). This is consistent with the fact that its prevalence in females is 3.5 times higher, and that it has a microbial origin (645–648).
General or Specific?
The fact that vaccination against organisms not usually associated with adverse pregnancy outcomes is protective can be interpreted in one (or both) of two ways, i.e., that the vaccine is unselective in terms of inhibiting the effects of its target organism, or the generally raised level of <some kind of> immune response is itself protective. Data to discriminate these are not yet to hand.
In a similar vein, the survival of the host in any “battle” between host and parasite (e.g., microbe) can be effected in one or both of two main ways: (i) the host invokes antimicrobial processes such as the immune systems described above, or produces antimicrobial compounds or (ii) the host modifies itself in ways that allow it to become tolerant to the presence of a certain standing crop of microbes. We consider each in turn.
Antimicrobial Components of Human Semen, a Part of Resistance in the Semen Microbiome
Antimicrobial peptides (AMPs) [http://aps.unmc.edu/AP/main.php (649)] are a well-known part of the defense systems of many animals [e.g., Ref. (650–659)] [and indeed plants (650, 660)], and are widely touted as potential anti-infectives [e.g., Ref. (661–663)]. Their presence in the cells and tissues of the uterus, fetus and the neonate indicates an important role in immunity during pregnancy and in early life (657, 664–668). Unsurprisingly, they have been proposed as agents for use in preventing the transmission of STDs (669, 670), and as antimicrobials for addition to stored semen for use in agriculture (671–675). Our interest here, however, is around whether there are natural AMPs in human (or animal) semen, and the answer is in the affirmative. They include secretory leukocyte protease inhibitor (659), semen-derived enhancer of viral infection (676), and in particular the semenogelins (677, 678). HE2 is another AMP that resides in the epididymis (679, 680), while the human cathelicidin hCAP-18 [cathelicidin AMP, 18 kDa)] is inactive in seminal plasma but is processed to the AMP LL-37 by the prostate-derived protease gastricsin (668, 681). Thus it is clear that at least some of the reason that the semen microbiome is not completely unchecked is down to AMPs. Stimulating their production, provided they are not also spermicidal, would seem like an excellent therapeutic option.
Host Tolerance to Microbial Pathogens
It is a commonplace that—for any number of systems biology reasons based on biochemical individuality (682)—even highly virulent diseases do not kill everyone who is exposed to them at the same level. As indicated above, this could be because the host is resistant and simply clears the infections; this is certainly the more traditional view. However, an additional or alternative contribution is because while hosts do not clear all of them they can develop “tolerance” to them. This latter view is gaining considerable ground, not least since the work of Schneider, Ayres et al. (683) showing that a variety of Drosophila mutants with known genetic defects could differentially tolerate infection by Listeria monocytogenes. This concept of tolerance (684–691) is very important to our considerations here, since it means that we do indeed have well-established methods of putting up with microbes more generally, without killing them. It is consistent with clearly established evolutionary theory (692–694), and the relative importance of resistance and tolerance within a population affects host–microbe coevolution (695). The concept of tolerance sits easily with the Matzinger model of danger/damage [e.g., Ref. (175, 177, 178, 180)], as well as the concept of a resident population of dormant microbes (45, 47, 48), and may indeed be seen in terms of a coevolution or mutualistic association (696, 697). Some specific mechanisms are becoming established, e.g., the variation by microbes of their danger signal to promote host defense (698). Others, such as the difference in the host metabolomes [that we reviewed (44)] as induced by resistance vs. tolerance responses (690) may allow one to infer the relative importance of each. At all events, it is clear from the concept of dormancy that we do not kill all the intracellular microbes that our bodies harbor, and that almost by definition we must then tolerate them. As well as the established maternal immunotolerance of pregnancy, tolerance of microbes seems to be another hallmark of pregnancy.
Sequelae of a Role of Infection in PE: Microbes, Molecules and Processes
The chief line taken in our previous review (44) and herein is that this should be detectable by various means. Those three chief means involve detecting the microbes themselves, detecting molecules whose concentration changes as a result of the microbes (and their inflammatory components) being present, and detecting host processes whose activities have been changed by the presence of the microbes.
Previously (44), updated here (Table 2), we provided considerable evidence for the presence of microbes within the mother as part of PE. Here we have adduced the equally considerable evidence that in many cases semen is very far from being sterile, and that the source of the originating infection may actually be the father. Equally, we showed (44) that a long list of proteins that were raised (or less commonly lowered) in PE were equally changed by known infections, consistent with the view that PE also involved such infections, albeit at a lower level at which their overt presence could be kept in check. One protein we did not discuss was Placental Protein 13 (PP13) or galectin 1, so we now discuss this briefly.
PP13 (Galectin 13)
Galectins are glycan-binding proteins that regulate innate and adaptive immune responses. Three of the five human cluster galectins are solely expressed in the placenta (699). One of these, encoded by the LGALS13 gene (700, 701), is known as galectin-13 or PP13 (702). Its β-sheet-rich “jelly-roll” structure places it strongly as a galectin homolog (701). It has a MW of ~16 kDa [32 kDa dimer (703)] and is expressed solely in the placenta (700, 704) (and see http://www.proteinatlas.org/ENSG00000105198-LGALS13/tissue). A decreased placental expression of PP13 and its low concentrations in first trimester maternal sera are associated with elevated risk of PE (699, 705–707), plausibly reflecting poor placentation. By contrast, and consistent with the usual oxidative stress, there is increased trophoblastic shedding of PP13-immunopositive microvesicles in PE, starting in the second trimester, which leads to high maternal blood PP13 concentrations (699, 708). Certain alleles such as promoter variant 98A-C predispose strongly to PE (709).
Galectin-1 is also highly overexpressed in PE (710). However, as with all the other proteomic biomarkers surveyed previously (44), galectins (including galectin-13 #http://amp.pharm.mssm.edu/Harmonizome/gene/LGALS13) are clear biomarkers of infection (711).
Toll-Like Receptors
Toll-like receptors are among the best known receptors for “DAMPs” such as LPS from Gram-negatives [TLR4 (156, 712–714)], LTAs from Gram-positives [TLR2 (715–726)] and viral DNA and its mimics (TLR3) (727). Note, however, that TLRs are not expressed solely at the cell surface, and that pathogens (and their DNA) may also be recognized intracellularly (728–733), often via a pathway involving an AIM2 (“absent in melanoma 2”) inflammasome and or STING (“stimulator of interferon genes”).
As expected, they are intimately involved in disorders of pregnancy such as PE (185, 727, 734–745). Indeed the animal model for PE developed by Faas et al. (746) actually involves injecting an ultralow dose of LPS into pregnant rat on day 14 of gestation. Overall, such data are fully consistent with the view that infection is a significant part of PE. In view of our suggestions surrounding the role of semen infection in PE it would be of interest to know if these markers were also raised in the semen of partners of women who later manifest PE. Sperm cells are well endowed with TLRs (498, 747–749). However, we can find only one study showing that increased semen expression of TLRs is indeed observed during inflammation and oxidative stress such as occurs during infection and infertility (750). A more wide-ranging assessment of TLR expression in sperm cells as a function of fertility seems warranted.
LPS Mimics
An interesting and striking feature of PE is the common appearance (2–7 weeks before the onset of clinical disease) of inositolphosphoglycan-P type (IPG-P) in the urine of patients destined to manifest PE (20, 751–762). These molecules are second messegers of insulin, and hence related to gestational diabetes. Robillard et al. (20) comment “These carbohydrate–lipid long-chain molecules mimic exactly endotoxins (such as E. coli or Plasmodium falciparum membranes). In theory, these compounds could circulate as endotoxins floating around in the bloodstream for weeks (before and during the appearance of clinical signs of PE). Would these greatly augment the systemic and more specific endothelial inflammation in the mother? This area needs urgent further research as anti-IPG-Pdrugs (or others, monoclonal antibodies, etc.) are intellectually conceivable.” In view of the arguments raised here about the role of other endotoxins such as LPS, we consider these observations as providing potentially significant clues. Surprisingly, little is known of changes in their levels that might accompany genuine infection.
Coagulopathies
Although we discussed this in the previous review (44), some further brief rehearsal is warranted, since coagulopathies are such a common feature of PE (44). Specifically, our finding that very low concentrations of cell wall products can induce amyloid formation during blood clotting (476, 478) has been further extended to recognize the ubiquity of the phenomenon in chronic, inflammatory diseases (477, 478, 648, 763–766). Often, an extreme example gives strong pointers, and the syndrome with the highest likelihood of developing PE is antiphospholipid syndrome (APS) (767–771), which is also caused by infection (772–777) and where the coagulopathies are also especially noteworthy (778–782). Consequently, the recognition of PE as an amyloidogenic coagulopathy (44, 783–785) is significant.
APS and Cardiolipin
Antiphospholipid syndrome is an autoimmune disorder defined in particular by the presence high circulating titers of what are referred to as antiphospholipid antibodies (aPL) [e.g., Ref. (786)]. Given that every human cell’s plasma membrane contains phospholipids, one might wonder how “antiphospholipid antibodies” do not simply attack every cell. The answer, most interestingly, is that, despite the name, anticardiolipin antibodies, anti-β2-glycoprotein-I, and lupus anticoagulant are the main autoantibodies found in APS (787).
In contrast to common phospholipids such as phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine, cardiolipins [1,3-bis(sn-3′-phosphatidyl)-sn-glycerol derivatives] (see Figure 6 for some structures) are synthesized in (Ref. (788–790)) and essentially confined to mitochondria, and in particular the inner mitochondrial membrane. While heart failure is a separate clinical condition, we note that such phospholipids can serve important functions in oxidative phosphorylation, apoptosis, and heart failure development (790–797).
Figure 6.
Some cardiolipin structures.
Overall, there seems to be little doubt that APS and aPL are the result of infection (773–777, 798–800), and that, as with RA (645–648, 801), the autoimmune responses are essentially due to molecular mimicry.
Now, of course, from an evolutionary point of view, mitochondria are considered to have evolved from (α-proteo)bacteria (802–808) that were engulfed by a protoeukaryote (809), and bacteria might consequently be expected to possess cardiolipin. This is very much the case for both Gram-negative and Gram-positive strains (810–814), with Gram-positive organisms typically having the greater content. Particularly significant, from our point of view, is that the relative content of cardiolipin among phospholipids increases enormously as (at least Gram-positive) bacterial cells become dormant (815).
Thus, the cardiolipin can come from two main sources: (i) host cell death that liberates mitochondrial products or (ii) invading bacteria (especially those that lay dormant and awaken). Serum ferritin is a cell death marker (816), and some evidence for the former source (817) [and see Ref. (818)] is that hyperferritinemia was present in 9% vs. 0% of APS patients and controls, respectively (P < 0.001), and that hyperferritinemia was present in 71% of catastrophic APS (cAPS) patients, and ferritin levels among this subgroup were significantly higher compared with APS-non-cAPS patients (816–847 vs. 120–230 ng/ml, P < 0.001). One easy hypothesis is that both are due to invading bacteria, but cAPS patients also exhibit comparatively large amounts of host cell death (Figure 7).
Figure 7.
Possible relationships between cardiolipin exposure and disease sequelae.
Treatment Options Based on (Or Consistent with) the Ideas Presented Here
Although often unwritten or implicit, the purposes of much of fundamental biomedical science are to find better diagnostics and treatments for diseases (a combination sometimes referred to as theranostics). Consequently, our purposes here are to rehearse some of those areas where appropriate tests (in the form, ultimately, of randomized clinical trials) may be performed. Clearly, as before (44), and recognizing the issues of antimicrobial resistance, one avenue would exploit antibiotics much more commonly than now. We note that pharmaceutical drugs are prescribed or taken during 50% or more of pregnancies (819–828). Anti-infectives are the most common such drugs, and some 20–25% of women or more are prescribed one or more antibiotics during their pregnancies (820, 821, 824, 826, 828–832).
Given the role of male semen infection, we suggest that more common testing of semen for infection is warranted, especially using molecular tests. Our analyses suggest that antibiotics might also be of benefit to those males presenting with high microbial semen loads or poor fertility (833). Another strategy might involve stimulating the production of AMPs in semen.
Of the list of bacteria given in Table 2 as being associated with PE, H. pylori stands out as the most frequent. One may wonder why a vaccine against it has not been developed, but it seems to be less straightforward than for other infections (834, 835), probably because—consistent with its ability to persist within its hosts—it elicits only a poor immune response (836, 837). Our own experience (838) is that many small molecules can improve the ability of other agents to increase the primary mechanisms that are the target assay, while having no direct effects on them themselves. Although “combinatorial” strategies often lead to quite unexpected beneficial effects [e.g., Ref. (839, 840)], this “binary weapon” strategy is both novel and untried.
As also rehearsed in more detail previously [e.g., Ref. (841, 842)] many polyphenolic antioxidants act through their ability to chelate unliganded iron, and thereby keep it from doing damage or acting as a source of iron for microbial proliferation. Such molecules may also be expected to be beneficial. Other strategies may be useful for inhibiting the downstream sequelae of latent infections, such as targeting inflammation or coagulopathies.
Conclusion, Summary, and Open Questions
We consider that our previous review (44) made a very convincing case for the role of (mostly dormant) microbes in the etiology of PE. However, we there paid relatively scant attention to two elements, viz (i) the importance of the immune system (164), especially in maternal immunotolerance and (ii) the idea that possibly the commonest cause of the microbes providing the initial infection was actually infected semen from the father. We also recognize that epigenetic information (389, 843–845) can be provided by the father and this can be hard to discriminate from infection (if not measured), at least in the F1 generation. This said, microbiological testing of semen seems to be a key discriminator if applied. The “danger model” (175, 177–180), in which it is recognized that immune activation owes more to the detection of specific damage signals than to “non-self,” thus seems to be highly relevant to PE (182).
Overall, we think the most important ideas and facts that we have rehearsed here include the following:
Following Medawar’s recognition of the potential conundrum of paternal alloantigens in pregnancy, most thinking has focused on the role of maternal immunotolerance, and the role of Tregs therein.
Many examples show that sexual familiarity with the father helps protect against PE; however, this does not explain why in many cases exposure to paternal antigens is actually protective (and not even merely neutral).
Semen contains many protective and immune-tolerance-inducing substances such as TGF-β.
However, semen is rarely sterile, and contains many microbes, some of which are not at all benign, and can be transferred to the mother during copulation.
If one accepts that there is often a microbial component to the development of PE, and we and others have rehearsed the considerable evidence that it is so, then semen seems to a substantial, and previous largely unconsidered source of microbes.
Some determinands, such as complement factor Bb, seem to reflect microbial infection and not just general inflammation that can have many other causes, and may therefore be of value in untangling the mechanisms involved.
An improved understanding of the microbiology of semen, and the role of antibiotics and vaccination in the father, seems particularly worthwhile; novel antioxidants may also hold promise (846–848).
Coagulopathies are a somewhat underappreciated accompaniment to PE and may contribute to its etiology.
The “danger model” of immune response seems much better suited to describing events in pregnancy and PE than is the classical self/non-self analysis.
The features of PE are not at all well recapitulated in animal models (26), and certainly not in rodents. However, it seems likely that they still have much to contribute (849–851).
Open questions and further research agenda items include the following:
There is a need for improved molecular and culture-based methods of detecting microbes in blood and tissues in which they are normally considered to be absent, both in the mother and the father.
Notwithstanding the promise of metabolomics [see e.g., Ref. (852, 853)], there remains a need for better diagnostics, especially early in pregnancy.
Issues of antimicrobial resistance are well known [e.g., Ref. (854–856)], and most antibiotics work only on growing cells, so there is a significant role for those that work on persisters and other non-replicating forms (857–859).
As increasing numbers of infectious diseases are seen to be associated with diseases previously considered noncommunicable [e.g., tuberculosis and Parkinson’s disease (860–862)], we may anticipate more careful study of such an association between overt infection and PE.
In these discussions, we have largely avoided discriminating between early-onset (<34 weeks) and late-onset (>34 weeks) PE, but recognize both the distinctions and their varying prevalences (20, 863–867).
The increasing online availability of patient information will permit greater exploitation to assess these ideas from an epidemiological point of view; in this sense, an improved understanding of the basis for the widely varying geographical incidence of PE (20) is also likely to offer important clues.
Author Contributions
In discussion, DK and LK jointly came up with the original idea for the role of semen in preeclampsia, and the many sequelae it entails, and during many subsequent discussions wrote the review.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
Funding. DK thanks the Biotechnology and Biological Sciences Research Council (grant BB/L025752/1) for financial support. LK is a Science Foundation Ireland Principal Investigator (grant number 08/IN.1/B2083). LK is also the Director of the Science Foundation Ireland-funded INFANT Research Centre (grant no. 12/RC/2272). The funders had no other role in the conception or submission of the manuscript, and have no conflicts of interest to declare.
References
- 1.Jeffcoate TNA. Pre-eclampsia and eclampsia: the disease of theories. Proc R Soc Med (1966) 59:397–404. [PMC free article] [PubMed] [Google Scholar]
- 2.Barad DH, Kushnir VA, Gleicher N. Focus on recurrent miscarriage phenotypes. Fertil Steril (2017) 107:64–5. 10.1016/j.fertnstert.2016.10.034 [DOI] [PubMed] [Google Scholar]
- 3.Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S, et al. Potential markers of preeclampsia – a review. Reprod Biol Endocrinol (2009) 7:70. 10.1186/1477-7827-7-70 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Steegers EAP, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet (2010) 376:631–44. 10.1016/S0140-6736(10)60279-6 [DOI] [PubMed] [Google Scholar]
- 5.North RA, Mccowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (2011) 342:d1875. 10.1136/bmj.d1875 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag (2011) 7:467–74. 10.2147/VHRM.S20181 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kenny L. Improving diagnosis and clinical management of pre-eclampsia. MLO Med Lab Obs (2012) 44(12):14. [PubMed] [Google Scholar]
- 8.Desai P. Obstetric Vasculopathies. New Delhi: Jaypee; (2013). [Google Scholar]
- 9.Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol (2014) 10:466–80. 10.1038/nrneph.2014.102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension (2014) 64:644–52. 10.1161/HYPERTENSIONAHA.114.03578 [DOI] [PubMed] [Google Scholar]
- 11.Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens (2015) 24:131–8. 10.1097/MNH.0000000000000105 [DOI] [PubMed] [Google Scholar]
- 12.Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol (2013) 170:1–7. 10.1016/j.ejogrb.2013.05.005 [DOI] [PubMed] [Google Scholar]
- 13.Vest AR, Cho LS. Hypertension in pregnancy. Curr Atheroscler Rep (2014) 16:395. 10.1007/s11883-013-0395-8 [DOI] [PubMed] [Google Scholar]
- 14.Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet (2006) 367:1066–74. 10.1016/S0140-6736(06)68397-9 [DOI] [PubMed] [Google Scholar]
- 15.Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol (2009) 33:130–7. 10.1053/j.semperi.2009.02.010 [DOI] [PubMed] [Google Scholar]
- 16.Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG (2011) 118(Suppl 1):1–203. 10.1111/j.1471-0528.2010.02847.x [DOI] [PubMed] [Google Scholar]
- 17.Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol (2012) 36:56–9. 10.1053/j.semperi.2011.09.011 [DOI] [PubMed] [Google Scholar]
- 18.Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization multicountry survey on maternal and newborn health. BJOG (2014) 121(Suppl 1):14–24. 10.1111/1471-0528.12629 [DOI] [PubMed] [Google Scholar]
- 19.Robillard PY, Dekker G, Chaouat G, Hulsey TC, Saftlas A. Epidemiological studies on primipaternity and immunology in preeclampsia – a statement after twelve years of workshops. J Reprod Immunol (2011) 89:104–17. 10.1016/j.jri.2011.02.003 [DOI] [PubMed] [Google Scholar]
- 20.Robillard PY, Dekker G, Iacobelli S, Chaouat G. An essay of reflection: why does preeclampsia exist in humans, and why are there such huge geographical differences in epidemiology? J Reprod Immunol (2016) 114:44–7. 10.1016/j.jri.2015.07.001 [DOI] [PubMed] [Google Scholar]
- 21.Brew O, Sullivan MH, Woodman A. Comparison of normal and pre-eclamptic placental gene expression: a systematic review with meta-analysis. PLoS One (2016) 11:e0161504. 10.1371/journal.pone.0161504 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. Unsupervised placental gene expression profiling identifies clinically relevant subclasses of human preeclampsia. Hypertension (2016) 68:137–47. 10.1161/HYPERTENSIONAHA.116.07293 [DOI] [PubMed] [Google Scholar]
- 23.Redman CWG. Current topic: pre-eclampsia and the placenta. Placenta (1991) 12:301–8. 10.1016/0143-4004(91)90339-H [DOI] [PubMed] [Google Scholar]
- 24.Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta (2009) 30(Suppl A):S32–7. 10.1016/j.placenta.2008.11.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Baker PN, Kenny LC. Obstetrics by Ten Teachers. Boca Raton, FL: CRC Press; (2011). [Google Scholar]
- 26.Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech (2012) 5:9–18. 10.1242/dmm.008516 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Redman CW, Sargent IL, Staff AC. IFPA senior award lecture: making sense of pre-eclampsia – two placental causes of preeclampsia? Placenta (2014) 35(Suppl):S20–5. 10.1016/j.placenta.2013.12.008 [DOI] [PubMed] [Google Scholar]
- 28.Redman CWG. The six stages of pre-eclampsia. Pregnancy Hypertens (2014) 4:246. 10.1016/j.preghy.2014.04.020 [DOI] [PubMed] [Google Scholar]
- 29.Perucci LO, Corrêa MD, Dusse LM, Gomes KB, Sousa LP. Resolution of inflammation pathways in preeclampsia-a narrative review. Immunol Res (2017) 65:774–89. 10.1007/s12026-017-8921-3 [DOI] [PubMed] [Google Scholar]
- 30.Hung TH, Skepper JN, Burton GJ. In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol (2001) 159:1031–43. 10.1016/S0002-9440(10)61778-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig (2004) 11:342–52. 10.1016/j.jsgi.2004.03.003 [DOI] [PubMed] [Google Scholar]
- 32.Burdon C, Mann C, Cindrova-Davies T, Ferguson-Smith AC, Burton GJ. Oxidative stress and the induction of cyclooxygenase enzymes and apoptosis in the murine placenta. Placenta (2007) 28:724–33. 10.1016/j.placenta.2006.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Charnock-Jones DS, Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol (2007) 170:1511–20. 10.2353/ajpath.2007.061035 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta (2009) 30(Suppl A):S43–8. 10.1016/j.placenta.2008.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Endocrinol Metab (2011) 25:287–99. 10.1016/j.bpobgyn.2010.10.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol (2014) 5:1. 10.3389/fphys.2014.00372 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Broughton Pipkin F, Rubin PC. Pre-eclampsia – the ‘disease of theories’. Br Med Bull (1994) 50:381–96. 10.1093/oxfordjournals.bmb.a072898 [DOI] [PubMed] [Google Scholar]
- 38.Schlembach D. Pre-eclampsia – still a disease of theories. Fukushima J Med Sci (2003) 49:69–115. 10.5387/fms.49.69 [DOI] [PubMed] [Google Scholar]
- 39.George EM. The disease of theories: unravelling the mechanisms of pre-eclampsia. Biochemist (2017) 39:22–5. [Google Scholar]
- 40.Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med (1999) 222:222–35. 10.1046/j.1525-1373.1999.d01-139.x [DOI] [PubMed] [Google Scholar]
- 41.George EM. New approaches for managing preeclampsia: clues from clinical and basic research. Clin Ther (2014) 36:1873–81. 10.1016/j.clinthera.2014.09.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Wu P, Kwok CS, Haththotuwa R, Kotronias RA, Babu A, Fryer AA, et al. Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia (2016) 59:2518–26. 10.1007/s00125-016-4098-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes (2017) 10:e003497. 10.1161/CIRCOUTCOMES.116.003497 [DOI] [PubMed] [Google Scholar]
- 44.Kell DB, Kenny LC. A dormant microbial component in the development of pre-eclampsia. Front Med Obs Gynecol (2016) 3:60. 10.3389/fmed.2016.00060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kaprelyants AS, Gottschal JC, Kell DB. Dormancy in non-sporulating bacteria. FEMS Microbiol Rev (1993) 10:271–86. 10.1111/j.1574-6968.1993.tb05871.x [DOI] [PubMed] [Google Scholar]
- 46.Kell DB, Kaprelyants AS, Weichart DH, Harwood CL, Barer MR. Viability and activity in readily culturable bacteria: a review and discussion of the practical issues. Antonie Van Leeuwenhoek (1998) 73:169–87. 10.1023/A:1000664013047 [DOI] [PubMed] [Google Scholar]
- 47.Kell DB, Potgieter M, Pretorius E. Individuality, phenotypic differentiation, dormancy and ‘persistence’ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research (2015) 4:179. 10.12688/f1000research.6709.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Potgieter M, Bester J, Kell DB, Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev (2015) 39:567–91. 10.1093/femsre/fuv013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Herrera JA, Chaudhuri G, López-Jaramillo P. Is infection a major risk factor for preeclampsia? Med Hypotheses (2001) 57:393–7. 10.1054/mehy.2001.1378 [DOI] [PubMed] [Google Scholar]
- 50.Trogstad LIS, Eskild A, Bruu AL, Jeansson S, Jenum PA. Is preeclampsia an infectious disease? Acta Obstet Gynecol Scand (2001) 80:1036–8. 10.1034/j.1600-0412.2001.801112.x [DOI] [PubMed] [Google Scholar]
- 51.Todros T, Vasario E, Cardaropoli S. Preeclampsia as an infectious disease. Exp Rev Obs Gynecol (2007) 2:735–41. 10.1586/17474108.2.6.735 [DOI] [Google Scholar]
- 52.Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol (2008) 198:7–22. 10.1016/j.ajog.2007.07.040 [DOI] [PubMed] [Google Scholar]
- 53.López-Jaramillo P, Herrera JA, Arenas-Mantilla M, Jauregui IE, Mendoza MA. Subclinical infection as a cause of inflammation in preeclampsia. Am J Ther (2008) 15:373–6. 10.1097/MJT.0b013e318164c149 [DOI] [PubMed] [Google Scholar]
- 54.Rustveld LO, Kelsey SF, Sharma R. Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies. Matern Child Health J (2008) 12:223–42. 10.1007/s10995-007-0224-1 [DOI] [PubMed] [Google Scholar]
- 55.Di Simone N, Tersigni C, Cardaropoli S, Franceschi F, Di Nicuolo F, Castellani R, et al. Helicobacter pylori infection contributes to placental impairment in preeclampsia: basic and clinical evidences. Helicobacter (2017) 22:e12347. 10.1111/hel.12347 [DOI] [PubMed] [Google Scholar]
- 56.Nourollahpour Shiadeh M, Behboodi Moghadam Z, Adam I, Saber V, Bagheri M, Rostami A. Human infectious diseases and risk of preeclampsia: an updated review of the literature. Infection (2017) 45:589–600. 10.1007/s15010-017-1031-2 [DOI] [PubMed] [Google Scholar]
- 57.Kleinrouweler CE, Van Uitert M, Moerland PD, Ris-Stalpers C, Van Der Post JA, Afink GB. Differentially expressed genes in the pre-eclamptic placenta: a systematic review and meta-analysis. PLoS One (2013) 8:e68991. 10.1371/journal.pone.0068991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Chung MC, Jorgensen SC, Popova TG, Tonry JH, Bailey CL, Popov SG. Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection. J Med Microbiol (2009) 58:737–44. 10.1099/jmm.0.007427-0 [DOI] [PubMed] [Google Scholar]
- 59.Ubagai T, Tansho S, Ieki R, Ono Y. Evaluation of TREM1 gene expression in circulating polymorphonuclear leukocytes and its inverse correlation with the severity of pathophysiological conditions in patients with acute bacterial infections. Jpn J Infect Dis (2012) 65:376–82. 10.7883/yoken.65.376 [DOI] [PubMed] [Google Scholar]
- 60.Ubagai T, Nakano R, Kikuchi H, Ono Y. Gene expression analysis of TREM1 and GRK2 in polymorphonuclear leukocytes as the surrogate biomarkers of acute bacterial infections. Int J Med Sci (2014) 11:215–21. 10.7150/ijms.7231 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Fillerova R, Gallo J, Radvansky M, Kraiczova V, Kudelka M, Kriegova E. Excellent diagnostic characteristics for ultrafast gene profiling of DEFA1-IL1B-LTF in detection of prosthetic joint infections. J Clin Microbiol (2017) 55:2686–97. 10.1128/JCM.00558-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol (1998) 179:1359–75. 10.1016/S0002-9378(98)70160-7 [DOI] [PubMed] [Google Scholar]
- 63.Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online (2006) 13:680–6. 10.1016/S1472-6483(10)60659-1 [DOI] [PubMed] [Google Scholar]
- 64.Dekker G, Robillard PY. Pre-eclampsia: is the immune maladaptation hypothesis still standing? An epidemiological update. J Reprod Immunol (2007) 76:8–16. 10.1016/j.jri.2007.03.015 [DOI] [PubMed] [Google Scholar]
- 65.Moffett A, Hiby SE. How does the maternal immune system contribute to the development of pre-eclampsia? Placenta (2007) 28(Suppl A):S51–6. 10.1016/j.placenta.2006.11.008 [DOI] [PubMed] [Google Scholar]
- 66.Cudihy D, Lee RV. The pathophysiology of pre-eclampsia: current clinical concepts. J Obstet Gynaecol (2009) 29:576–82. 10.1080/01443610903061751 [DOI] [PubMed] [Google Scholar]
- 67.James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol (2010) 221:363–78. 10.1002/path.2719 [DOI] [PubMed] [Google Scholar]
- 68.Jianjun Z, Yali H, Zhiqun W, Mingming Z, Xia Z. Imbalance of T-cell transcription factors contributes to the Th1 type immunity predominant in pre-eclampsia. Am J Reprod Immunol (2010) 63:38–45. 10.1111/j.1600-0897.2009.00763.x [DOI] [PubMed] [Google Scholar]
- 69.Redman CWG, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol (2010) 63:534–43. 10.1111/j.1600-0897.2010.00831.x [DOI] [PubMed] [Google Scholar]
- 70.Hsu P, Nanan RK. Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia. Front Immunol (2014) 5:125. 10.3389/fimmu.2014.00125 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Dekker GA, Robillard PY, Hulsey TC. Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv (1998) 53:377–82. 10.1097/00006254-199806000-00023 [DOI] [PubMed] [Google Scholar]
- 72.Buzan T. How to Mind Map. London: Thorsons; (2002). [Google Scholar]
- 73.Kenny LC, Kell DB. Immunological Tolerance, Pregnancy and Pre-Eclampsia: The Roles of Semen Microbes and the Father. bioRxiv Preprint. bioRxiv, 198796 (2017). 10.1101/198796 [DOI] [PMC free article] [PubMed]
- 74.Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol (1953) 7:320–38. [Google Scholar]
- 75.Billington WD. The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J Reprod Immunol (2003) 60:1–11. 10.1016/S0165-0378(03)00083-4 [DOI] [PubMed] [Google Scholar]
- 76.Trowsdale J, Betz AG. Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol (2006) 7:241–6. 10.1038/ni1317 [DOI] [PubMed] [Google Scholar]
- 77.Munoz-Suano A, Hamilton AB, Betz AG. Gimme shelter: the immune system during pregnancy. Immunol Rev (2011) 241:20–38. 10.1111/j.1600-065X.2011.01002.x [DOI] [PubMed] [Google Scholar]
- 78.Colucci F, Moffett A, Trowsdale J. Medawar and the immunological paradox of pregnancy: 60 years on. Eur J Immunol (2014) 44:1883–5. 10.1002/eji.201470065 [DOI] [PubMed] [Google Scholar]
- 79.Bonney EA. Immune regulation in pregnancy: a matter of perspective? Obstet Gynecol Clin North Am (2016) 43:679–98. 10.1016/j.ogc.2016.07.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Haig D. Genetic conflicts in human pregnancy. Q Rev Biol (1993) 68:495–532. 10.1086/418300 [DOI] [PubMed] [Google Scholar]
- 81.Robertson SA, Sharkey DJ. The role of semen in induction of maternal immune tolerance to pregnancy. Semin Immunol (2001) 13:243–54. 10.1006/smim.2000.0320 [DOI] [PubMed] [Google Scholar]
- 82.Clark GF, Schust DJ. Manifestations of immune tolerance in the human female reproductive tract. Front Immunol (2013) 4:26. 10.3389/fimmu.2013.00026 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Gleicher N, Kushnir VA, Barad DH. Redirecting reproductive immunology research toward pregnancy as a period of temporary immune tolerance. J Assist Reprod Genet (2017) 34:425–30. 10.1007/s10815-017-0874-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol (2006) 6:584–94. 10.1038/nri1897 [DOI] [PubMed] [Google Scholar]
- 85.Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol (2007) 29:151–62. 10.1007/s00281-007-0071-6 [DOI] [PubMed] [Google Scholar]
- 86.Dutta P, Burlingham WJ. Microchimerism: tolerance vs. sensitization. Curr Opin Organ Transplant (2011) 16:359–65. 10.1097/MOT.0b013e3283484b57 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Rusterholz C, Messerli M, Hoesli I, Hahn S. Placental microparticles, DNA, and RNA in preeclampsia. Hypertens Pregnancy (2011) 30:364–75. 10.3109/10641951003599571 [DOI] [PubMed] [Google Scholar]
- 88.Kinder JM, Stelzer IA, Arck PC, Way SS. Immunological implications of pregnancy-induced microchimerism. Nat Rev Immunol (2017) 17:483–94. 10.1038/nri.2017.38 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Knight M, Redman CWG, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol (1998) 105:632–40. 10.1111/j.1471-0528.1998.tb10178.x [DOI] [PubMed] [Google Scholar]
- 90.Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H, et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta (2003) 24:181–90. 10.1053/plac.2002.0903 [DOI] [PubMed] [Google Scholar]
- 91.Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CWG. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol (2003) 59:153–60. 10.1016/S0165-0378(03)00044-5 [DOI] [PubMed] [Google Scholar]
- 92.Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol (2005) 66:1146–54. 10.1016/j.humimm.2005.11.003 [DOI] [PubMed] [Google Scholar]
- 93.Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Redman CWG, Sargent IL, et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta (2006) 27:56–61. 10.1016/j.placenta.2004.11.007 [DOI] [PubMed] [Google Scholar]
- 94.Reddy A, Zhong XY, Rusterholz C, Hahn S, Holzgreve W, Redman CWG, et al. The effect of labour and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free DNA and mRNA in normal pregnancy and pre-eclampsia. Placenta (2008) 29:942–9. 10.1016/j.placenta.2008.08.018 [DOI] [PubMed] [Google Scholar]
- 95.Hartley JDR, Ferguson BJ, Moffett A. The role of shed placental DNA in the systemic inflammatory syndrome of preeclampsia. Am J Obstet Gynecol (2015) 213:268–77. 10.1016/j.ajog.2015.03.026 [DOI] [PubMed] [Google Scholar]
- 96.Clark DA, Chaput A, Tutton D. Active suppression of host-vs-graft reaction in pregnant mice. VII. Spontaneous abortion of allogeneic CBA/J x DBA/2 fetuses in the uterus of CBA/J mice correlates with deficient non-T suppressor cell activity. J Immunol (1986) 136:1668–75. [PubMed] [Google Scholar]
- 97.Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol (2001) 2:64–8. 10.1038/83183 [DOI] [PubMed] [Google Scholar]
- 98.Wilczyński JR. Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia – the same basic mechanism? Hum Immunol (2006) 67:492–511. 10.1016/j.humimm.2006.04.007 [DOI] [PubMed] [Google Scholar]
- 99.Warning JC, Mccracken SA, Morris JM. A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. Reproduction (2011) 141:715–24. 10.1530/REP-10-0360 [DOI] [PubMed] [Google Scholar]
- 100.Kim CJ, Romero R, Chaemsaithong P, Kim JS. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol (2015) 213:S53–69. 10.1016/j.ajog.2015.08.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Raman K, Wang H, Troncone MJ, Khan WI, Pare G, Terry J. Overlap chronic placental inflammation is associated with a unique gene expression pattern. PLoS One (2015) 10:e0133738. 10.1371/journal.pone.0133738 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Hyde KJ, Schust DJ. Immunologic challenges of human reproduction: an evolving story. Fertil Steril (2016) 106:499–510. 10.1016/j.fertnstert.2016.07.1073 [DOI] [PubMed] [Google Scholar]
- 103.Zelante T, Pieraccini G, Scaringi L, Aversa F, Romani L. Learning from other diseases: protection and pathology in chronic fungal infections. Semin Immunopathol (2016) 38:239–48. 10.1007/s00281-015-0523-3 [DOI] [PubMed] [Google Scholar]
- 104.Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci (2011) 1221:80–7. 10.1111/j.1749-6632.2010.05938.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol (2014) 72:107–16. 10.1111/aji.12289 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol (2017) 17:469–82. 10.1038/nri.2017.64 [DOI] [PubMed] [Google Scholar]
- 107.Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis and intermittent hydrarthritis. Mayo Clin Proc (1938) 13:161–7. [Google Scholar]
- 108.Glyn J. The discovery and early use of cortisone. J R Soc Med (1998) 91:513–7. 10.1177/014107689809101004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.de Man YA, Dolhain RJ, Van De Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum (2008) 59:1241–8. 10.1002/art.24003 [DOI] [PubMed] [Google Scholar]
- 110.Muñoz-Valle JF, Vazquez-Del Mercado M, García-Iglesias T, Orozco-Barocio G, Bernard-Medina G, Martínez-Bonilla G, et al. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol (2003) 131:377–84. 10.1046/j.1365-2249.2003.02059.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med (1993) 329:466–71. 10.1056/NEJM199308123290704 [DOI] [PubMed] [Google Scholar]
- 112.Chiam NP, Lim LL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol (2014) 2014:401915. 10.1155/2014/401915 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.James D, Steer PL, Weiner C, Gonik B, Crowther C, Robson S, editors. High Risk Pregnancy. Amsterdam: Elsevier/Saunders; (2010). [Google Scholar]
- 114.Khashan AS, Kenny LC, Laursen TM, Mahmood U, Mortensen PB, Henriksen TB, et al. Pregnancy and the risk of autoimmune disease. PLoS One (2011) 6:e19658. 10.1371/journal.pone.0019658 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Hunt JS, Petroff MG, Mcintire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J (2005) 19:681–93. 10.1096/fj.04-2078rev [DOI] [PubMed] [Google Scholar]
- 116.Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update (2006) 12:209–32. 10.1093/humupd/dmi048 [DOI] [PubMed] [Google Scholar]
- 117.Guleria I, Sayegh MH. Maternal acceptance of the fetus: true human tolerance. J Immunol (2007) 178:3345–51. 10.4049/jimmunol.178.6.3345 [DOI] [PubMed] [Google Scholar]
- 118.Dahl M, Perin TL, Djurisic S, Rasmussen M, Ohlsson J, Buus S, et al. Soluble human leukocyte antigen-G in seminal plasma is associated with HLA-G genotype: possible implications for fertility success. Am J Reprod Immunol (2014) 72:89–105. 10.1111/aji.12251 [DOI] [PubMed] [Google Scholar]
- 119.Lynge Nilsson L, Djurisic S, Hviid TVF. Controlling the immunological crosstalk during conception and pregnancy: HLA-G in reproduction. Front Immunol (2014) 5:198. 10.3389/fimmu.2014.00198 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Martínez-Varea A, Pellicer B, Perales-Marin A, Pellicer A. Relationship between maternal immunological response during pregnancy and onset of preeclampsia. J Immunol Res (2014) 2014:210241. 10.1155/2014/210241 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 133:775–87. 10.1016/j.cell.2008.05.009 [DOI] [PubMed] [Google Scholar]
- 122.Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol (2004) 5:266–71. 10.1038/ni1037 [DOI] [PubMed] [Google Scholar]
- 123.Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update (2009) 15:517–35. 10.1093/humupd/dmp004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Saito S. Th17 cells and regulatory T cells: new light on pathophysiology of preeclampsia. Immunol Cell Biol (2010) 88:615–7. 10.1038/icb.2010.68 [DOI] [PubMed] [Google Scholar]
- 125.Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol (2010) 63:601–10. 10.1111/j.1600-0897.2010.00852.x [DOI] [PubMed] [Google Scholar]
- 126.Clark DA, Chaouat G. Regulatory T cells and reproduction: how do they do it? J Reprod Immunol (2012) 96:1–7. 10.1016/j.jri.2012.07.007 [DOI] [PubMed] [Google Scholar]
- 127.Alijotas-Reig J, Llurba E, Gris JM. Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta (2014) 35:241–8. 10.1016/j.placenta.2014.02.004 [DOI] [PubMed] [Google Scholar]
- 128.Jiang TT, Chaturvedi V, Ertelt JM, Kinder JM, Clark DR, Valent AM, et al. Regulatory T cells: new keys for further unlocking the enigma of fetal tolerance and pregnancy complications. J Immunol (2014) 192:4949–56. 10.4049/jimmunol.1400498 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.La Rocca C, Carbone F, Longobardi S, Matarese G. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett (2014) 162:41–8. 10.1016/j.imlet.2014.06.013 [DOI] [PubMed] [Google Scholar]
- 130.Clark DA. The importance of being a regulatory T cell in pregnancy. J Reprod Immunol (2016) 116:60–9. 10.1016/j.jri.2016.04.288 [DOI] [PubMed] [Google Scholar]
- 131.Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW, Jr, Wallace K, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond) (2016) 130:409–19. 10.1042/CS20150702 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.LaMarca B, Cornelius DC, Harmon AC, Amaral LM, Cunningham MW, Faulkner JL, et al. Identifying immune mechanisms mediating the hypertension during preeclampsia. Am J Physiol Regul Integr Comp Physiol (2016) 311:R1–9. 10.1152/ajpregu.00052.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A. Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. Science (2012) 336:1317–21. 10.1126/science.1220030 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Williams Z. Inducing tolerance to pregnancy. N Engl J Med (2012) 367:1159–61. 10.1056/NEJMcibr1207279 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell (2012) 150:29–38. 10.1016/j.cell.2012.05.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 112:38–43. 10.1111/j.1365-2567.2004.01869.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137.Schumacher A, Zenclussen AC. Effects of heme oxygenase-1 on innate and adaptive immune responses promoting pregnancy success and allograft tolerance. Front Pharmacol (2014) 5:288. 10.3389/fphar.2014.00288 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Carp HJA, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun (2012) 38:J266–74. 10.1016/j.jaut.2011.11.016 [DOI] [PubMed] [Google Scholar]
- 139.Mittrücker H-W, Kaufmann SHE. Mini-review: regulatory T cells and infection: suppression revisited. Eur J Immunol (2004) 34:306–12. 10.1002/eji.200324578 [DOI] [PubMed] [Google Scholar]
- 140.Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol (2007) 7:875–88. 10.1038/nri2189 [DOI] [PubMed] [Google Scholar]
- 141.Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol (2009) 27:551–89. 10.1146/annurev.immunol.021908.132723 [DOI] [PubMed] [Google Scholar]
- 142.Maizels RM, Smith KA. Regulatory T cells in infection. Adv Immunol (2011) 112:73–136. 10.1016/B978-0-12-387827-4.00003-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Sanchez AM, Yang Y. The role of natural regulatory T cells in infection. Immunol Res (2011) 49:124–34. 10.1007/s12026-010-8176-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144.Berod L, Puttur F, Huehn J, Sparwasser T. Tregs in infection and vaccinology: heroes or traitors? Microb Biotechnol (2012) 5:260–9. 10.1111/j.1751-7915.2011.00299.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Williams Z, Zepf D, Longtine J, Anchan R, Broadman B, Missmer SA, et al. Foreign fetal cells persist in the maternal circulation. Fertil Steril (2009) 91:2593–5. 10.1016/j.fertnstert.2008.02.008 [DOI] [PubMed] [Google Scholar]
- 146.Hahn S, Rusterholz C, Hösli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta (2011) 32(Suppl):S17–20. 10.1016/j.placenta.2010.06.018 [DOI] [PubMed] [Google Scholar]
- 147.Visca E, Lapaire O, Hosli I, Hahn S. Cell-free fetal nucleic acids as prenatal biomarkers. Expert Opin Med Diagn (2011) 5:151–60. 10.1517/17530059.2011.554821 [DOI] [PubMed] [Google Scholar]
- 148.Robertson SA, Bromfield JJ, Tremellen KP. Seminal ‘priming’ for protection from pre-eclampsia-a unifying hypothesis. J Reprod Immunol (2003) 59:253–65. 10.1016/S0165-0378(03)00052-4 [DOI] [PubMed] [Google Scholar]
- 149.Getz GS. Thematic review series: the immune system and atherogenesis. Bridging the innate and adaptive immune systems. J Lipid Res (2005) 46:619–22. 10.1194/jlr.E500002-JLR200 [DOI] [PubMed] [Google Scholar]
- 150.Sarma JV, Ward PA. The complement system. Cell Tissue Res (2011) 343:227–35. 10.1007/s00441-010-1034-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Kennedy MA. A brief review of the basics of immunology: the innate and adaptive response. Vet Clin North Am Small Anim Pract (2010) 40:369–79. 10.1016/j.cvsm.2010.01.003 [DOI] [PubMed] [Google Scholar]
- 152.Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol (2011) 7(Suppl 1):S1. 10.1186/1710-1492-7-S1-S1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Abbas AK, Lichtman AH, Pillai S. Basic Immunology: Functions and Disorders of the Immune System. 8th ed St Louis, MO: Elsevier; (2012). [Google Scholar]
- 154.Abbas AK, Lichtman AH, Pillai S. Basic Immunology: Functions and Disorders of the Immune System. 5th ed St Louis, MO: Elsevier; (2016). [Google Scholar]
- 155.Murphy K, Weaver C, editors. Janeway’s Immunobiology. New York: Garland Science; (2016). [Google Scholar]
- 156.Kell DB, Pretorius E. On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biol (2015) 7:1339–77. 10.1039/C5IB00158G [DOI] [PubMed] [Google Scholar]
- 157.Legutki JB, Magee DM, Stafford P, Johnston SA. A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine (2010) 28:4529–37. 10.1016/j.vaccine.2010.04.061 [DOI] [PubMed] [Google Scholar]
- 158.Stafford P, Halperin R, Legutki JB, Magee DM, Galgiani J, Johnston SA. Physical characterization of the “immunosignaturing effect”. Mol Cell Proteomics (2012) 11:M111011593. 10.1074/mcp.M111.011593 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159.Sykes KF, Legutki JB, Stafford P. Immunosignaturing: a critical review. Trends Biotechnol (2013) 31:45–51. 10.1016/j.tibtech.2012.10.012 [DOI] [PubMed] [Google Scholar]
- 160.King AE, Kelly RW, Sallenave J-M, Bocking AD, Challis JRG. Innate immune defences in the human uterus during pregnancy. Placenta (2007) 28:1099–106. 10.1016/j.placenta.2007.06.002 [DOI] [PubMed] [Google Scholar]
- 161.Schminkey DL, Groer M. Imitating a stress response: a new hypothesis about the innate immune system’s role in pregnancy. Med Hypotheses (2014) 82:721–9. 10.1016/j.mehy.2014.03.013 [DOI] [PubMed] [Google Scholar]
- 162.Zhang J, Dunk C, Croy AB, Lye SJ. To serve and to protect: the role of decidual innate immune cells on human pregnancy. Cell Tissue Res (2016) 363:249–65. 10.1007/s00441-015-2315-4 [DOI] [PubMed] [Google Scholar]
- 163.Redman CW. Immunological aspects of pre-eclampsia. Baillieres Clin Obstet Gynaecol (1992) 6:601–15. 10.1016/S0950-3552(05)80012-4 [DOI] [PubMed] [Google Scholar]
- 164.Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Mol Aspects Med (2007) 28:192–209. 10.1016/j.mam.2007.02.006 [DOI] [PubMed] [Google Scholar]
- 165.Visser N, Van Rijn BB, Rijkers GT, Franx A, Bruinse HW. Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv (2007) 62:191–201. 10.1097/01.ogx.0000256779.06275.c4 [DOI] [PubMed] [Google Scholar]
- 166.Brewster JA, Orsi NM, Gopichandran N, Mcshane P, Ekbote UV, Walker JJ. Gestational effects on host inflammatory response in normal and pre-eclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol (2008) 140:21–6. 10.1016/j.ejogrb.2007.12.020 [DOI] [PubMed] [Google Scholar]
- 167.Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol (2013) 94:247–57. 10.1189/jlb.1112603 [DOI] [PubMed] [Google Scholar]
- 168.Perez-Sepulveda A, Torres MJ, Khoury M, Illanes SE. Innate immune system and preeclampsia. Front Immunol (2014) 5:244. 10.3389/fimmu.2014.00244 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 169.Staff AC, Johnsen GM, Dechend R, Redman CWG. Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol (2014) 10(1–102):120–6. 10.1016/j.jri.2013.09.001 [DOI] [PubMed] [Google Scholar]
- 170.Redman CWG, Sargent IL, Taylor RN. Immunology of normal pregnancy and preeclampsia. 4th ed Chesley’s Hypertensive Disorders in Pregnancy. (2015). p. 161–79. 10.1016/B978-0-12-407866-6.00008-0 [DOI] [Google Scholar]
- 171.Parker LC, Prince LR, Sabroe I. Translational mini-review series on toll-like receptors: networks regulated by toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol (2007) 147:199–207. 10.1111/j.1365-2249.2006.03203.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 172.Trinchieri G, Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7:179–90. 10.1038/nri2038 [DOI] [PubMed] [Google Scholar]
- 173.Nelson DE, Ihekwaba AEC, Elliott M, Gibney CA, Foreman BE, Nelson G, et al. Oscillations in NF-κB signalling control the dynamics of gene expression. Science (2004) 306:704–8. 10.1126/science.1099962 [DOI] [PubMed] [Google Scholar]
- 174.Ashall L, Horton CA, Nelson DE, Paszek P, Ryan S, Sillitoe K, et al. Pulsatile stimulation determines timing and specificity of NFkappa-B-dependent transcription. Science (2009) 324:242–6. 10.1126/science.1164860 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 175.Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991–1045. 10.1146/annurev.iy.12.040194.005015 [DOI] [PubMed] [Google Scholar]
- 176.Anderson CC, Matzinger P. Danger: the view from the bottom of the cliff. Semin Immunol (2000) 12:231–8; discussion 257–344. 10.1006/smim.2000.0236 [DOI] [PubMed] [Google Scholar]
- 177.Matzinger P. Essay 1: the danger model in its historical context. Scand J Immunol (2001) 54:4–9. 10.1046/j.1365-3083.2001.00974.x [DOI] [PubMed] [Google Scholar]
- 178.Matzinger P. The danger model: a renewed sense of self. Science (2002) 296:301–5. 10.1126/science.1071059 [DOI] [PubMed] [Google Scholar]
- 179.Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol (2011) 11:221–30. 10.1038/nri2940 [DOI] [PubMed] [Google Scholar]
- 180.Matzinger P. The evolution of the danger theory. Expert Rev Clin Immunol (2012) 8:311–7. 10.1586/eci.12.21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 181.McCarthy CM, Kenny LC. Immunostimulatory role of mitochondrial DAMPs: alarming for pre-eclampsia? Am J Reprod Immunol (2016) 76:341–7. 10.1111/aji.12526 [DOI] [PubMed] [Google Scholar]
- 182.Bonney EA. Preeclampsia: a view through the danger model. J Reprod Immunol (2007) 76:68–74. 10.1016/j.jri.2007.03.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 183.Sacks GP, Studena K, Sargent K, Redman CWG. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol (1998) 179:80–6. 10.1016/S0002-9378(98)70254-6 [DOI] [PubMed] [Google Scholar]
- 184.Redman CWG, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol (1999) 180:499–506. 10.1016/S0002-9378(99)70239-5 [DOI] [PubMed] [Google Scholar]
- 185.Kim YM, Romero R, Oh SY, Kim CJ, Kilburn BA, Armant DR, et al. Toll-like receptor 4: a potential link between “danger signals,” the innate immune system and preeclampsia? Am J Obstet Gynecol (2005) 193:921–7. 10.1016/j.ajog.2005.06.053 [DOI] [PubMed] [Google Scholar]
- 186.Wang CC, Yim KW, Poon TCW, Choy KW, Chu CY, Lui WT, et al. Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem (2007) 53:42–52. 10.1373/clinchem.2007.074401 [DOI] [PubMed] [Google Scholar]
- 187.Yeh CC, Chao KC, Huang SJ. Innate immunity, decidual cells, and preeclampsia. Reprod Sci (2013) 20:339–53. 10.1177/1933719112450330 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 188.Bounds KR, Newell-Rogers MK, Mitchell BM. Four pathways involving innate immunity in the pathogenesis of preeclampsia. Front Cardiovasc Med (2015) 2:20. 10.3389/fcvm.2015.00020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 189.Triggianese P, Perricone C, Chimenti MS, De Carolis C, Perricone R. Innate immune system at the maternal-fetal interface: mechanisms of disease and targets of therapy in pregnancy syndromes. Am J Reprod Immunol (2016) 76:245–57. 10.1111/aji.12509 [DOI] [PubMed] [Google Scholar]
- 190.Redman CWG, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response – a review. Placenta (2003) 24(Suppl A):S21–7. 10.1053/plac.2002.0930 [DOI] [PubMed] [Google Scholar]
- 191.Hubel CA. Dyslipidemia and pre-eclampsia. In: Belfort MA, Lydall F, editors. Pre-Eclampsia-Aetiology and Clinical Practice. Cambridge: Cambridge University Press; (2006). p. 164–82. [Google Scholar]
- 192.Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol (1999) 21:339–59. 10.1007/BF00812261 [DOI] [PubMed] [Google Scholar]
- 193.Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol (2003) 59:161–73. 10.1016/S0165-0378(03)00045-7 [DOI] [PubMed] [Google Scholar]
- 194.Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol (2007) 29:95–113. 10.1007/s00281-007-0069-0 [DOI] [PubMed] [Google Scholar]
- 195.Short SM, Wolfner MF, Lazzaro BP. Female Drosophila melanogaster suffer reduced defense against infection due to seminal fluid components. J Insect Physiol (2012) 58:1192–201. 10.1016/j.jinsphys.2012.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 196.Short SM, Lazzaro BP. Reproductive status alters transcriptomic response to infection in female Drosophila melanogaster. G3 (Bethesda) (2013) 3:827–40. 10.1534/g3.112.005306 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 197.Schjenken JE, Robertson SA. Seminal fluid signalling in the female reproductive tract: implications for reproductive success and offspring health. Adv Exp Med Biol (2015) 868:127–58. 10.1007/978-3-319-18881-2_6 [DOI] [PubMed] [Google Scholar]
- 198.Pejcic-Karapetrovic B, Gurnani K, Russell MS, Finlay BB, Sad S, Krishnan L. Pregnancy impairs the innate immune resistance to Salmonella typhimurium leading to rapid fatal infection. J Immunol (2007) 179:6088–96. 10.4049/jimmunol.179.9.6088 [DOI] [PubMed] [Google Scholar]
- 199.Sappenfield E, Jamieson DJ, Kourtis AP. Pregnancy and susceptibility to infectious diseases. Infect Dis Obstet Gynecol (2013) 2013:752852. 10.1155/2013/752852 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 200.Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med (2014) 370:2211–8. 10.1056/NEJMra1213566 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 201.Kraus TA, Engel SM, Sperling RS, Kellerman L, Lo Y, Wallenstein S, et al. Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J Clin Immunol (2012) 32:300–11. 10.1007/s10875-011-9627-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 202.Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res (2012) 54:254–61. 10.1007/s12026-012-8303-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 203.Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC, et al. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol (2008) 199(354):e351–8. 10.1016/j.ajog.2008.07.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 204.Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol (2008) 198:385.e381–9. 10.1016/j.ajog.2007.10.793 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 205.Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG (2010) 117:456–62. 10.1111/j.1471-0528.2009.02473.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 206.Soto E, Romero R, Richani K, Espinoza J, Chaiworapongsa T, Nien JK, et al. Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 23:646–57. 10.3109/14767050903301009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 207.Girardi G, Prohaszka Z, Bulla R, Tedesco F, Scherjon S. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol (2011) 48:1621–30. 10.1016/j.molimm.2011.04.011 [DOI] [PubMed] [Google Scholar]
- 208.Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obs Gynecol (2011) 117:75–83. 10.1097/AOG.0b013e3181fc3afa [DOI] [PMC free article] [PubMed] [Google Scholar]
- 209.Qing X, Redecha PB, Burmeister MA, Tomlinson S, D’agati VD, Davisson RL, et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int (2011) 79:331–9. 10.1038/ki.2010.393 [DOI] [PubMed] [Google Scholar]
- 210.Buurma A, Cohen D, Veraar K, Schonkeren D, Claas FH, Bruijn JA, et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension (2012) 60:1332–7. 10.1161/HYPERTENSIONAHA.112.194324 [DOI] [PubMed] [Google Scholar]
- 211.Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, et al. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension (2012) 60:712–21. 10.1161/HYPERTENSIONAHA.112.191817 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 212.Denny KJ, Coulthard LG, Finnell RH, Callaway LK, Taylor SM, Woodruff TM. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol (2013) 97:211–6. 10.1016/j.jri.2012.11.006 [DOI] [PubMed] [Google Scholar]
- 213.Denny KJ, Woodruff TM, Taylor SM, Callaway LK. Complement in pregnancy: a delicate balance. Am J Reprod Immunol (2013) 69:3–11. 10.1111/aji.12000 [DOI] [PubMed] [Google Scholar]
- 214.Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol (2014) 71:55–60. 10.1111/aji.12162 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 215.Banadakoppa M, Vidaeff AC, Yallampalli U, Ramin SM, Belfort MA, Yallampalli C. Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia. Dis Markers (2015) 2015:263109. 10.1155/2015/263109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 216.He Y, Xu B, Song D, Yu F, Chen Q, Zhao M. Expression of the complement system’s activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol (2016) 76:205–11. 10.1111/aji.12541 [DOI] [PubMed] [Google Scholar]
- 217.Wu W, Yang H, Feng Y, Zhang P, Li S, Wang X, et al. Polymorphisms in complement genes and risk of preeclampsia in Taiyuan, China. Inflamm Res (2016) 65:837–45. 10.1007/s00011-016-0968-4 [DOI] [PubMed] [Google Scholar]
- 218.Velickovic I, Dalloul M, Wong KA, Bakare O, Schweis F, Garala M, et al. Complement factor B activation in patients with preeclampsia. J Reprod Immunol (2015) 109:94–100. 10.1016/j.jri.2014.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 219.Soto E, Romero R, Vaisbuch E, Erez O, Mazaki-Tovi S, Kusanovic JP, et al. Fragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. J Matern Fetal Neonatal Med (2010) 23:1085–90. 10.3109/14767051003649870 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 220.He Y, Xu B, Song D, Yu F, Chen Q, Zhao M. Correlations between complement system’s activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. Hypertens Pregnancy (2016) 35:499–509. 10.1080/10641955.2016.1190845 [DOI] [PubMed] [Google Scholar]
- 221.Lynch AM, Eckel RH, Murphy JR, Gibbs RS, West NA, Giclas PC, et al. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol (2012) 206:428.e421–28. 10.1016/j.ajog.2012.02.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 222.Halmos A, Rigo J, Jr, Szijarto J, Fust G, Prohaszka Z, Molvarec A. Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin Exp Immunol (2012) 169:49–56. 10.1111/j.1365-2249.2012.04590.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 223.Haeger M, Bengtson A, Karlsson K, Heideman M. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol (1989) 73:551–6. [PubMed] [Google Scholar]
- 224.Haeger M, Unander M, Bengtsson A. Complement activation in relation to development of preeclampsia. Obstet Gynecol (1991) 78:46–9. [PubMed] [Google Scholar]
- 225.Ye Y, Kong Y, Zhang Y. Complement split products C3a/C5a and receptors: are they regulated by circulating angiotensin II type 1 receptor autoantibody in severe preeclampsia? Gynecol Obstet Invest (2016) 81:28–33. 10.1159/000440651 [DOI] [PubMed] [Google Scholar]
- 226.Kestlerová A, Feyereisl J, Frisová V, Měchurová A, Šůla K, Zima T, et al. Immunological and biochemical markers in preeclampsia. J Reprod Immunol (2012) 96:90–4. 10.1016/j.jri.2012.10.002 [DOI] [PubMed] [Google Scholar]
- 227.Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension (2013) 62:1040–5. 10.1161/HYPERTENSIONAHA.113.01420 [DOI] [PubMed] [Google Scholar]
- 228.Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I – molecular mechanisms of activation and regulation. Front Immunol (2015) 6:262. 10.3389/fimmu.2015.00262 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 229.Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol (2015) 6:257. 10.3389/fimmu.2015.00257 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 230.Ponnuraj K, Xu Y, Macon K, Moore D, Volanakis JE, Narayana SVL. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell (2004) 14:17–28. 10.1016/S1097-2765(04)00160-1 [DOI] [PubMed] [Google Scholar]
- 231.Rooijakkers SHM, Wu J, Ruyken M, Van Domselaar R, Planken KL, Tzekou A, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 10:721–7. 10.1038/ni.1756 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 232.Vaisbuch E, Romero R, Erez O, Mazaki-Tovi S, Kusanovic JP, Soto E, et al. Fragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med (2009) 22:905–16. 10.1080/14767050902994663 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 233.Li Q, Li YX, Stahl GL, Thurman JM, He Y, Tong HH. Essential role of factor B of the alternative complement pathway in complement activation and opsonophagocytosis during acute pneumococcal otitis media in mice. Infect Immun (2011) 79:2578–85. 10.1128/IAI.00168-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 234.Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension (2011) 58:716–24. 10.1161/HYPERTENSIONAHA.111.175919 [DOI] [PubMed] [Google Scholar]
- 235.Marti JJ, Herrmann U. Immunogestosis: a new etiologic concept of “essential” EPH gestosis, with special consideration of the primigravid patient; preliminary report of a clinical study. Am J Obstet Gynecol (1977) 128:489–93. 10.1016/0002-9378(77)90030-8 [DOI] [PubMed] [Google Scholar]
- 236.Dekker G, Sukcharoen N. Etiology of preeclampsia: an update. J Med Assoc Thai (2004) 87(Suppl 3):S96–103. [PubMed] [Google Scholar]
- 237.Johansson M, Bromfield JJ, Jasper MJ, Robertson SA. Semen activates the female immune response during early pregnancy in mice. Immunology (2004) 112:290–300. 10.1111/j.1365-2567.2004.01876.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 238.Robertson SA, Guerin LR, Bromfield JJ, Branson KM, Ahlström AC, Care AS. Seminal fluid drives expansion of the CD4+CD25+ T regulatory cell pool and induces tolerance to paternal alloantigens in mice. Biol Reprod (2009) 80:1036–45. 10.1095/biolreprod.108.074658 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 239.Larsen MH, Bzorek M, Pass MB, Larsen LG, Nielsen MW, Svendsen SG, et al. Human leukocyte antigen-G in the male reproductive system and in seminal plasma. Mol Hum Reprod (2011) 17:727–38. 10.1093/molehr/gar052 [DOI] [PubMed] [Google Scholar]
- 240.Hviid TVF. Human leukocyte antigen-G within the male reproductive system: implications for reproduction. Adv Exp Med Biol (2015) 868:171–90. 10.1007/978-3-319-18881-2_8 [DOI] [PubMed] [Google Scholar]
- 241.Anderson DJ, Politch JA. Role of seminal plasma in human female reproductive failure: immunomodulation, inflammation, and infections. Adv Exp Med Biol (2015) 868:159–69. 10.1007/978-3-319-18881-2_7 [DOI] [PubMed] [Google Scholar]
- 242.Milardi D, Grande G, Vincenzoni F, Castagnola M, Marana R. Proteomics of human seminal plasma: identification of biomarker candidates for fertility and infertility and the evolution of technology. Mol Reprod Dev (2013) 80:350–7. 10.1002/mrd.22178 [DOI] [PubMed] [Google Scholar]
- 243.Drabovich AP, Saraon P, Jarvi K, Diamandis EP. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol (2014) 11:278–88. 10.1038/nrurol.2014.74 [DOI] [PubMed] [Google Scholar]
- 244.Robertson SA. Seminal plasma and male factor signalling in the female reproductive tract. Cell Tissue Res (2005) 322:43–52. 10.1007/s00441-005-1127-3 [DOI] [PubMed] [Google Scholar]
- 245.Robertson SA. Seminal fluid signaling in the female reproductive tract: lessons from rodents and pigs. J Anim Sci (2007) 85:E36–44. 10.2527/jas.2006-578 [DOI] [PubMed] [Google Scholar]
- 246.Bromfield JJ. Seminal fluid and reproduction: much more than previously thought. J Assist Reprod Genet (2014) 31:627–36. 10.1007/s10815-014-0243-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 247.Bromfield JJ, Schjenken JE, Chin PY, Care AS, Jasper MJ, Robertson SA. Maternal tract factors contribute to paternal seminal fluid impact on metabolic phenotype in offspring. Proc Natl Acad Sci U S A (2014) 111:2200–5. 10.1073/pnas.1305609111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 248.Robertson SA, Sharkey DJ. Seminal fluid and fertility in women. Fertil Steril (2016) 106:511–9. 10.1016/j.fertnstert.2016.07.1101 [DOI] [PubMed] [Google Scholar]
- 249.García-Montalvo IA, Mayoral Andrade G, Perez-Campos Mayoral L, Pina Canseco S, Martinez Cruz R, Martinez-Cruz M, et al. Molecules in seminal plasma related to platelets in preeclampsia. Med Hypotheses (2016) 93:27–9. 10.1016/j.mehy.2016.05.009 [DOI] [PubMed] [Google Scholar]
- 250.Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD. Activating T regulatory cells for tolerance in early pregnancy – the contribution of seminal fluid. J Reprod Immunol (2009) 83:109–16. 10.1016/j.jri.2009.08.003 [DOI] [PubMed] [Google Scholar]
- 251.Robertson SA, Prins JR, Sharkey DJ, Moldenhauer LM. Seminal fluid and the generation of regulatory T cells for embryo implantation. Am J Reprod Immunol (2013) 69:315–30. 10.1111/aji.12107 [DOI] [PubMed] [Google Scholar]
- 252.Shima T, Inada K, Nakashima A, Ushijima A, Ito M, Yoshino O, et al. Paternal antigen-specific proliferating regulatory T cells are increased in uterine-draining lymph nodes just before implantation and in pregnant uterus just after implantation by seminal plasma-priming in allogeneic mouse pregnancy. J Reprod Immunol (2015) 108:72–82. 10.1016/j.jri.2015.02.005 [DOI] [PubMed] [Google Scholar]
- 253.Saito S, Shima T, Nakashima A, Inada K, Yoshino O. Role of paternal antigen-specific treg cells in successful implantation. Am J Reprod Immunol (2016) 75:310–6. 10.1111/aji.12469 [DOI] [PubMed] [Google Scholar]
- 254.Okazaki T, Akiyoshi T, Kan M, Mori M, Teshima H, Shimada M. Artificial insemination with seminal plasma improves the reproductive performance of frozen-thawed boar epididymal spermatozoa. J Androl (2012) 33:990–8. 10.2164/jandrol.111.015115 [DOI] [PubMed] [Google Scholar]
- 255.Bromfield JJ. A role for seminal plasma in modulating pregnancy outcomes in domestic species. Reproduction (2016) 152:R223–32. 10.1530/REP-16-0313 [DOI] [PubMed] [Google Scholar]
- 256.Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J (2005) 330:565–7. 10.1136/bmj.38380.674340.E0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 257.Bartsch E, Medcalf KE, Park AL, Ray JG, High Risk of Pre-eclampsia Identification Group . Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ (2016) 353:i1753. 10.1136/bmj.i1753 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 258.Bdolah Y, Elchalal U, Natanson-Yaron S, Yechiam H, Bdolah-Abram T, Greenfield C, et al. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy (2014) 33:250–9. 10.3109/10641955.2013.858745 [DOI] [PubMed] [Google Scholar]
- 259.Tandberg A, Klungsoyr K, Romundstad LB, Skjaerven R. Pre-eclampsia and assisted reproductive technologies: consequences of advanced maternal age, interbirth intervals, new partner and smoking habits. BJOG (2015) 122:915–22. 10.1111/1471-0528.13051 [DOI] [PubMed] [Google Scholar]
- 260.Robillard PY, Hulsey TC, Perianin J, Janky E, Miri EH, Papiernik E. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet (1994) 344:973–5. 10.1016/S0140-6736(94)91638-1 [DOI] [PubMed] [Google Scholar]
- 261.Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol (2003) 188:1241–3. 10.1067/mob.2003.401 [DOI] [PubMed] [Google Scholar]
- 262.Saftlas AF, Levine RJ, Klebanoff MA, Martz KL, Ewell MG, Morris CD, et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol (2003) 157:1108–14. 10.1093/aje/kwg101 [DOI] [PubMed] [Google Scholar]
- 263.Klonoff-Cohen HS, Savitz DA, Cefalo RC, Mccann MF. An epidemiologic study of contraception and preeclampsia. JAMA (1989) 262:3143–7. 10.1001/jama.262.22.3143 [DOI] [PubMed] [Google Scholar]
- 264.Hernández-Valencia M, Saldaña Quezada L, Alvarez Muñoz M, Valdez Martínez E. Barrier family planning methods as risk factor which predisposes to preeclampsia. Ginecol Obstet Mex (2000) 68:333–8. [PubMed] [Google Scholar]
- 265.Letur-Köenirsch H, Peigné M, Ohl J, Cédrin I, D’argent EM, Scheffler F, et al. Pregnancies issued from egg donation are associated to a higher risk of hypertensive pathologies then control ART pregnancies. Results of a large comparative cohort study. Hum Reprod (2014) 29:68–9. [Google Scholar]
- 266.Letur H, Peigné M, Ohl J, Cédrin-Durnerin I, Mathieu-D’argent E, Scheffler F, et al. Hypertensive pathologies and egg donation pregnancies: results of a large comparative cohort study. Fertil Steril (2016) 106:284–90. 10.1016/j.fertnstert.2016.03.031 [DOI] [PubMed] [Google Scholar]
- 267.Tarlatzi TB, Imbert R, Alvaro Mercadal B, Demeestere I, Venetis CA, Englert Y, et al. Does oocyte donation compared with autologous oocyte IVF pregnancies have a higher risk of preeclampsia? Reprod Biomed Online (2017) 34:11–8. 10.1016/j.rbmo.2016.10.002 [DOI] [PubMed] [Google Scholar]
- 268.Giannubilo SR, Landi B, Ciavattini A. Preeclampsia: what could happen in a subsequent pregnancy? Obstet Gynecol Surv (2014) 69:747–62. 10.1097/OGX.0000000000000126 [DOI] [PubMed] [Google Scholar]
- 269.Koelman CA, Coumans ABC, Nijman HW, Doxiadis IIN, Dekker GA, Claas FHJ. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol (2000) 46:155–66. 10.1016/S0165-0378(99)00062-5 [DOI] [PubMed] [Google Scholar]
- 270.Martin RD. A Biological Function for Oral Sex? Psychology Today (2016). Available from: https://www.psychologytoday.com/blog/how-we-do-it/201602/biological-function-oral-sex
- 271.Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United-States, 1979–1986. Am J Obstet Gynecol (1990) 163:460–5. 10.1016/0002-9378(90)91176-D [DOI] [PubMed] [Google Scholar]
- 272.Zhang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev (1997) 19:218–32. 10.1093/oxfordjournals.epirev.a017954 [DOI] [PubMed] [Google Scholar]
- 273.Lamminpää R, Vehvilainen-Julkunen K, Gissler M, Heinonen S. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997–2008. BMC Pregnancy Childbirth (2012) 12:47. 10.1186/1471-2393-12-47 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 274.Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ (2013) 347:f6564. 10.1136/bmj.f6564 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 275.Carolan M. Maternal age >= 45 years and maternal and perinatal outcomes: a review of the evidence. Midwifery (2013) 29:479–89. 10.1016/j.midw.2012.04.001 [DOI] [PubMed] [Google Scholar]
- 276.Need JA, Bell B, Meffin E, Jones WR. Pre-eclampsia in pregnancies from donor inseminations. J Reprod Immunol (1983) 5:329–38. 10.1016/0165-0378(83)90242-5 [DOI] [PubMed] [Google Scholar]
- 277.Smith GN, Walker M, Tessier JL, Millar KG. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obs Gynecol (1997) 177:455–8. 10.1016/S0002-9378(97)70215-1 [DOI] [PubMed] [Google Scholar]
- 278.Hoy J, Venn A, Halliday J, Kovacs G, Waalwyk K. Perinatal and obstetric outcomes of donor insemination using cryopreserved semen in Victoria, Australia. Hum Reprod (1999) 14:1760–4. 10.1093/humrep/14.7.1760 [DOI] [PubMed] [Google Scholar]
- 279.Davis JA, Gallup GG. Preeclampsia and other pregnancy complications as an adaptive response to unfamiliar semen. In: Platek SM, Shackelford TK, editors. Female Infidelity and Paternal Uncertainty: Evolutionary Perspectives on Male Anti-Cuckoldry Tactics. Cambridge: CUPpip; (2006). p. 191–204. [Google Scholar]
- 280.Gleicher N, Boler LR, Jr, Norusis M, Del Granado A. Hypertensive diseases of pregnancy and parity. Am J Obstet Gynecol (1986) 154:1044–9. 10.1016/0002-9378(86)90747-7 [DOI] [PubMed] [Google Scholar]
- 281.Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet (1993) 341:1447–51. 10.1016/0140-6736(93)90889-O [DOI] [PubMed] [Google Scholar]
- 282.Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet (2005) 365:785–99. 10.1016/S0140-6736(05)71003-5 [DOI] [PubMed] [Google Scholar]
- 283.Luo ZC, An N, Xu HR, Larante A, Audibert F, Fraser WD. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol (2007) 21(Suppl 1):36–45. 10.1111/j.1365-3016.2007.00836.x [DOI] [PubMed] [Google Scholar]
- 284.Hernández-Díaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ (2009) 338:b2255. 10.1136/bmj.b2255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 285.Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Health of children born to mothers who had preeclampsia: a population-based cohort study. Am J Obstet Gynecol (2009) 201:269.e261–269.e210. 10.1016/j.ajog.2009.06.060 [DOI] [PubMed] [Google Scholar]
- 286.Wikström AK, Gunnarsdóttir J, Cnattingius S. The paternal role in pre-eclampsia and giving birth to a small for gestational age infant; a population-based cohort study. BMJ Open (2012) 2:e001178. 10.1136/bmjopen-2012-001178 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 287.English FA, Kenny LC, Mccarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control (2015) 8:7–12. 10.2147/IBPC.S50641 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 288.Rich-Edwards JW, Ness RB, Roberts JM. Epidemiology of pregnancy-related hypertension. 4th ed Chesley’s Hypertensive Disorders in Pregnancy. (2015). p. 37–55. 10.1016/B978-0-12-407866-6.00003-1 [DOI] [Google Scholar]
- 289.Dildy GA, III, Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol (2007) 31:135–41. 10.1053/j.semperi.2007.03.005 [DOI] [PubMed] [Google Scholar]
- 290.Conde-Agudelo A, Belizán JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. BJOG (2000) 107:75–83. 10.1111/j.1471-0528.2000.tb11582.x [DOI] [PubMed] [Google Scholar]
- 291.Feeney JG, Scott JS. Pre-eclampsia and changed paternity. Eur J Obstet Gynecol Reprod Biol (1980) 11:35–8. 10.1016/0028-2243(80)90051-9 [DOI] [PubMed] [Google Scholar]
- 292.Ikedife D. Eclampsia in multipara. Br Med J (1980) 280:985–6. 10.1136/bmj.280.6219.985-a [DOI] [PMC free article] [PubMed] [Google Scholar]
- 293.Chng PK. Occurrence of pre-eclampsia in pregnancies to three husbands. Case report. Br J Obstet Gynaecol (1982) 89:862–3. 10.1111/j.1471-0528.1982.tb05042.x [DOI] [PubMed] [Google Scholar]
- 294.Robillard PY, Hulsey TC, Alexander GR, Keenan A, De Caunes F, Papiernik E. Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol (1993) 24:1–12. 10.1016/0165-0378(93)90032-D [DOI] [PubMed] [Google Scholar]
- 295.Trupin LS, Simon LP, Eskenazi B. Change in paternity: a risk factor for preeclampsia in multiparas. Epidemiology (1996) 7:240–4. 10.1097/00001648-199605000-00004 [DOI] [PubMed] [Google Scholar]
- 296.Robillard PY, Dekker GA, Hulsey TC. Revisiting the epidemiological standard of preeclampsia: primigravidity or primipaternity? Eur J Obstet Gynecol Reprod Biol (1999) 84:37–41. 10.1016/S0301-2115(98)00250-4 [DOI] [PubMed] [Google Scholar]
- 297.Tubbergen P, Lachmeijer AMA, Althuisius SM, Vlak MEJ, Van Geijn HP, Dekker GA. Change in paternity: a risk factor for preeclampsia in multiparous women? J Reprod Immunol (1999) 45:81–8. 10.1016/S0165-0378(99)00040-6 [DOI] [PubMed] [Google Scholar]
- 298.Li DK, Wi S. Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol (2000) 151:57–62. 10.1093/oxfordjournals.aje.a010122 [DOI] [PubMed] [Google Scholar]
- 299.Dekker GA, Robillard PY. Preeclampsia: a couple’s disease with maternal and fetal manifestations. Curr Pharm Des (2005) 11:699–710. 10.2174/1381612053381828 [DOI] [PubMed] [Google Scholar]
- 300.Deen ME, Ruurda LG, Wang J, Dekker GA. Risk factors for preeclampsia in multiparous women: primipaternity versus the birth interval hypothesis. J Matern Fetal Neonatal Med (2006) 19:79–84. 10.1080/14767050500361653 [DOI] [PubMed] [Google Scholar]
- 301.Dekker G, Robillard PY, Roberts C. The etiology of preeclampsia: the role of the father. J Reprod Immunol (2011) 89:126–32. 10.1016/j.jri.2010.12.010 [DOI] [PubMed] [Google Scholar]
- 302.Nagayama S, Ohkuchi A, Usui R, Matsubara S, Suzuki M. The role of the father in the occurrence of preeclampsia. Med J Obs Gynecol (2014) 2:1029–32. [Google Scholar]
- 303.Robillard PY, Dekker G, Chaouat G, Scioscia M, Iacobelli S, Hulsey TC. Historical evolution of ideas on eclampsia/preeclampsia: a proposed optimistic view of preeclampsia. J Reprod Immunol (2017) 123:72–7. 10.1016/j.jri.2017.09.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 304.Trogstad LIS, Eskild A, Magnus P, Samuelsen SO, Nesheim BI. Changing paternity and time since last pregnancy; the impact on pre-eclampsia risk. A study of 547 238 women with and without previous pre-eclampsia. Int J Epidemiol (2001) 30:1317–22. 10.1093/ije/30.6.1317 [DOI] [PubMed] [Google Scholar]
- 305.Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ (1998) 316:1343–7. 10.1136/bmj.316.7141.1343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 306.Triche EW, Harland KK, Field EH, Rubenstein LM, Saftlas AF. Maternal-fetal HLA sharing and preeclampsia: variation in effects by seminal fluid exposure in a case-control study of nulliparous women in Iowa. J Reprod Immunol (2014) 101-102:111–9. 10.1016/j.jri.2013.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 307.Saftlas AF, Rubenstein L, Prater K, Harland KK, Field E, Triche EW. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol (2014) 101-102:104–10. 10.1016/j.jri.2013.07.006 [DOI] [PubMed] [Google Scholar]
- 308.Kho EM, Mccowan LM, North RA, Roberts CT, Chan E, Black MA, et al. Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome. J Reprod Immunol (2009) 82:66–73. 10.1016/j.jri.2009.04.011 [DOI] [PubMed] [Google Scholar]
- 309.Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ (2007) 335:974. 10.1136/bmj.39335.385301.BE [DOI] [PMC free article] [PubMed] [Google Scholar]
- 310.Salha O, Sharma V, Dada T, Nugent D, Rutherford AJ, Tomlinson AJ, et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod (1999) 14:2268–73. 10.1093/humrep/14.9.2268 [DOI] [PubMed] [Google Scholar]
- 311.Gelbaya TA. Short and long-term risks to women who conceive through in vitro fertilization. Hum Fertil (Camb) (2010) 13:19–27. 10.3109/14647270903437923 [DOI] [PubMed] [Google Scholar]
- 312.van der Hoorn ML, Lashley EE, Bianchi DW, Claas FH, Schonkeren CM, Scherjon SA. Clinical and immunologic aspects of egg donation pregnancies: a systematic review. Hum Reprod Update (2010) 16:704–12. 10.1093/humupd/dmq017 [DOI] [PubMed] [Google Scholar]
- 313.Masoudian P, Nasr A, De Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. Am J Obstet Gynecol (2016) 214:328–39. 10.1016/j.ajog.2015.11.020 [DOI] [PubMed] [Google Scholar]
- 314.Porreco RP, Heyborne KD. Immunogenesis of preeclampsia: lessons from donor gametes. J Matern Fetal Neonatal Med (2017):1–7. 10.1080/14767058.2017.1309385 [DOI] [PubMed] [Google Scholar]
- 315.Dude AM, Yeh JS, Muasher SJ. Donor oocytes are associated with preterm birth when compared to fresh autologous in vitro fertilization cycles in singleton pregnancies. Fertil Steril (2016) 106:660–5. 10.1016/j.fertnstert.2016.05.029 [DOI] [PubMed] [Google Scholar]
- 316.Stoop D, Baumgarten M, Haentjens P, Polyzos NP, De Vos M, Verheyen G, et al. Obstetric outcome in donor oocyte pregnancies: a matched-pair analysis. Reprod Biol Endocrinol (2012) 10:42. 10.1186/1477-7827-10-42 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 317.Levron Y, Dviri M, Segol I, Yerushalmi GM, Hourvitz A, Orvieto R, et al. The ’immunologic theory’ of preeclampsia revisited: a lesson from donor oocyte gestations. Am J Obstet Gynecol (2014) 211(383):e381–5. 10.1016/j.ajog.2014.03.044 [DOI] [PubMed] [Google Scholar]
- 318.Fox NS, Roman AS, Saltzman DH, Hourizadeh T, Hastings J, Rebarber A. Risk factors for preeclampsia in twin pregnancies. Am J Perinatol (2014) 31:163–6. 10.1055/s-0033-1343775 [DOI] [PubMed] [Google Scholar]
- 319.Thomopoulos C, Salamalekis G, Kintis K, Andrianopoulou I, Michalopoulou H, Skalis G, et al. Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis. J Clin Hypertens (Greenwich) (2017) 19:173–83. 10.1111/jch.12945 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 320.Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Vernaeve V. Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. J Assist Reprod Genet (2016) 33:855–63. 10.1007/s10815-016-0701-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 321.Klatsky PC, Delaney SS, Caughey AB, Tran ND, Schattman GL, Rosenwaks Z. The role of embryonic origin in preeclampsia: a comparison of autologous in vitro fertilization and ovum donor pregnancies. Obstet Gynecol (2010) 116:1387–92. 10.1097/AOG.0b013e3181fb8e59 [DOI] [PubMed] [Google Scholar]
- 322.Kroon B, Hart RJ, Wong BM, Ford E, Yazdani A. Antibiotics prior to embryo transfer in ART. Cochrane Database Syst Rev (2012) (3):CD008995. 10.1002/14651858.CD008995.pub2 [DOI] [PubMed] [Google Scholar]
- 323.Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol (1991) 165:1408–12. 10.1016/S0002-9378(12)90773-5 [DOI] [PubMed] [Google Scholar]
- 324.van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol (2006) 195:723–8. 10.1016/j.ajog.2006.06.044 [DOI] [PubMed] [Google Scholar]
- 325.Mostello D, Kallogjeri D, Tungsiripat R, Leet T. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol (2008) 199(55):e51–7. 10.1016/j.ajog.2007.11.058 [DOI] [PubMed] [Google Scholar]
- 326.Rasmussen S, Irgens LM, Albrechtsen S, Dalaker K. Predicting preeclampsia in the second pregnancy from low birth weight in the first pregnancy. Obstet Gynecol (2000) 96:696–700. 10.1097/00006250-200011000-00010 [DOI] [PubMed] [Google Scholar]
- 327.Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi JC, Verschoor CP, et al. Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host Microbe (2017) 21(455–466):e454. 10.1016/j.chom.2017.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 328.Astin M, Scott JR, Worley RJ. Pre-eclampsia/eclampsia: a fatal father factor. Lancet (1981) 2:533. 10.1016/S0140-6736(81)90925-9 [DOI] [PubMed] [Google Scholar]
- 329.Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet (2002) 359:673–4. 10.1016/S0140-6736(02)07804-2 [DOI] [PubMed] [Google Scholar]
- 330.Le Ray C, Scherier S, Anselem O, Marszalek A, Tsatsaris V, Cabrol D, et al. Association between oocyte donation and maternal and perinatal outcomes in women aged 43 years or older. Hum Reprod (2012) 27:896–901. 10.1093/humrep/der469 [DOI] [PubMed] [Google Scholar]
- 331.González-Comadran M, Avila JU, Tascón AS, Jimenéz R, Solà I, Brassesco M, et al. The impact of donor insemination on the risk of preeclampsia: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol (2014) 182:160–6. 10.1016/j.ejogrb.2014.09.022 [DOI] [PubMed] [Google Scholar]
- 332.Thomopoulos C, Tsioufis C, Michalopoulou H, Makris T, Papademetriou V, Stefanadis C. Assisted reproductive technology and pregnancy-related hypertensive complications: a systematic review. J Hum Hypertens (2013) 27:148–57. 10.1038/jhh.2012.13 [DOI] [PubMed] [Google Scholar]
- 333.Baud D, Greub G. Intracellular bacteria and adverse pregnancy outcomes. Clin Microbiol Infect (2011) 17:1312–22. 10.1111/j.1469-0691.2011.03604.x [DOI] [PubMed] [Google Scholar]
- 334.Vigliani MB, Bakardjiev AI. Intracellular organisms as placental invaders. Fetal Matern Med Rev (2014) 25:332–8. 10.1017/S0965539515000066 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 335.Parnell LA, Briggs CM, Cao B, Delannoy-Bruno O, Schrieffer AE, Mysorekar IU. Microbial communities in placentas from term normal pregnancy exhibit spatially variable profiles. Sci Rep (2017) 7:11200. 10.1038/s41598-017-11514-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 336.Wu H, Estill MS, Shershebnev A, Suvorov A, Krawetz SA, Whitcomb BW, et al. Preconception urinary phthalate concentrations and sperm DNA methylation profiles among men undergoing IVF treatment: a cross-sectional study. Hum Reprod (2017) 32(11):2159–69. 10.1093/humrep/dex283 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 337.Verstraelen H, Senok AC. Vaginal lactobacilli, probiotics, and IVF. Reprod Biomed Online (2005) 11:674–5. 10.1016/S1472-6483(10)61683-5 [DOI] [PubMed] [Google Scholar]
- 338.Sirota I, Zarek SM, Segars JH. Potential influence of the microbiome on infertility and assisted reproductive technology. Semin Reprod Med (2014) 32:35–42. 10.1055/s-0033-1361821 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 339.Reid G, Brigidi P, Burton JP, Contractor N, Duncan S, Fargier E, et al. Microbes central to human reproduction. Am J Reprod Immunol (2015) 73:1–11. 10.1111/aji.12319 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 340.Xie F, Hu Y, Magee LA, Money DM, Patrick DM, Brunham RM, et al. Chlamydia pneumoniae infection in preeclampsia. Hypertens Pregnancy (2010) 29:468–77. 10.3109/10641950903242642 [DOI] [PubMed] [Google Scholar]
- 341.Heine RP, Ness RB, Roberts JM. Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia. Obstet Gynecol (2003) 101:221–6. 10.1016/S0029-7844(02)02591-7 [DOI] [PubMed] [Google Scholar]
- 342.El-Shourbagy MAA, El-Refaie TA, Sayed KKA, Wahba KAH, El-Din ASS, Fathy MM. Impact of seroconversion and antichlamydial treatment on the rate of pre-eclampsia among Egyptian primigravidae. Int J Gynaecol Obstet (2011) 113:137–40. 10.1016/j.ijgo.2010.11.014 [DOI] [PubMed] [Google Scholar]
- 343.Mosbah A, Nabiel Y. Helicobacter pylori, Chlamydiae pneumoniae and trachomatis as probable etiological agents of preeclampsia. J Matern Fetal Neonat Med (2016) 29:1607–12. 10.3109/14767058.2015.1056146 [DOI] [PubMed] [Google Scholar]
- 344.Gomez LM, Parry S. Trophoblast infection with Chlamydia pneumoniae and adverse pregnancy outcomes associated with placental dysfunction. Am J Obstet Gynecol (2009) 200(526):e521–7. 10.1016/j.ajog.2009.03.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 345.Haggerty CL, Klebanoff MA, Panum I, Uldum SA, Bass DC, Olsen J, et al. Prenatal Chlamydia trachomatis infection increases the risk of preeclampsia. Pregnancy Hypertens (2013) 3:151–4. 10.1016/j.preghy.2013.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 346.Haggerty CL, Panum I, Uldum SA, Bass DC, Olsen J, Darville T, et al. Chlamydia trachomatis infection may increase the risk of preeclampsia. Pregnancy Hypertens (2013) 3:28–33. 10.1016/j.preghy.2012.09.002 [DOI] [PubMed] [Google Scholar]
- 347.Xie F, Hu Y, Magee LA, Money DM, Patrick DM, Krajden M, et al. An association between cytomegalovirus infection and pre-eclampsia: a case-control study and data synthesis. Acta Obstet Gynecol Scand (2010) 89:1162–7. 10.3109/00016349.2010.499449 [DOI] [PubMed] [Google Scholar]
- 348.Xie F, Von Dadelszen P, Nadeau J. CMV infection, TLR-2 and -4 expression, and cytokine profiles in early-onset preeclampsia with HELLP syndrome. Am J Reprod Immunol (2014) 71:379–86. 10.1111/aji.12199 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 349.Ponzetto A, Cardaropoli S, Piccoli E, Rolfo A, Gennero L, Kanduc D, et al. Pre-eclampsia is associated with Helicobacter pylori seropositivity in Italy. J Hypertens (2006) 24:2445–9. 10.1097/HJH.0b013e3280109e8c [DOI] [PubMed] [Google Scholar]
- 350.Panarelli M, Sattar N. Pre-eclampsia associated with Helicobacter pylori seropositivity. J Hypertens (2006) 24:2353–4. 10.1097/HJH.0b013e3280113638 [DOI] [PubMed] [Google Scholar]
- 351.Tersigni C, Franceschi F, Todros T, Cardaropoli S, Scambia G, Di Simone N. Insights into the role of Helicobacter pylori infection in preeclampsia: from the bench to the bedside. Front Immunol (2014) 5:484. 10.3389/fimmu.2014.00484 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 352.Üstün Y, Engin-Üstün Y, Ozkaplan E, Otlu B, Sait Tekerekoğlu M. Association of Helicobacter pylori infection with systemic inflammation in preeclampsia. J Matern Fetal Neonatal Med (2010) 23:311–4. 10.3109/14767050903121456 [DOI] [PubMed] [Google Scholar]
- 353.Aksoy H, Ozkan A, Aktas F, Borekci B. Helicobacter pylori seropositivity and its relationship with serum malondialdehyde and lipid profile in preeclampsia. J Clin Lab Anal (2009) 23:219–22. 10.1002/jcla.20330 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 354.Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol (2014) 20:654–64. 10.3748/wjg.v20.i3.654 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 355.Pugliese A, Beltramo T, Todros T, Cardaropoli S, Ponzetto A. Interleukin-18 and gestosis: correlation with Helicobacter pylori seropositivity. Cell Biochem Funct (2008) 26:817–9. 10.1002/cbf.1503 [DOI] [PubMed] [Google Scholar]
- 356.Cardaropoli S, Giuffrida D, Piazzese A, Todros T. Helicobacter pylori seropositivity and pregnancy-related diseases: a prospective cohort study. J Reprod Immunol (2015) 109:41–7. 10.1016/j.jri.2015.02.004 [DOI] [PubMed] [Google Scholar]
- 357.Cardaropoli S, Rolfo A, Piazzese A, Ponzetto A, Todros T. Helicobacter pylori’s virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation. World J Gastroenterol (2011) 17:5156–65. 10.3748/wjg.v17.i47.5156 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 358.den Hollander WJ, Schalekamp-Timmermans S, Holster IL, Jaddoe VW, Hofman A, Moll HA, et al. Helicobacter pylori colonization and pregnancies complicated by preeclampsia, spontaneous prematurity, and small for gestational age birth. Helicobacter (2017) 22:e12364. 10.1111/hel.12364 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 359.Sansone M, Sarno L, Saccone G, Berghella V, Maruotti GM, Migliucci A, et al. Risk of preeclampsia in human immunodeficiency virus-infected pregnant women. Obstet Gynecol (2016) 127:1027–32. 10.1097/AOG.0000000000001424 [DOI] [PubMed] [Google Scholar]
- 360.McDonnold M, Dunn H, Hester A, Pacheco LD, Hankins GD, Saade GR, et al. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol (2014) 210(138):e131–5. 10.1016/j.ajog.2013.09.040 [DOI] [PubMed] [Google Scholar]
- 361.Hill JA, Devoe LD, Bryans CI, Jr. Frequency of asymptomatic bacteriuria in preeclampsia. Obstet Gynecol (1986) 67:529–32. [PubMed] [Google Scholar]
- 362.Hsu CD, Witter FR. Urogenital infection in preeclampsia. Int J Gynaecol Obstet (1995) 49:271–5. 10.1016/0020-7292(95)02373-K [DOI] [PubMed] [Google Scholar]
- 363.Mittendorf R, Lain KY, Williams MA, Walker CK. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med (1996) 41:491–6. [PubMed] [Google Scholar]
- 364.Easter SR, Cantonwine DE, Zera CA, Lim KH, Parry SI, Mcelrath TF. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia. Am J Obs Gynecol (2016) 214:387.e1–7. 10.1016/j.ajog.2015.09.101 [DOI] [PubMed] [Google Scholar]
- 365.Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome? J Matern Fetal Neonatal Med (2009) 22:124–8. 10.1080/14767050802488246 [DOI] [PubMed] [Google Scholar]
- 366.Minassian C, Thomas SL, Williams DJ, Campbell O, Smeeth L. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. PLoS One (2013) 8:e73047. 10.1371/journal.pone.0073047 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 367.Rezavand N, Veisi F, Zangane M, Amini R, Almasi A. Association between asymptomatic bacteriuria and pre-eclampsia. Glob J Health Sci (2016) 8:235–9. 10.5539/gjhs.v8n7p235 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 368.Karmon A, Sheiner E. The relationship between urinary tract infection during pregnancy and preeclampsia: causal, confounded or spurious? Arch Gynecol Obstet (2008) 277:479–81. 10.1007/s00404-008-0643-2 [DOI] [PubMed] [Google Scholar]
- 369.Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba’aqeel H, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol (2006) 194:921–31. 10.1016/j.ajog.2005.10.813 [DOI] [PubMed] [Google Scholar]
- 370.Bánhidy F, Ács N, Puhó EH, Czeizel AE. Pregnancy complications and birth outcomes of pregnant women with urinary tract infections and related drug treatments. Scand J Infect Dis (2007) 39:390–7. 10.1080/00365540601087566 [DOI] [PubMed] [Google Scholar]
- 371.Ide M, Papapanou PN. Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes – systematic review. J Periodontol (2013) 84:S181–94. 10.1902/jop.2013.134009 [DOI] [PubMed] [Google Scholar]
- 372.Dunlop AL, Mulle JG, Ferranti EP, Edwards S, Dunn AB, Corwin EJ. Maternal microbiome and pregnancy outcomes that impact infant health: a review. Adv Neonatal Care (2015) 15:377–85. 10.1097/ANC.0000000000000218 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 373.Doron MW, Makhlouf RA, Katz VL, Lawson EE, Stiles AD. Increased incidence of sepsis at birth in neutropenic infants of mothers with preeclampsia. J Pediatr (1994) 125:452–8. 10.1016/S0022-3476(05)83294-9 [DOI] [PubMed] [Google Scholar]
- 374.Wei B-J, Chen Y-J, Yu L, Wu B. Periodontal disease and risk of preeclampsia: a meta-analysis of observational studies. PLoS One (2013) 8:e70901. 10.1371/journal.pone.0070901 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 375.Shetty M, Shetty PK, Ramesh A, Thomas B, Prabhu S, Rao A. Periodontal disease in pregnancy is a risk factor for preeclampsia. Acta Obstet Gynecol Scand (2010) 89:718–21. 10.3109/00016341003623738 [DOI] [PubMed] [Google Scholar]
- 376.Kumar A, Basra M, Begum N, Rani V, Prasad S, Lamba AK, et al. Association of maternal periodontal health with adverse pregnancy outcome. J Obstet Gynaecol Res (2013) 39:40–5. 10.1111/j.1447-0756.2012.01957.x [DOI] [PubMed] [Google Scholar]
- 377.Amarasekara R, Jayasekara RW, Senanayake H, Dissanayake VHW. Microbiome of the placenta in pre-eclampsia supports the role of bacteria in the multifactorial cause of pre-eclampsia. J Obstet Gynaecol Res (2015) 41:662–9. 10.1111/jog.12619 [DOI] [PubMed] [Google Scholar]
- 378.Hlimi T. Association of anemia, pre-eclampsia and eclampsia with seasonality: a realist systematic review. Health Place (2015) 31:180–92. 10.1016/j.healthplace.2014.12.003 [DOI] [PubMed] [Google Scholar]
- 379.Brabin BJ, Johnson PM. Placental malaria and pre-eclampsia through the looking glass backwards? J Reprod Immunol (2005) 65:1–15. 10.1016/j.jri.2004.09.006 [DOI] [PubMed] [Google Scholar]
- 380.Anya SE. Seasonal variation in the risk and causes of maternal death in the Gambia: malaria appears to be an important factor. Am J Trop Med Hyg (2004) 70:510–3. [PubMed] [Google Scholar]
- 381.Sartelet H, Rogier C, Milko-Sartelet I, Angel G, Michel G. Malaria associated pre-eclampsia in Senegal. Lancet (1996) 347:1121. 10.1016/S0140-6736(96)90321-9 [DOI] [PubMed] [Google Scholar]
- 382.Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol (2015) 73:199–213. 10.1111/aji.12355 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 383.Racicot K, Mor G. Risks associated with viral infections during pregnancy. J Clin Invest (2017) 127:1591–9. 10.1172/JCI87490 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 384.Keck C, Gerber-Schafer C, Clad A, Wilhelm C, Breckwoldt M. Seminal tract infections: impact on male fertility and treatment options. Hum Reprod Update (1998) 4:891–903. 10.1093/humupd/4.6.891 [DOI] [PubMed] [Google Scholar]
- 385.Ochsendorf FR. Sexually transmitted infections: impact on male fertility. Andrologia (2008) 40:72–5. 10.1111/j.1439-0272.2007.00825.x [DOI] [PubMed] [Google Scholar]
- 386.Swidsinski A, Dörffel Y, Loening-Baucke V, Mendling W, Verstraelen H, Dieterle S, et al. Desquamated epithelial cells covered with a polymicrobial biofilm typical for bacterial vaginosis are present in randomly selected cryopreserved donor semen. FEMS Immunol Med Microbiol (2010) 59:399–404. 10.1111/j.1574-695X.2010.00688.x [DOI] [PubMed] [Google Scholar]
- 387.Gallo MF, Warner L, King CC, Sobel JD, Klein RS, Cu-Uvin S, et al. Association between semen exposure and incident bacterial vaginosis. Infect Dis Obstet Gynecol (2011) 2011:842652. 10.1155/2011/842652 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 388.Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update (1999) 5:433–47. 10.1093/humupd/5.5.433 [DOI] [PubMed] [Google Scholar]
- 389.Rando OJ, Simmons RA. I’m eating for two: parental dietary effects on offspring metabolism. Cell (2015) 161:93–105. 10.1016/j.cell.2015.02.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 390.Dehghan Marvast L, Aflatoonian A, Talebi AR, Ghasemzadeh J, Pacey AA. Semen inflammatory markers and Chlamydia trachomatis infection in male partners of infertile couples. Andrologia (2016) 48:729–36. 10.1111/and.12501 [DOI] [PubMed] [Google Scholar]
- 391.López-Hurtado M, Velazco-Fernández M, Pedraza-Sánchez MJE, Flores-Salazar VR, Villagrana Zesati R, Guerra-Infante FM. Molecular detection of Chlamydia trachomatis and semen quality of sexual partners of infertile women. Andrologia (2017) e12812. 10.1111/and.12812 [DOI] [PubMed] [Google Scholar]
- 392.Delwart EL, Mullins JI, Gupta P, Learn GH, Jr, Holodniy M, Katzenstein D, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol (1998) 72:617–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 393.Winter AJ, Taylor S, Workman J, White D, Ross JD, Swan AV, et al. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect (1999) 75:261–3. 10.1136/sti.75.4.261 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 394.Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 21:1723–30. 10.1097/QAD.0b013e3281532c82 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 395.Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 8:447–57. 10.1038/nri2302 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 396.Liu CM, Osborne BJW, Hungate BA, Shahabi K, Huibner S, Lester R, et al. The semen microbiome and its relationship with local immunology and viral load in HIV infection. PloS Path (2014) 10:e1004262. 10.1371/journal.ppat.1004262 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 397.Rametse CL, Olivier AJ, Masson L, Barnabas S, Mckinnon LR, Ngcapu S, et al. Role of semen in altering the balance between inflammation and tolerance in the female genital tract: does it contribute to HIV risk? Viral Immunol (2014) 27:200–6. 10.1089/vim.2013.0136 [DOI] [PubMed] [Google Scholar]
- 398.Gruber F, Lipozencic J, Kehler T. History of venereal diseases from antiquity to the renaissance. Acta Dermatovenerol Croat (2015) 23:1–11. [PubMed] [Google Scholar]
- 399.Sherman JK, Rosenfeld J. Importance of frozen-stored human semen in the spread of gonorrhea. Fertil Steril (1975) 26:1043–7. 10.1016/S0015-0282(16)41468-8 [DOI] [PubMed] [Google Scholar]
- 400.Zheng H. Analysis of the antigen-antibody specificity in the semen of patients with Neisseria gonorrhoeae. Chin Med Sci J (1997) 12:47–9. [PubMed] [Google Scholar]
- 401.Isbey SF, Alcorn TM, Davis RH, Haizlip J, Leone PA, Cohen MS. Characterisation of Neisseria gonorrhoeae in semen during urethral infection in men. Genitourin Med (1997) 73:378–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 402.Kertséz G. A new method of inoculation to prove the infectivity of the semen in latent syphilis. Br J Dermatol Syph (1931) 43:588–92. 10.1111/j.1365-2133.1931.tb09454.x [DOI] [Google Scholar]
- 403.Adeoba A. Interpretation of positive serological tests for syphilis in pregnancy. Br J Vener Dis (1967) 43:249–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 404.Burchell AN, Allen VG, Gardner SL, Moravan V, Tan DHS, Grewal R, et al. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infect Dis (2015) 15:356. 10.1186/s12879-015-1098-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 405.Punjabi U, Wyns C, Mahmoud A, Vernelen K, China B, Verheyen G. Fifteen years of Belgian experience with external quality assessment of semen analysis. Andrology (2016) 4:1084–93. 10.1111/andr.12230 [DOI] [PubMed] [Google Scholar]
- 406.Trompoukis C, Kalaitzis C, Giannakopoulos S, Sofikitis N, Touloupidis S. Semen and the diagnosis of infertility in Aristotle. Andrologia (2007) 39:33–7. 10.1111/j.1439-0272.2006.00757.x [DOI] [PubMed] [Google Scholar]
- 407.Jungwirth A, Diemer T, Dohle GR, Giwercman A, Kopa Z, Krausz C, et al. Guidelines on Male Infertility. Eur Assoc Urol; (2015). [DOI] [PubMed] [Google Scholar]
- 408.Mändar R, Punab M, Borovkova N, Lapp E, Kiiker R, Korrovits P, et al. Complementary seminovaginal microbiome in couples. Res Microbiol (2015) 166:440–7. 10.1016/j.resmic.2015.03.009 [DOI] [PubMed] [Google Scholar]
- 409.Fowlkes DM, Dooher GB, O’Leary WM. Evidence by scanning electron microscopy for an association between spermatozoa and T-mycoplasmas in men of infertile marriage. Fertil Steril (1975) 26:1203–11. 10.1016/S0015-0282(16)41536-0 [DOI] [PubMed] [Google Scholar]
- 410.Fowlkes DM, Macleod J, O’Leary WM. T-mycoplasmas and human infertility: correlation of infection with alterations in seminal parameters. Fertil Steril (1975) 26:1212–8. 10.1016/S0015-0282(16)41537-2 [DOI] [PubMed] [Google Scholar]
- 411.Rehewy MS, Hafez ES, Thomas A, Brown WJ. Aerobic and anaerobic bacterial flora in semen from fertile and infertile groups of men. Arch Androl (1979) 2:263–8. 10.3109/01485017908987323 [DOI] [PubMed] [Google Scholar]
- 412.Swenson CE, Toth A, Toth C, Wolfgruber L, O’Leary WM. Asymptomatic bacteriospermia in infertile men. Andrologia (1980) 12:7–11. 10.1111/j.1439-0272.1980.tb00567.x [DOI] [PubMed] [Google Scholar]
- 413.Mogra N, Dhruva A, Kothari LK. Non-specific seminal tract infection and male infertility: a bacteriological study. J Postgrad Med (1981) 27:99–104. [PubMed] [Google Scholar]
- 414.Busolo F, Zanchetta R, Lanzone E, Cusinato R. Microbial flora in semen of asymptomatic infertile men. Andrologia (1984) 16:269–75. 10.1111/j.1439-0272.1984.tb00282.x [DOI] [PubMed] [Google Scholar]
- 415.Naessens A, Foulon W, Debrucker P, Devroey P, Lauwers S. Recovery of microorganisms in semen and relationship to semen evaluation. Fertil Steril (1986) 45:101–5. 10.1016/S0015-0282(16)49105-3 [DOI] [PubMed] [Google Scholar]
- 416.Eggert-Kruse W, Rohr G, Strock W, Pohl S, Schwalbach B, Runnebaum B. Anaerobes in ejaculates of subfertile men. Hum Reprod Update (1995) 1:462–78. 10.1093/humupd/1.5.462 [DOI] [PubMed] [Google Scholar]
- 417.Merino G, Carranza-Lira S, Murrieta S, Rodriguez L, Cuevas E, Moran C. Bacterial infection and semen characteristics in infertile men. Arch Androl (1995) 35:43–7. 10.3109/01485019508987852 [DOI] [PubMed] [Google Scholar]
- 418.Jarvi K, Lacroix JM, Jain A, Dumitru I, Heritz D, Mittelman MW. Polymerase chain reaction-based detection of bacteria in semen. Fertil Steril (1996) 66:463–7. 10.1016/S0015-0282(16)58520-3 [DOI] [PubMed] [Google Scholar]
- 419.Lacroix JM, Jarvi K, Batra SD, Heritz DM, Mittelman MW. PCR-based technique for the detection of bacteria in semen and urine. J Microbiol Meth (1996) 26:61–71. 10.1016/0167-7012(96)00844-5 [DOI] [Google Scholar]
- 420.Byrn RA, Kiessling AA. Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir. J Reprod Immunol (1998) 41:161–76. 10.1016/S0165-0378(98)00056-4 [DOI] [PubMed] [Google Scholar]
- 421.Cardoso EM, Santoianni JE, De Paulis AN, Andrada JA, Predari SC, Arregger AL. Improvement of semen quality in infected asymptomatic infertile male after bacteriological cure. Medicina (B Aires) (1998) 58:160–4. [PubMed] [Google Scholar]
- 422.Köhn FM, Erdmann I, Oeda T, El Mulla KF, Schiefer HG, Schill WB. Influence of urogenital infections on sperm functions. Andrologia (1998) 30(Suppl 1):73–80. 10.1111/j.1439-0272.1998.tb02829.x [DOI] [PubMed] [Google Scholar]
- 423.Onemu SO, Ibeh IN. Studies on the significance of positive bacterial semen cultures in male fertility in Nigeria. Int J Fertil Womens Med (2001) 46:210–4. [PubMed] [Google Scholar]
- 424.Esfandiari N, Saleh RA, Abdoos M, Rouzrokh A, Nazemian Z. Positive bacterial culture of semen from infertile men with asymptomatic leukocytospermia. Int J Fertil Womens Med (2002) 47:265–70. [PubMed] [Google Scholar]
- 425.Sanocka D, Fraczek M, Jedrzejczak P, Szumala-Kakol A, Kurpisz M. Male genital tract infection: an influence of leukocytes and bacteria on semen. J Reprod Immunol (2004) 62:111–24. 10.1016/j.jri.2003.10.005 [DOI] [PubMed] [Google Scholar]
- 426.Sanocka-Maciejewska D, Ciupińska M, Kurpisz M. Bacterial infection and semen quality. J Reprod Immunol (2005) 67:51–6. 10.1016/j.jri.2005.06.003 [DOI] [PubMed] [Google Scholar]
- 427.Gdoura R, Kchaou W, Chaari C, Znazen A, Keskes L, Rebai T, et al. Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis and Mycoplasma genitalium infections and semen quality of infertile men. BMC Infect Dis (2007) 7:129. 10.1186/1471-2334-7-129 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 428.Ikechukwu O, George E, Sabinus AE, Florence O. Role of enriched media in bacterial isolation from semen and effect of microbial infection on semen quality: a study on 100 infertile men. Pak J Med Sci (2007) 23:885–8. [Google Scholar]
- 429.Kiessling AA, Desmarais BM, Yin HZ, Loverde J, Eyre RC. Detection and identification of bacterial DNA in semen. Fertil Steril (2008) 90:1744–56. 10.1016/j.fertnstert.2007.08.083 [DOI] [PubMed] [Google Scholar]
- 430.Pellati D, Mylonakis I, Bertoloni G, Fiore C, Andrisani A, Ambrosini G, et al. Genital tract infections and infertility. Eur J Obstet Gynecol Reprod Biol (2008) 140:3–11. 10.1016/j.ejogrb.2008.03.009 [DOI] [PubMed] [Google Scholar]
- 431.Moretti E, Capitani S, Figura N, Pammolli A, Federico MG, Giannerini V, et al. The presence of bacteria species in semen and sperm quality. J Assist Reprod Genet (2009) 26:47–56. 10.1007/s10815-008-9283-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 432.Kokab A, Akhondi MM, Sadeghi MR, Modarresi MH, Aarabi M, Jennings R, et al. Raised inflammatory markers in semen from men with asymptomatic chlamydial infection. J Androl (2010) 31:114–20. 10.2164/jandrol.109.008300 [DOI] [PubMed] [Google Scholar]
- 433.Onemu SO, Ogbimi AO, Ophori EA. Microbiology and semen indices of sexually-active males in Benin City, Edo State, Nigeria. J Bacteriol Res (2010) 2:55–9. [Google Scholar]
- 434.Uneke CJ, Ugwuoru CD. Antibiotic susceptibility of urogenital microbial profile of infertile men in South-eastern Nigeria. Andrologia (2010) 42:268–73. 10.1111/j.1439-0272.2009.00988.x [DOI] [PubMed] [Google Scholar]
- 435.De Francesco MA, Negrini R, Ravizzola G, Galli P, Manca N. Bacterial species present in the lower male genital tract: a five-year retrospective study. Eur J Contracept Reprod Health Care (2011) 16:47–53. 10.3109/13625187.2010.533219 [DOI] [PubMed] [Google Scholar]
- 436.Hamada A, Agarwal A, Sharma R, French DB, Ragheb A, Sabanegh ES, Jr. Empirical treatment of low-level leukocytospermia with doxycycline in male infertility patients. Urology (2011) 78:1320–5. 10.1016/j.urology.2011.08.062 [DOI] [PubMed] [Google Scholar]
- 437.Isaiah IN, Nche BT, Nwagu IG, Nnanna II. Current studies on bacterospermia the leading cause of male infertility: a protégé and potential threat towards mans extinction. N Am J Med Sci (2011) 3:562–4. 10.4297/najms.2011.3559 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 438.La Vignera S, Vicari E, Condorelli RA, D’agata R, Calogero AE. Male accessory gland infection and sperm parameters (review). Int J Androl (2011) 34:e330–47. 10.1111/j.1365-2605.2011.01200.x [DOI] [PubMed] [Google Scholar]
- 439.Momoh ARM, Idonije BO, Nwoke EO, Osifo UC, Okhai O, Omoroguiwa A, et al. Pathogenic bacteria-a probable cause of primary infertility among couples in Ekpoma. J Microbiol Biotechnol Res (2011) 1:66–71. [Google Scholar]
- 440.Kaur S, Prabha V. Infertility as a consequence of spermagglutinating Staphylococcus aureus colonization in genital tract of female mice. PLoS One (2012) 7:e52325. 10.1371/journal.pone.0052325 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 441.Rusz A, Pilatz A, Wagenlehner F, Linn T, Diemer T, Schuppe HC, et al. Influence of urogenital infections and inflammation on semen quality and male fertility. World J Urol (2012) 30:23–30. 10.1007/s00345-011-0726-8 [DOI] [PubMed] [Google Scholar]
- 442.Salmeri M, Valenti D, La Vignera S, Bellanca S, Morello A, Toscano MA, et al. Prevalence of Ureaplasma urealyticum and Mycoplasma hominis infection in unselected infertile men. J Chemother (2012) 24:81–6. 10.1179/1120009X12Z.00000000021 [DOI] [PubMed] [Google Scholar]
- 443.Nabi A, Khalili MA, Halvaei I, Ghasemzadeh J, Zare E. Seminal bacterial contaminations: probable factor in unexplained recurrent pregnancy loss. Iran J Reprod Med (2013) 11:925–32. [PMC free article] [PubMed] [Google Scholar]
- 444.Sleha R, Boštíková V, Salavec M, Mosio P, Kusáková E, Kukla R, et al. Bacterial infection as a cause of infertility in humans(paper in Czech). Epidemiol Mikrobiol Imunol (2013) 62:26–32. [PubMed] [Google Scholar]
- 445.La Vignera S, Condorelli RA, Vicari E, Salmeri M, Morgia G, Favilla V, et al. Microbiological investigation in male infertility: a practical overview. J Med Microbiol (2014) 63:1–14. 10.1099/jmm.0.062968-0 [DOI] [PubMed] [Google Scholar]
- 446.Weng SL, Chiu CM, Lin FM, Huang WC, Liang C, Yang T, et al. Bacterial communities in semen from men of infertile couples: metagenomic sequencing reveals relationships of seminal microbiota to semen quality. PLoS One (2014) 9:e110152. 10.1371/journal.pone.0110152 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 447.Fraczek M, Kurpisz M. Mechanisms of the harmful effects of bacterial semen infection on ejaculated human spermatozoa: potential inflammatory markers in semen. Folia Histochem Cytobiol (2015) 53:201–17. 10.5603/fhc.a2015.0019 [DOI] [PubMed] [Google Scholar]
- 448.Vander H, Prabha V. Evaluation of fertility outcome as a consequence of intravaginal inoculation with sperm-impairing micro-organisms in a mouse model. J Med Microbiol (2015) 64:344–7. 10.1099/jmm.0.000036 [DOI] [PubMed] [Google Scholar]
- 449.Fraczek M, Hryhorowicz M, Gill K, Zarzycka M, Gaczarzewicz D, Jedrzejczak P, et al. The effect of bacteriospermia and leukocytospermia on conventional and nonconventional semen parameters in healthy young normozoospermic males. J Reprod Immunol (2016) 118:18–27. 10.1016/j.jri.2016.08.006 [DOI] [PubMed] [Google Scholar]
- 450.Ruggeri M, Cannas S, Cubeddu M, Molicotti P, Piras GL, Dessole S, et al. Bacterial agents as a cause of infertility in humans. New Microbiol (2016) 39:206–9. [PubMed] [Google Scholar]
- 451.Shiadeh MN, Niyyati M, Fallahi S, Rostami A. Human parasitic protozoan infection to infertility: a systematic review. Parasitol Res (2016) 115:469–77. 10.1007/s00436-015-4827-y [DOI] [PubMed] [Google Scholar]
- 452.Vicari LO, Castiglione R, Salemi M, Vicari BO, Mazzarino MC, Vicari E. Effect of levofloxacin treatment on semen hyperviscosity in chronic bacterial prostatitis patients. Andrologia (2016) 48:380–8. 10.1111/and.12456 [DOI] [PubMed] [Google Scholar]
- 453.Ahmadi MH, Mirsalehian A, Sadighi Gilani MA, Bahador A, Talebi M. Asymptomatic infection with Mycoplasma hominis negatively affects semen parameters and leads to male infertility as confirmed by improved semen parameters after antibiotic treatment. Urology (2017) 100:97–102. 10.1016/j.urology.2016.11.018 [DOI] [PubMed] [Google Scholar]
- 454.Kjaergaard N, Kristensen B, Hansen ES, Farholt S, Schønheyder HC, Uldbjerg N, et al. Microbiology of semen specimens from males attending a fertility clinic. APMIS (1997) 105:566–70. 10.1111/j.1699-0463.1997.tb05054.x [DOI] [PubMed] [Google Scholar]
- 455.Hillier SL, Rabe LK, Muller CH, Zarutskie P, Kuzan FB, Stenchever MA. Relationship of bacteriologic characteristics to semen indices in men attending an infertility clinic. Obstet Gynecol (1990) 75:800–4. [PubMed] [Google Scholar]
- 456.Dieterle S. Urogenital infections in reproductive medicine. Andrologia (2008) 40:117–9. 10.1111/j.1439-0272.2008.00833.x [DOI] [PubMed] [Google Scholar]
- 457.Vilvanathan S, Kandasamy B, Jayachandran AL, Sathiyanarayanan S, Tanjore Singaravelu V, Krishnamurthy V, et al. Bacteriospermia and its impact on basic semen parameters among infertile men. Interdiscip Perspect Infect Dis (2016) 2016:2614692. 10.1155/2016/2614692 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 458.Liversedge NH, Jenkins JM, Keay SD, Mclaughlin EA, Al-Sufyan H, Maile LA, et al. Antibiotic treatment based on seminal cultures from asymptomatic male partners in in-vitro fertilization is unnecessary and may be detrimental. Hum Reprod (1996) 11:1227–31. 10.1093/oxfordjournals.humrep.a019361 [DOI] [PubMed] [Google Scholar]
- 459.Bhandari P, Rishi P, Prabha V. Positive effect of probiotic Lactobacillus plantarum in reversing the LPS induced infertility in mouse model. J Med Microbiol (2016) 65:345–50. 10.1099/jmm.0.000230 [DOI] [PubMed] [Google Scholar]
- 460.Hou D, Zhou X, Zhong X, Settles ML, Herring J, Wang L, et al. Microbiota of the seminal fluid from healthy and infertile men. Fertil Steril (2013) 100:1261–9. 10.1016/j.fertnstert.2013.07.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 461.Javurek AB, Spollen WG, Ali AMM, Johnson SA, Lubahn DB, Bivens NJ, et al. Discovery of a novel seminal fluid microbiome and influence of estrogen receptor alpha genetic status. Sci Rep (2016) 6 10.1038/srep23027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 462.Craig LB, Peck JD, Xu J, Sankaranarayanan K, Warinner C, Hansen KR, et al. Characterizing the semen microbiome and associations with semen parameters: the Chasm study. Fertil Steril (2015) 104:E66. 10.1016/j.fertnstert.2015.07.202 [DOI] [Google Scholar]
- 463.Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C, et al. Ebola RNA persistence in semen of ebola virus disease survivors – preliminary report. N Engl J Med (2015). 10.1056/NEJMoa1511410 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 464.Soka MJ, Choi MJ, Baller A, White S, Rogers E, Purpura LJ, et al. Prevention of sexual transmission of ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of ebola virus RNA results and behavioural data. Lancet Glob Health (2016) 4:e736–43. 10.1016/S2214-109X(16)30175-9 [DOI] [PubMed] [Google Scholar]
- 465.Thorson A, Formenty P, Lofthouse C, Broutet N. Systematic review of the literature on viral persistence and sexual transmission from recovered ebola survivors: evidence and recommendations. BMJ Open (2016) 6:e008859. 10.1136/bmjopen-2015-008859 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 466.Sissoko D, Duraffour S, Kerber R, Kolie JS, Beavogui AH, Camara AM, et al. Persistence and clearance of ebola virus RNA from seminal fluid of ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob Health (2017) 5:e80–8. 10.1016/S2214-109X(16)30243-1 [DOI] [PubMed] [Google Scholar]
- 467.Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noël-Romas L, et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science (2017) 356:938–45. 10.1126/science.aai9383 [DOI] [PubMed] [Google Scholar]
- 468.Ma W, Li S, Ma S, Jia L, Zhang F, Zhang Y, et al. Zika virus causes testis damage and leads to male infertility in mice. Cell (2016) 167:1511–24.e1510. 10.1016/j.cell.2016.11.016 [DOI] [PubMed] [Google Scholar]
- 469.Baud D, Musso D, Vouga M, Alves MP, Vulliemoz N. Zika virus: a new threat to human reproduction. Am J Reprod Immunol (2017) 77:e12614. 10.1111/aji.12614 [DOI] [PubMed] [Google Scholar]
- 470.Hamer DH, Wilson ME, Jean J, Chen LH. Epidemiology, prevention, and potential future treatments of sexually transmitted zika virus infection. Curr Infect Dis Rep (2017) 19:16. 10.1007/s11908-017-0571-z [DOI] [PubMed] [Google Scholar]
- 471.Ohri M, Prabha V. Isolation of a sperm-agglutinating factor from Staphylococcus aureus isolated from a woman with unexplained infertility. Fertil Steril (2005) 84:1539–41. 10.1016/j.fertnstert.2005.05.030 [DOI] [PubMed] [Google Scholar]
- 472.Diemer T, Huwe P, Ludwig M, Hauck EW, Weidner W. Urogenital infection and sperm motility. Andrologia (2003) 35:283–7. 10.1111/j.1439-0272.2003.tb00858.x [DOI] [PubMed] [Google Scholar]
- 473.Prabha V, Sandhu R, Kaur S, Kaur K, Sarwal A, Mavuduru RS, et al. Mechanism of sperm immobilization by Escherichia coli. Adv Urol (2010) 2010:240268. 10.1155/2010/240268 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 474.Fraczek M, Wiland E, Piasecka M, Boksa M, Gaczarzewicz D, Szumala-Kakol A, et al. Fertilizing potential of ejaculated human spermatozoa during in vitro semen bacterial infection. Fertil Steril (2014) 102(711–719):e711. 10.1016/j.fertnstert.2014.06.002 [DOI] [PubMed] [Google Scholar]
- 475.Kaur K, Prabha V. Spermagglutinating Escherichia coli and its role in infertility: in vivo study. Microb Pathog (2014) 6(9–70):33–8. 10.1016/j.micpath.2014.03.010 [DOI] [PubMed] [Google Scholar]
- 476.Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface (2016) 123:20160539. 10.1098/rsif.2016.0539 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 477.Kell DB, Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progr Biophys Mol Biol (2017) 123:16–41. 10.1016/j.pbiomolbio.2016.08.006 [DOI] [PubMed] [Google Scholar]
- 478.Pretorius E, Page MJ, Hendricks L, Nkosi NB, Benson SR, Kell DB. Both Lipopolysaccharide and Lipoteichoic Acids Potently Induce Anomalous Fibrin Amyloid Formation: Assessment with Novel Amytracker™ Stains. bioRxiv preprint. bioRxiv, 143867 (2017). 10.1101/143867 [DOI] [PMC free article] [PubMed]
- 479.Gupta S, Prabha V. Human sperm interaction with Staphylococcus aureus: a molecular approach. J Pathog (2012) 2012:816536. 10.1155/2012/816536 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 480.Enwuru CA, Iwalokun B, Enwuru VN, Ezechi O, Oluwadun A. The effect of presence of facultative bacteria species on semen and sperm quality of men seeking fertility care. Afr J Urol (2016) 22:213–22. 10.1016/j.afju.2016.03.010 [DOI] [Google Scholar]
- 481.Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and mate fertility. Science (2005) 308:1466–9. 10.1126/science.1108190 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 482.Fenech M. Micronuclei and their association with sperm abnormalities, infertility, pregnancy loss, pre-eclampsia and intra-uterine growth restriction in humans. Mutagenesis (2011) 26:63–7. 10.1093/mutage/geq084 [DOI] [PubMed] [Google Scholar]
- 483.Pandian Z, Bhattacharya S, Templeton A. Review of unexplained infertility and obstetric outcome: a 10 year review. Hum Reprod (2001) 16:2593–7. 10.1093/humrep/16.12.2593 [DOI] [PubMed] [Google Scholar]
- 484.Trogstad L, Magnus P, Moffett A, Stoltenberg C. The effect of recurrent miscarriage and infertility on the risk of pre-eclampsia. BJOG (2009) 116:108–13. 10.1111/j.1471-0528.2008.01978.x [DOI] [PubMed] [Google Scholar]
- 485.Basso O, Baird DD. Infertility and preterm delivery, birthweight, and Caesarean section: a study within the Danish National Birth Cohort. Hum Reprod (2003) 18:2478–84. 10.1093/humrep/deg444 [DOI] [PubMed] [Google Scholar]
- 486.Basso O, Weinberg CR, Baird DD, Wilcox AJ, Olsen J. Subfecundity as a correlate of preeclampsia: a study within the Danish National Birth Cohort. Am J Epidemiol (2003) 157:195–202. 10.1093/aje/kwf194 [DOI] [PubMed] [Google Scholar]
- 487.Sohrabvand F, Jafari M, Shariat M, Haghollahi F, Lotfi M. Frequency and epidemiologic aspects of male infertility. Acta Med Iran (2015) 53:231–5. [PubMed] [Google Scholar]
- 488.Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Disc (2008) 7:205–20. 10.1038/nrd2438 [DOI] [PubMed] [Google Scholar]
- 489.Kell DB, Dobson PD, Bilsland E, Oliver SG. The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Disc Today (2013) 18:218–39. 10.1016/j.drudis.2012.11.008 [DOI] [PubMed] [Google Scholar]
- 490.Kell DB, Oliver SG. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 5:231. 10.3389/fphar.2014.00231 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 491.Pajovic B, Radojevic N, Vukovic M, Stjepcevic A. Semen analysis before and after antibiotic treatment of asymptomatic Chlamydia- and Ureaplasma-related pyospermia. Andrologia (2013) 45:266–71. 10.1111/and.12004 [DOI] [PubMed] [Google Scholar]
- 492.Schoor RA. Prostatitis and male infertility: evidence and links. Curr Urol Rep (2002) 3:324–9. 10.1007/s11934-002-0058-8 [DOI] [PubMed] [Google Scholar]
- 493.Everaert K, Mahmoud A, Depuydt C, Maeyaert M, Comhaire F. Chronic prostatitis and male accessory gland infection – is there an impact on male infertility (diagnosis and therapy)? Andrologia (2003) 35:325–30. 10.1111/j.1439-0272.2003.tb00867.x [DOI] [PubMed] [Google Scholar]
- 494.La Vignera S, Condorelli R, Vicari E, D’agata R, Calogero AE. High frequency of sexual dysfunction in patients with male accessory gland infections. Andrologia (2012) 44(Suppl 1):438–46. 10.1111/j.1439-0272.2011.01202.x [DOI] [PubMed] [Google Scholar]
- 495.Alshahrani S, Mcgill J, Agarwal A. Prostatitis and male infertility. J Reprod Immunol (2013) 100:30–6. 10.1016/j.jri.2013.05.004 [DOI] [PubMed] [Google Scholar]
- 496.La Vignera S, Vicari E, Condorelli RA, Franchina C, Scalia G, Morgia G, et al. Prevalence of human papilloma virus infection in patients with male accessory gland infection. Reprod Biomed Online (2015) 30:385–91. 10.1016/j.rbmo.2014.12.016 [DOI] [PubMed] [Google Scholar]
- 497.Estemalik J, Demko C, Bissada NF, Joshi N, Bodner D, Shankar E, et al. Simultaneous detection of oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontol (2017) 88:823–29. 10.1902/jop.2017.160477 [DOI] [PubMed] [Google Scholar]
- 498.Hedger MP. Toll-like receptors and signalling in spermatogenesis and testicular responses to inflammation – a perspective. J Reprod Immunol (2011) 88:130–41. 10.1016/j.jri.2011.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 499.Bhushan S, Schuppe HC, Fijak M, Meinhardt A. Testicular infection: microorganisms, clinical implications and host-pathogen interaction. J Reprod Immunol (2009) 83:164–7. 10.1016/j.jri.2009.07.007 [DOI] [PubMed] [Google Scholar]
- 500.Bhushan S, Schuppe HC, Tchatalbachev S, Fijak M, Weidner W, Chakraborty T, et al. Testicular innate immune defense against bacteria. Mol Cell Endocrinol (2009) 306:37–44. 10.1016/j.mce.2008.10.017 [DOI] [PubMed] [Google Scholar]
- 501.Chen B, Yu L, Wang J, Li C, Zhao K, Zhang H. Involvement of prokineticin 2 and prokineticin receptor 1 in lipopolysaccharide-induced testitis in rats. Inflammation (2016) 39:534–42. 10.1007/s10753-015-0277-z [DOI] [PubMed] [Google Scholar]
- 502.Lipsky BA. Prostatitis and urinary tract infection in men: what’s new; what’s true? Am J Med (1999) 106:327–34. 10.1016/S0002-9343(99)00017-0 [DOI] [PubMed] [Google Scholar]
- 503.Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis (2010) 50:1641–52. 10.1086/652861 [DOI] [PubMed] [Google Scholar]
- 504.Vicari E, Calogero AE, Condorelli RA, Vicari LO, La Vignera S. Male accessory gland infection frequency in infertile patients with chronic microbial prostatitis and irritable bowel syndrome. Int J Androl (2012) 35:183–9. 10.1111/j.1365-2605.2011.01216.x [DOI] [PubMed] [Google Scholar]
- 505.Wagenlehner FME, Pilatz A, Bschleipfer T, Diemer T, Linn T, Meinhardt A, et al. Bacterial prostatitis. World J Urol (2013) 31:711–6. 10.1007/s00345-013-1055-x [DOI] [PubMed] [Google Scholar]
- 506.Krebs J, Bartel P, Pannek J. Bacterial persistence in the prostate after antibiotic treatment of chronic bacterial prostatitis in men with spinal cord injury. Urology (2014) 83:515–20. 10.1016/j.urology.2013.11.023 [DOI] [PubMed] [Google Scholar]
- 507.Krebs J, Bartel P, Pannek J. Chronic bacterial prostatitis in men with spinal cord injury. World J Urol (2014) 32:1579–85. 10.1007/s00345-013-1235-8 [DOI] [PubMed] [Google Scholar]
- 508.Wagenlehner FME, Weidner W, Pilatz A, Naber KG. Urinary tract infections and bacterial prostatitis in men. Curr Opin Infect Dis (2014) 27:97–101. 10.1097/QCO.0000000000000024 [DOI] [PubMed] [Google Scholar]
- 509.Videčnik Zorman J, Matičič M, Jeverica S, Smrkolj T. Diagnosis and treatment of bacterial prostatitis. Acta Dermatovenereol (2015) 24:25–9. [DOI] [PubMed] [Google Scholar]
- 510.Condorelli RA, Vicari E, Mongioi LM, Russo GI, Morgia G, La Vignera S, et al. Human papilloma virus infection in patients with male accessory gland infection: usefulness of the ultrasound evaluation. Int J Endocrinol (2016) 2016:9174609. 10.1155/2016/9174609 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 511.Gill BC, Shoskes DA. Bacterial prostatitis. Curr Opin Infect Dis (2016) 29:86–91. 10.1097/QCO.0000000000000222 [DOI] [PubMed] [Google Scholar]
- 512.Krieger JN, Thumbikat P. Bacterial prostatitis: bacterial virulence, clinical outcomes, and new directions. Microbiol Spectr (2016) 4(1):UTI-0004-2012. 10.1128/microbiolspec.UTI-0004-2012 [DOI] [PubMed] [Google Scholar]
- 513.Alvarado-Esquivel C, Pacheco-Vega SJ, Hernández-Tinoco J, Centeno-Tinoco MM, Beristain-Garcia I, Sánchez-Anguiano LF, et al. Miscarriage history and Toxoplasma gondii infection: a cross-sectional study in women in Durango City, Mexico. Eur J Microbiol Immunol (Bp) (2014) 4:117–22. 10.1556/EuJMI.4.2014.2.4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 514.Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SEM, Horne AW. The role of infection in miscarriage. Hum Reprod Update (2015). 10.1093/humupd/dmv041 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 515.van der Eijk AA, Van Genderen PJ, Verdijk RM, Reusken CB, Mogling R, Van Kampen JJ, et al. Miscarriage associated with zika virus infection. N Engl J Med (2016) 375:1002–4. 10.1056/NEJMc1605898 [DOI] [PubMed] [Google Scholar]
- 516.McDonald HM, Chambers HM. Intrauterine infection and spontaneous midgestation abortion: is the spectrum of microorganisms similar to that in preterm labor? Infect Dis Obstet Gynecol (2000) 8:220–7. 10.1155/S1064744900000314 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 517.Romero R, Espinoza J, Mazor M. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization? Fertil Steril (2004) 82:799–804. 10.1016/j.fertnstert.2004.05.076 [DOI] [PubMed] [Google Scholar]
- 518.Conde-Ferráez L, Chan May ADA, Carrillo-Martínez JR, Ayora-Talavera G, González-Losa MDR. Human papillomavirus infection and spontaneous abortion: a case-control study performed in Mexico. Eur J Obstet Gynecol Reprod Biol (2013) 170:468–73. 10.1016/j.ejogrb.2013.07.002 [DOI] [PubMed] [Google Scholar]
- 519.Wang H, Cao Q, Ge J, Liu C, Ma Y, Meng Y, et al. LncRNA-regulated infection and inflammation pathways associated with pregnancy loss: genome wide differential expression of lncRNAs in early spontaneous abortion. Am J Reprod Immunol (2014) 72:359–75. 10.1111/aji.12275 [DOI] [PubMed] [Google Scholar]
- 520.Ahmadi A, Khodabandehloo M, Ramazanzadeh R, Farhadifar F, Roshani D, Ghaderi E, et al. The relationship between Chlamydia trachomatis genital infection and spontaneous abortion. J Reprod Infertil (2016) 17:110–6. [PMC free article] [PubMed] [Google Scholar]
- 521.Ambühl LMM, Baandrup U, Dybkaer K, Blaakaer J, Uldbjerg N, Sørensen S. Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery. Infect Dis Obstet Gynecol (2016) 2016:3086036. 10.1155/2016/3086036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 522.Golding B, Scott DE, Scharf O, Huang LY, Zaitseva M, Lapham C, et al. Immunity and protection against Brucella abortus. Microbes Infect (2001) 3:43–8. 10.1016/S1286-4579(00)01350-2 [DOI] [PubMed] [Google Scholar]
- 523.Corbel MJ, Elberg SS, Cosivi O. Brucellosis in Humans and Animals. Geneva: World Health Organization; (2006). [Google Scholar]
- 524.Oliveira SC, De Oliveira FS, Macedo GC, De Almeida LA, Carvalho NB. The role of innate immune receptors in the control of Brucella abortus infection: toll-like receptors and beyond. Microbes Infect (2008) 10:1005–9. 10.1016/j.micinf.2008.07.005 [DOI] [PubMed] [Google Scholar]
- 525.Kuster CE, Althouse GC. The impact of bacteriospermia on boar sperm storage and reproductive performance. Theriogenology (2016) 85:21–6. 10.1016/j.theriogenology.2015.09.049 [DOI] [PubMed] [Google Scholar]
- 526.Dorneles EMS, Sriranganathan N, Lage AP. Recent advances in Brucella abortus vaccines. Vet Res (2015) 46:76. 10.1186/s13567-015-0199-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 527.Brown VG, Schollum LM, Jarvis BDW. Microbiology of bovine semen and artificial breeding practices under New-Zealand conditions. NZ J Agric Res (1974) 17:431–2. 10.1080/00288233.1974.10421030 [DOI] [Google Scholar]
- 528.Schollum LM. The Microbiology of Bovine Serum and the Antimicrobial Activity of Bovine Seminal Plasma [PhD thesis] Palmerston North: Massey University; (1977). [Google Scholar]
- 529.Yániz JL, Marco-Aguado MA, Mateos JA, Santolaria P. Bacterial contamination of ram semen, antibiotic sensitivities, and effects on sperm quality during storage at 15 degrees C. Anim Reprod Sci (2010) 122:142–9. 10.1016/j.anireprosci.2010.08.006 [DOI] [PubMed] [Google Scholar]
- 530.Gaczarzewicz D, Udała J, Piasecka M, Błaszczyk B, Stankiewicz T. Bacterial contamination of boar semen and its relationship to sperm quality preserved in commercial extender containing gentamicin sulfate. Pol J Vet Sci (2016) 19:451–9. 10.1515/pjvs-2016-0057 [DOI] [PubMed] [Google Scholar]
- 531.Romero R, Mazor M, Wu YK, Sirtori M, Oyarzun E, Mitchell MD, et al. Infection in the pathogenesis of preterm labor. Semin Perinatol (1988) 12:262–79. [PubMed] [Google Scholar]
- 532.Toth M, Witkin SS, Ledger W, Thaler H. The role of infection in the etiology of preterm birth. Obstet Gynecol (1988) 71:723–6. [PubMed] [Google Scholar]
- 533.Cassell GH, Waites KB, Watson HL, Crouse DT, Harasawa R. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin Microbiol Rev (1993) 6:69–87. 10.1128/CMR.6.1.69 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 534.McGregor JA, French JI, Jones W, Milligan K, Mckinney PJ, Patterson E, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol (1994) 170:1048–59; discussion 1059–60. 10.1016/S0002-9378(94)70098-2 [DOI] [PubMed] [Google Scholar]
- 535.Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med (2000) 342:1500–7. 10.1056/NEJM200005183422007 [DOI] [PubMed] [Google Scholar]
- 536.Gonçalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 8:3–13. 10.1002/mrdd.10008 [DOI] [PubMed] [Google Scholar]
- 537.Gerber S, Vial Y, Hohlfeld P, Witkin SS. Detection of Ureaplasma urealyticum in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery. J Infect Dis (2003) 187:518–21. 10.1086/368205 [DOI] [PubMed] [Google Scholar]
- 538.Gardella C, Riley DE, Hitti J, Agnew K, Krieger JN, Eschenbach D. Identification and sequencing of bacterial rDNAs in culture-negative amniotic fluid from women in premature labor. Am J Perinatol (2004) 21:319–23. 10.1055/s-2004-831884 [DOI] [PubMed] [Google Scholar]
- 539.Espinoza J, Erez O, Romero R. Preconceptional antibiotic treatment to prevent preterm birth in women with a previous preterm delivery. Am J Obstet Gynecol (2006) 194:630–7. 10.1016/j.ajog.2005.11.050 [DOI] [PubMed] [Google Scholar]
- 540.Lee SE, Romero R, Kim CJ, Shim SS, Yoon BH. Funisitis in term pregnancy is associated with microbial invasion of the amniotic cavity and intra-amniotic inflammation. J Matern Fetal Neonatal Med (2006) 19:693–7. 10.1080/14767050600927353 [DOI] [PubMed] [Google Scholar]
- 541.Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet (2008) 371:75–84. 10.1016/S0140-6736(08)60074-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 542.Check JH. A practical approach to the prevention of miscarriage part 4-role of infection. Clin Exp Obstet Gyn (2010) 37:252–5. [PubMed] [Google Scholar]
- 543.Bastek JA, Gómez LM, Elovitz MA. The role of inflammation and infection in preterm birth. Clin Perinatol (2011) 38:385–406. 10.1016/j.clp.2011.06.003 [DOI] [PubMed] [Google Scholar]
- 544.Johnson HL, Ghanem KG, Zenilman JM, Erbelding EJ. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex Transm Dis (2011) 38:167–71. 10.1097/OLQ.0b013e3181f2e85f [DOI] [PubMed] [Google Scholar]
- 545.Manzoni P, Rizzollo S, Decembrino L, Ruffinazzi G, Rossi Ricci A, Gallo E, et al. Recent advances in prevention of sepsis in the premature neonates in NICU. Early Hum Dev (2011) 87(Suppl 1):S31–3. 10.1016/j.earlhumdev.2011.01.008 [DOI] [PubMed] [Google Scholar]
- 546.Rours GIJG, Duijts L, Moll HA, Arends LR, De Groot R, Jaddoe VW, et al. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol (2011) 26:493–502. 10.1007/s10654-011-9586-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 547.Jefferson KK. The bacterial etiology of preterm birth. Adv Appl Microbiol (2012) 80:1–22. 10.1016/B978-0-12-394381-1.00001-5 [DOI] [PubMed] [Google Scholar]
- 548.Lee SYR, Leung CW. Histological chorioamnionitis – implication for bacterial colonization, laboratory markers of infection, and early onset sepsis in very-low-birth-weight neonates. J Matern Fetal Neonatal Med (2012) 25:364–8. 10.3109/14767058.2011.579208 [DOI] [PubMed] [Google Scholar]
- 549.Shinar S, Skornick-Rapaport A, Rimon E. Placental abruption remote from term associated with Q fever infection. Obstet Gynecol (2012) 120:503–5. 10.1097/AOG.0b013e318260590f [DOI] [PubMed] [Google Scholar]
- 550.Subramaniam A, Abramovici A, Andrews WW, Tita AT. Antimicrobials for preterm birth prevention: an overview. Infect Dis Obs Gynecol (2012). 10.1155/2012/157159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 551.Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med (2014) 6:237ra265. 10.1126/scitranslmed.3008599 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 552.Joergensen JS, Kjaer Weile LK, Lamont RF. The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology. Expert Opin Pharmacother (2014) 15:2173–91. 10.1517/14656566.2014.950225 [DOI] [PubMed] [Google Scholar]
- 553.Allen-Daniels MJ, Serrano MG, Pflugner LP, Fettweis JM, Prestosa MA, Koparde VN, et al. Identification of a gene in Mycoplasma hominis associated with preterm birth and microbial burden in intraamniotic infection. Am J Obstet Gynecol (2015) 212:779.e1–779.e13. 10.1016/j.ajog.2015.01.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 554.de Andrade Ramos B, Kanninen TT, Sisti G, Witkin SS. Microorganisms in the female genital tract during pregnancy: tolerance versus pathogenesis. Am J Reprod Immunol (2015) 73:383–9. 10.1111/aji.12326 [DOI] [PubMed] [Google Scholar]
- 555.Kacerovsky M, Vrbacky F, Kutova R, Pliskova L, Andrys C, Musilova I, et al. Cervical microbiota in women with preterm prelabor rupture of membranes. PLoS One (2015) 10:e0126884. 10.1371/journal.pone.0126884 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 556.Lamont RF. Advances in the prevention of infection-related preterm birth. Front Immunol (2015) 6:566. 10.3389/fimmu.2015.00566 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 557.Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis (2015) 61:418–26. 10.1093/cid/civ312 [DOI] [PubMed] [Google Scholar]
- 558.Pammi M, Weisman LE. Late-onset sepsis in preterm infants: update on strategies for therapy and prevention. Expert Rev Anti Infect Ther (2015) 13:487–504. 10.1586/14787210.2015.1008450 [DOI] [PubMed] [Google Scholar]
- 559.Ueno T, Niimi H, Yoneda N, Yoneda S, Mori M, Tabata H, et al. Eukaryote-made thermostable DNA polymerase enables rapid PCR-based detection of mycoplasma, ureaplasma and other bacteria in the amniotic fluid of preterm labor cases. PLoS One (2015) 10:e0129032. 10.1371/journal.pone.0129032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 560.Frey HA, Klebanoff MA. The epidemiology, etiology, and costs of preterm birth. Semin Fetal Neonatal Med (2016) 21:68–73. 10.1016/j.siny.2015.12.011 [DOI] [PubMed] [Google Scholar]
- 561.Nadeau HCG, Subramaniam A, Andrews WW. Infection and preterm birth. Semin Fetal Neonatal Med (2016) 21:100–5. 10.1016/j.siny.2015.12.008 [DOI] [PubMed] [Google Scholar]
- 562.Vinturache AE, Gyamfi-Bannerman C, Hwang J, Mysorekar IU, Jacobsson B, Preterm Birth International Collaborative (Prebic) Maternal microbiome – a pathway to preterm birth. Semin Fetal Neonatal Med (2016) 21:94–9. 10.1016/j.siny.2016.02.004 [DOI] [PubMed] [Google Scholar]
- 563.Yoneda S, Shiozaki A, Yoneda N, Ito M, Shima T, Fukuda K, et al. Antibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high-sensitive PCR system. Am J Reprod Immunol (2016) 75:440–50. 10.1111/aji.12484 [DOI] [PubMed] [Google Scholar]
- 564.García-Velasco JA, Menabrito M, Catalán IB. What fertility specialists should know about the vaginal microbiome: a review. Reprod Biomed Online (2017) 35:103–12. 10.1016/j.rbmo.2017.04.005 [DOI] [PubMed] [Google Scholar]
- 565.van Well GTJ, Daalderop LA, Wolfs T, Kramer BW. Human perinatal immunity in physiological conditions and during infection. Mol Cell Pediatr (2017) 4:4. 10.1186/s40348-017-0070-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 566.Zini A, Boman JM, Belzile E, Ciampi A. Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: systematic review and meta-analysis. Hum Reprod (2008) 23:2663–8. 10.1093/humrep/den321 [DOI] [PubMed] [Google Scholar]
- 567.Gil-Villa AM, Cardona-Maya W, Agarwal A, Sharma R, Cadavid Á. Assessment of sperm factors possibly involved in early recurrent pregnancy loss. Fertil Steril (2010) 94:1465–72. 10.1016/j.fertnstert.2009.05.042 [DOI] [PubMed] [Google Scholar]
- 568.Brahem S, Mehdi M, Landolsi H, Mougou S, Elghezal H, Saad A. Semen parameters and sperm DNA fragmentation as causes of recurrent pregnancy loss. Urology (2011) 78:792–6. 10.1016/j.urology.2011.05.049 [DOI] [PubMed] [Google Scholar]
- 569.Shina A, Carp HJA. Recurrent pregnancy loss – beyond evidence based medicine. Gynecol Endocrinol (2012) 28:991–2. 10.3109/09513590.2012.683083 [DOI] [PubMed] [Google Scholar]
- 570.Lewis SEM, John Aitken R, Conner SJ, Iuliis GD, Evenson DP, Henkel R, et al. The impact of sperm DNA damage in assisted conception and beyond: recent advances in diagnosis and treatment. Reprod Biomed Online (2013) 27:325–37. 10.1016/j.rbmo.2013.06.014 [DOI] [PubMed] [Google Scholar]
- 571.Simon L, Proutski I, Stevenson M, Jennings D, Mcmanus J, Lutton D, et al. Sperm DNA damage has a negative association with live-birth rates after IVF. Reprod Biomed Online (2013) 26:68–78. 10.1016/j.rbmo.2012.09.019 [DOI] [PubMed] [Google Scholar]
- 572.Wang R, Zhou H, Zhang Z, Dai R, Geng D, Liu R. The impact of semen quality, occupational exposure to environmental factors and lifestyle on recurrent pregnancy loss. J Assist Reprod Genet (2013) 30:1513–8. 10.1007/s10815-013-0091-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 573.Belloc S, Benkhalifa M, Cohen-Bacrie M, Dalleac A, Chahine H, Amar E, et al. Which isolated sperm abnormality is most related to sperm DNA damage in men presenting for infertility evaluation. J Assist Reprod Genet (2014) 31:527–32. 10.1007/s10815-014-0194-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 574.Bonney EA, Brown SA. To drive or be driven: the path of a mouse model of recurrent pregnancy loss. Reproduction (2014) 147:R153–67. 10.1530/REP-13-0583 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 575.Kavitha P, Malini SS. Positive association of sperm dysfunction in the pathogenesis of recurrent pregnancy loss. J Clin Diagn Res (2014) 8:OC07–10. 10.7860/JCDR/2014/9109.5172 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 576.Zhao J, Zhang Q, Wang Y, Li Y. Whether sperm deoxyribonucleic acid fragmentation has an effect on pregnancy and miscarriage after in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Fertil Steril (2014) 102:998–1005.e1008. 10.1016/j.fertnstert.2014.06.033 [DOI] [PubMed] [Google Scholar]
- 577.Bronson R, editor. The Male Role in Pregnancy Loss and Embryo Implantation Failure. Berlin: Springer; (2015). [Google Scholar]
- 578.Esteves SC, Sánchez-Martin F, Sánchez-Martin P, Schneider DT, Gosálvez J. Comparison of reproductive outcome in oligozoospermic men with high sperm DNA fragmentation undergoing intracytoplasmic sperm injection with ejaculated and testicular sperm. Fertil Steril (2015) 104:1398–405. 10.1016/j.fertnstert.2015.08.028 [DOI] [PubMed] [Google Scholar]
- 579.Zidi-Jrah I, Hajlaoui A, Mougou-Zerelli S, Kammoun M, Meniaoui I, Sallem A, et al. Relationship between sperm aneuploidy, sperm DNA integrity, chromatin packaging, traditional semen parameters, and recurrent pregnancy loss. Fertil Steril (2016) 105:58–64. 10.1016/j.fertnstert.2015.09.041 [DOI] [PubMed] [Google Scholar]
- 580.Simon L, Zini A, Dyachenko A, Ciampi A, Carrell DT. A systematic review and meta-analysis to determine the effect of sperm DNA damage on in vitro fertilization and intracytoplasmic sperm injection outcome. Asian J Androl (2017) 19:80–90. 10.4103/1008-682X.182822 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 581.Agarwal A, Majzoub A, Esteves SC, Ko E, Ramasamy R, Zini A. Clinical utility of sperm DNA fragmentation testing: practice recommendations based on clinical scenarios. Transl Androl Urol (2016) 5:935–50. 10.21037/tau.2016.10.03 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 582.Usmani S, Liu HC, Pilcher CD, Witkowska HE, Kirchhoff F, Greene WC, et al. HIV-enhancing amyloids are prevalent in fresh semen and are a determinant for semen’s ability to enhance HIV infection: relevance for HIV transmission. AIDS Res Hum Retroviruses (2014) 30:A183–4. 10.1089/aid.2014.5392.abstract [DOI] [Google Scholar]
- 583.Binder NK, Sheedy JR, Hannan NJ, Gardner DK. Male obesity is associated with changed spermatozoa Cox4i1 mRNA level and altered seminal vesicle fluid composition in a mouse model. Mol Hum Reprod (2015) 21:424–34. 10.1093/molehr/gav010 [DOI] [PubMed] [Google Scholar]
- 584.Gil-Villa AM, Cardona-Maya W, Agarwal A, Sharma R, Cadavid Á. Role of male factor in early recurrent embryo loss: do antioxidants have any effect? Fertil Steril (2009) 92:565–71. 10.1016/j.fertnstert.2008.07.1715 [DOI] [PubMed] [Google Scholar]
- 585.Shiva M, Gautam AK, Verma Y, Shivgotra V, Doshi H, Kumar S. Association between sperm quality, oxidative stress, and seminal antioxidant activity. Clin Biochem (2011) 44:319–24. 10.1016/j.clinbiochem.2010.11.009 [DOI] [PubMed] [Google Scholar]
- 586.Agarwal A, Durairajanayagam D, Halabi J, Peng J, Vazquez-Levin M. Proteomics, oxidative stress and male infertility. Reprod Biomed Online (2014) 29:32–58. 10.1016/j.rbmo.2014.02.013 [DOI] [PubMed] [Google Scholar]
- 587.Durairajanayagam D, Agarwal A, Ong C, Prashast P. Lycopene and male infertility. Asian J Androl (2014) 16:420–5. 10.4103/1008-682X.126384 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 588.Ko EY, Sabanegh ES, Jr, Agarwal A. Male infertility testing: reactive oxygen species and antioxidant capacity. Fertil Steril (2014) 102:1518–27. 10.1016/j.fertnstert.2014.10.020 [DOI] [PubMed] [Google Scholar]
- 589.Cruz DF, Lume C, Silva JV, Nunes A, Castro I, Silva R, et al. Oxidative stress markers: can they be used to evaluate human sperm quality? Turk J Urol (2015) 41:198–207. 10.5152/tud.2015.06887 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 590.Agarwal A, Roychoudhury S, Sharma R, Gupta S, Majzoub A, Sabanegh E. Diagnostic application of oxidation-reduction potential assay for measurement of oxidative stress: clinical utility in male factor infertility. Reprod Biomed Online (2017) 34:48–57. 10.1016/j.rbmo.2016.10.008 [DOI] [PubMed] [Google Scholar]
- 591.Agarwal A, Wang SM. Clinical relevance of oxidation-reduction potential in the evaluation of male infertility. Urology (2017) 104:84–9. 10.1016/j.urology.2017.02.016 [DOI] [PubMed] [Google Scholar]
- 592.Bouziat R, Hinterleitner R, Brown JJ, Stencel-Baerenwald JE, Ikizler M, Mayassi T, et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science (2017) 356:44–50. 10.1126/science.aah5298 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 593.Verdu EF, Caminero A. How infection can incite sensitivity to food. Science (2017) 356:29–30. 10.1126/science.aan1500 [DOI] [PubMed] [Google Scholar]
- 594.Ludvigsson JF, Montgomery SM, Ekbom A. Celiac disease and risk of adverse fetal outcome: a population-based cohort study. Gastroenterology (2005) 129:454–63. 10.1016/j.gastro.2005.05.065 [DOI] [PubMed] [Google Scholar]
- 595.Wolf H, Ilsen A, Van Pampus MG, Sahebdien S, Pena S, Von Blomberg ME. Celiac serology in women with severe pre-eclampsia or delivery of a small for gestational age neonate. Int J Gynaecol Obstet (2008) 103:175–7. 10.1016/j.ijgo.2008.05.024 [DOI] [PubMed] [Google Scholar]
- 596.Bast A, O’Bryan T, Bast E. Celiac disease and reproductive health. Practical Gastroenterol (2009):10–21. [Google Scholar]
- 597.Özgör B, Selimoğlu MA. Coeliac disease and reproductive disorders. Scand J Gastroenterol (2010) 45:395–402. 10.3109/00365520903508902 [DOI] [PubMed] [Google Scholar]
- 598.Soni S, Badawy SZ. Celiac disease and its effect on human reproduction: a review. J Reprod Med (2010) 55:3–8. [PubMed] [Google Scholar]
- 599.Tersigni C, Castellani R, De Waure C, Fattorossi A, De Spirito M, Gasbarrini A, et al. Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. Hum Reprod Update (2014) 20:582–93. 10.1093/humupd/dmu007 [DOI] [PubMed] [Google Scholar]
- 600.Moleski SM, Lindenmeyer CC, Veloski JJ, Miller RS, Miller CL, Kastenberg D, et al. Increased rates of pregnancy complications in women with celiac disease. Ann Gastroenterol (2015) 28:236–40. [PMC free article] [PubMed] [Google Scholar]
- 601.Saccone G, Berghella V, Sarno L, Maruotti GM, Cetin I, Greco L, et al. Celiac disease and obstetric complications: a systematic review and metaanalysis. Am J Obstet Gynecol (2016) 214:225–34. 10.1016/j.ajog.2015.09.080 [DOI] [PubMed] [Google Scholar]
- 602.Byberg KK, Ogland B, Eide GE, Øymar K. Birth after preeclamptic pregnancies: association with allergic sensitization and allergic rhinoconjunctivitis in late childhood; a historically matched cohort study. BMC Pediatr (2014) 14:101. 10.1186/1471-2431-14-101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 603.Liu AH. Revisiting the hygiene hypothesis for allergy and asthma. J Allergy Clin Immunol (2015) 136:860–5. 10.1016/j.jaci.2015.08.012 [DOI] [PubMed] [Google Scholar]
- 604.Stokholm J, Sevelsted A, Anderson UD, Bisgaard H. Preeclampsia associates with asthma, allergy, and eczema in childhood. Am J Respir Crit Care Med (2017) 195:614–21. 10.1164/rccm.201604-0806OC [DOI] [PubMed] [Google Scholar]
- 605.Omer SB, Goodman D, Steinhoff MC, Rochat R, Klugman KP, Stoll BJ, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med (2011) 8:e1000441. 10.1371/journal.pmed.1000441 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 606.Adedinsewo DA, Noory L, Bednarczyk RA, Steinhoff MC, Davis R, Ogbuanu C, et al. Impact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine (2013) 31:5827–33. 10.1016/j.vaccine.2013.09.071 [DOI] [PubMed] [Google Scholar]
- 607.Richards JL, Hansen C, Bredfeldt C, Bednarczyk RA, Steinhoff MC, Adjaye-Gbewonyo D, et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clin Infect Dis (2013) 56:1216–22. 10.1093/cid/cit045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 608.Olsen SJ, Mirza SA, Vonglokham P, Khanthamaly V, Chitry B, Pholsena V, et al. The effect of influenza vaccination on birth outcomes in a cohort of pregnant women in Lao PDR, 2014–2015. Clin Infect Dis (2016) 63:487–94. 10.1093/cid/ciw290 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 609.Phadke VK, Steinhoff MC, Omer SB, Macdonald NE. Maternal influenza immunization and adverse birth outcomes: using data and practice to inform theory and research design. Am J Epidemiol (2016) 184:789–92. 10.1093/aje/kww110 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 610.Leslie M. Can flu shots help women get pregnant? Science (2017) 355:1247–8. 10.1126/science.355.6331.1247 [DOI] [PubMed] [Google Scholar]
- 611.Nordin JD, Kharbanda EO, Vazquez Benitez G, Lipkind H, Vellozzi C, Destefano F, et al. Maternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr (2014) 164:1051–7.e1052. 10.1016/j.jpeds.2014.01.037 [DOI] [PubMed] [Google Scholar]
- 612.Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis (2015) 60:e11–9. 10.1093/cid/ciu915 [DOI] [PubMed] [Google Scholar]
- 613.Coenders A, Koopmans NK, Broekhuijsen K, Groen H, Karstenberg-Kramer JMA, Van Goor K, et al. Adjuvanted vaccines in pregnancy: no evidence for effect of the adjuvanted H1N1/09 vaccination on occurrence of preeclampsia or intra-uterine growth restriction. Eur J Obstet Gynecol Reprod Biol (2015) 187:14–9. 10.1016/j.ejogrb.2015.01.011 [DOI] [PubMed] [Google Scholar]
- 614.Munoz FM, Greisinger AJ, Wehmanen OA, Mouzoon ME, Hoyle JC, Smith FA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol (2005) 192:1098–106. 10.1016/j.ajog.2004.12.019 [DOI] [PubMed] [Google Scholar]
- 615.Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis (2008) 8:44–52. 10.1016/S1473-3099(07)70311-0 [DOI] [PubMed] [Google Scholar]
- 616.Tamma PD, Ault KA, Del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol (2009) 201:547–52. 10.1016/j.ajog.2009.09.034 [DOI] [PubMed] [Google Scholar]
- 617.Yamaguchi K, Hisano M, Isojima S, Irie S, Arata N, Watanabe N, et al. Relationship of Th1/Th2 cell balance with the immune response to influenza vaccine during pregnancy. J Med Virol (2009) 81:1923–8. 10.1002/jmv.21620 [DOI] [PubMed] [Google Scholar]
- 618.Bednarczyk RA, Adjaye-Gbewonyo D, Omer SB. Safety of influenza immunization during pregnancy for the fetus and the neonate. Am J Obstet Gynecol (2012) 207:S38–46. 10.1016/j.ajog.2012.07.002 [DOI] [PubMed] [Google Scholar]
- 619.Jamieson DJ, Kissin DM, Bridges CB, Rasmussen SA. Benefits of influenza vaccination during pregnancy for pregnant women. Am J Obstet Gynecol (2012) 207:S17–20. 10.1016/j.ajog.2012.06.070 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 620.Kharbanda EO, Vazquez-Benitez G, Shi WX, Lipkind H, Naleway A, Molitor B, et al. Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink. Am J Obstet Gynecol (2012) 207:S47–51. 10.1016/j.ajog.2012.06.073 [DOI] [PubMed] [Google Scholar]
- 621.Moro PL, Tepper NK, Grohskopf LA, Vellozzi C, Broder K. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. Expert Rev Vaccines (2012) 11:911–21. 10.1586/erv.12.72 [DOI] [PubMed] [Google Scholar]
- 622.Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA (2012) 308:165–74. 10.1001/jama.2012.6131 [DOI] [PubMed] [Google Scholar]
- 623.Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ (2012) 344:e2794. 10.1136/bmj.e2794 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 624.Beau AB, Hurault-Delarue C, Vidal S, Guitard C, Vayssière C, Petiot D, et al. Pandemic A/H1N1 influenza vaccination during pregnancy: a comparative study using the EFEMERIS database. Vaccine (2014) 32:1254–8. 10.1016/j.vaccine.2014.01.021 [DOI] [PubMed] [Google Scholar]
- 625.Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynek H, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine (2014) 32:7057–64. 10.1016/j.vaccine.2014.09.052 [DOI] [PubMed] [Google Scholar]
- 626.Naleway AL, Irving SA, Henninger ML, Li DK, Shifflett P, Ball S, et al. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine (2014) 32:3122–7. 10.1016/j.vaccine.2014.04.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 627.Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, et al. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials. Hum Vaccin Immunother (2014) 10:2942–57. 10.4161/21645515.2014.972149 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 628.Baum U, Leino T, Gissler M, Kilpi T, Jokinen J. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: a cohort study of pregnancies stratified by trimester of vaccination. Vaccine (2015) 33:4850–7. 10.1016/j.vaccine.2015.07.061 [DOI] [PubMed] [Google Scholar]
- 629.Fabiani M, Bella A, Rota MC, Clagnan E, Gallo T, D’amato M, et al. A/H1N1 pandemic influenza vaccination: a retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine (2015) 33:2240–7. 10.1016/j.vaccine.2015.03.041 [DOI] [PubMed] [Google Scholar]
- 630.Fell DB, Platt RW, Lanes A, Wilson K, Kaufman JS, Basso O, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG (2015) 122:17–26. 10.1111/1471-0528.12977 [DOI] [PubMed] [Google Scholar]
- 631.Ludvigsson JF, Ström P, Lundholm C, Cnattingius S, Ekbom A, Örtqvist Å, et al. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ (2015) 351:h5585. 10.1136/bmj.h5585 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 632.Savitz DA, Fell DB, Ortiz JR, Bhat N. Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. Vaccine (2015) 33:6430–5. 10.1016/j.vaccine.2015.08.041 [DOI] [PubMed] [Google Scholar]
- 633.Walls T, Graham P, Petousis-Harris H, Hill L, Austin N. Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. BMJ Open (2016) 6:e009536. 10.1136/bmjopen-2015-009536 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 634.Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ (2014) 349:g4219. 10.1136/bmj.g4219 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 635.Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway AL, et al. Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. Vaccine (2016) 34:968–73. 10.1016/j.vaccine.2015.12.046 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 636.Petousis-Harris H, Walls T, Watson D, Paynter J, Graham P, Turner N. Safety of Tdap vaccine in pregnant women: an observational study. BMJ Open (2016) 6:e010911. 10.1136/bmjopen-2015-010911 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 637.Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis (2016) 16:1154–68. 10.1016/S1473-3099(16)30120-7 [DOI] [PubMed] [Google Scholar]
- 638.Raj RS, Bonney EA, Phillippe M. Influenza, immune system, and pregnancy. Reprod Sci (2014) 21:1434–51. 10.1177/1933719114537720 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 639.Staff AC, Benton SJ, Von Dadelszen P, Roberts JM, Taylor RN, Powers RW, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension (2013) 61:932–42. 10.1161/HYPERTENSIONAHA.111.00250 [DOI] [PubMed] [Google Scholar]
- 640.Scheminske M, Henninger M, Irving SA, Thompson M, Williams J, Shifflett P, et al. The association between influenza vaccination and other preventative health behaviors in a cohort of pregnant women. Health Educ Behav (2015) 42:402–8. 10.1177/1090198114560021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 641.Steinhoff MC, Omer SB, Roy E, El Arifeen S, Raqib R, Dodd C, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ (2012) 184:645–53. 10.1503/cmaj.110754 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 642.Porter TF, Lacoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev (2006):CD000112. 10.1002/14651858.CD000112.pub2 [DOI] [PubMed] [Google Scholar]
- 643.Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev (2014):CD000112. 10.1002/14651858.CD000112.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 644.Jørgensen KT, Pedersen BV, Jacobsen S, Biggar RJ, Frisch M. National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia? Ann Rheum Dis (2010) 69:358–63. 10.1136/ard.2008.099945 [DOI] [PubMed] [Google Scholar]
- 645.Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev (2010) 9:216–23. 10.1016/j.autrev.2009.10.006 [DOI] [PubMed] [Google Scholar]
- 646.Ebringer A. Rheumatoid Arthritis and Proteus. London: Springer; (2012). [Google Scholar]
- 647.Ebringer A, Rashid T. Rheumatoid arthritis is caused by a Proteus urinary tract infection. APMIS (2014) 122:363–8. 10.1111/apm.12154 [DOI] [PubMed] [Google Scholar]
- 648.Pretorius E, Akeredolu O-O, Soma P, Kell DB. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp Biol Med (2017) 242:355–73. 10.1177/1535370216681549 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 649.Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res (2016) 44:D1087–93. 10.1093/nar/gkv1278 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 650.Zasloff M. Antimicrobial peptides of multicellular organisms. Nature (2002) 415:389–95. 10.1038/415389a [DOI] [PubMed] [Google Scholar]
- 651.Auvynet C, Rosenstein Y. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J (2009) 276:6497–508. 10.1111/j.1742-4658.2009.07360.x [DOI] [PubMed] [Google Scholar]
- 652.Gustafsson A, Olin AI, Ljunggren L. LPS interactions with immobilized and soluble antimicrobial peptides. Scand J Clin Lab Invest (2010) 70:194–200. 10.3109/00365511003663622 [DOI] [PubMed] [Google Scholar]
- 653.Lee SH, Jun HK, Lee HR, Chung CP, Choi BK. Antibacterial and lipopolysaccharide (LPS)-neutralising activity of human cationic antimicrobial peptides against periodontopathogens. Int J Antimicrob Agents (2010) 35:138–45. 10.1016/j.ijantimicag.2009.09.024 [DOI] [PubMed] [Google Scholar]
- 654.Kościuczuk EM, Lisowski P, Jarczak J, Strzałkowska N, Jóźwik A, Horbańczuk J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep (2012) 39:10957–70. 10.1007/s11033-012-1997-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 655.Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. Antimicrobial peptides for therapeutic applications: a review. Molecules (2012) 17:12276–86. 10.3390/molecules171012276 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 656.Zhao J, Zhao C, Liang G, Zhang M, Zheng J. Engineering antimicrobial peptides with improved antimicrobial and hemolytic activities. J Chem Inf Model (2013) 53:3280–96. 10.1021/ci400477e [DOI] [PubMed] [Google Scholar]
- 657.Ashby M, Petkova A, Hilpert K. Cationic antimicrobial peptides as potential new therapeutic agents in neonates and children: a review. Curr Opin Infect Dis (2014) 27:258–67. 10.1097/QCO.0000000000000057 [DOI] [PubMed] [Google Scholar]
- 658.Waghu FH, Gopi L, Barai RS, Ramteke P, Nizami B, Idicula-Thomas S. CAMP: collection of sequences and structures of antimicrobial peptides. Nucleic Acids Res (2014) 42:D1154–8. 10.1093/nar/gkt1157 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 659.Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel) (2014) 7:545–94. 10.3390/ph7050545 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 660.Kido EA, Pandolfi V, Houllou-Kido LM, Andrade PP, Marcelino FC, Nepomuceno AL, et al. Plant antimicrobial peptides: an overview of SuperSAGE transcriptional profile and a functional review. Curr Protein Pept Sci (2010) 11:220–30. 10.2174/138920310791112110 [DOI] [PubMed] [Google Scholar]
- 661.Li W, Tailhades J, O’brien-Simpson NM, Separovic F, Otvos L, Jr, Hossain MA, et al. Proline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria. Amino Acids (2014) 46:2287–94. 10.1007/s00726-014-1820-1 [DOI] [PubMed] [Google Scholar]
- 662.Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat (2016) 26:689–702. 10.1080/13543776.2016.1176149 [DOI] [PubMed] [Google Scholar]
- 663.Kang HK, Kim C, Seo CH, Park Y. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J Microbiol (2017) 55:1–12. 10.1007/s12275-017-6452-1 [DOI] [PubMed] [Google Scholar]
- 664.Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jornvall H, Marchini G, et al. Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res (2003) 53:211–6. 10.1203/01.PDR.0000047471.47777.B0 [DOI] [PubMed] [Google Scholar]
- 665.Frew L, Stock SJ. Antimicrobial peptides and pregnancy. Reproduction (2011) 141:725–35. 10.1530/REP-10-0537 [DOI] [PubMed] [Google Scholar]
- 666.Kai-Larsen Y, Gudmundsson GH, Agerberth B. A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides. Acta Paediatr (2014) 103:1000–8. 10.1111/apa.12700 [DOI] [PubMed] [Google Scholar]
- 667.Tribe RM. Small peptides with a big role: antimicrobial peptides in the pregnant female reproductive tract. Am J Reprod Immunol (2015) 74:123–5. 10.1111/aji.12379 [DOI] [PubMed] [Google Scholar]
- 668.Yarbrough VL, Winkle S, Herbst-Kralovetz MM. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. Hum Reprod Update (2015) 21:353–77. 10.1093/humupd/dmu065 [DOI] [PubMed] [Google Scholar]
- 669.Yedery RD, Reddy KVR. Antimicrobial peptides as microbicidal contraceptives: prophecies for prophylactics – a mini review. Eur J Contracept Reprod Health Care (2005) 10:32–42. 10.1080/13625180500035124 [DOI] [PubMed] [Google Scholar]
- 670.Zairi A, Tangy F, Bouassida K, Hani K. Dermaseptins and magainins: antimicrobial peptides from frogs’ skin-new sources for a promising spermicides microbicides-a mini review. J Biomed Biotechnol (2009) 2009:452567. 10.1155/2009/452567 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 671.Schulze M, Junkes C, Mueller P, Speck S, Ruediger K, Dathe M, et al. Effects of cationic antimicrobial peptides on liquid-preserved boar spermatozoa. PLoS One (2014) 9:e100490. 10.1371/journal.pone.0100490 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 672.Speck S, Courtiol A, Junkes C, Dathe M, Müller K, Schulze M. Cationic synthetic peptides: assessment of their antimicrobial potency in liquid preserved boar semen. PLoS One (2014) 9:e105949. 10.1371/journal.pone.0105949 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 673.Schulze M, Grobbel M, Müller K, Junkes C, Dathe M, Rüdiger K, et al. Challenges and limits using antimicrobial peptides in boar semen preservation. Reprod Domest Anim (2015) 50(Suppl 2):5–10. 10.1111/rda.12553 [DOI] [PubMed] [Google Scholar]
- 674.Schulze M, Dathe M, Waberski D, Müller K. Liquid storage of boar semen: current and future perspectives on the use of cationic antimicrobial peptides to replace antibiotics in semen extenders. Theriogenology (2016) 85:39–46. 10.1016/j.theriogenology.2015.07.016 [DOI] [PubMed] [Google Scholar]
- 675.Bussalleu E, Sancho S, Briz MD, Yeste M, Bonet S. Do antimicrobial peptides PR-39, PMAP-36 and PMAP-37 have any effect on bacterial growth and quality of liquid-stored boar semen? Theriogenology (2017) 89:235–43. 10.1016/j.theriogenology.2016.11.017 [DOI] [PubMed] [Google Scholar]
- 676.Easterhoff D, Ontiveros F, Brooks LR, Kim Y, Ross B, Silva JN, et al. Semen-derived enhancer of viral infection (SEVI) binds bacteria, enhances bacterial phagocytosis by macrophages, and can protect against vaginal infection by a sexually transmitted bacterial pathogen. Antimicrob Agents Chemother (2013) 57:2443–50. 10.1128/AAC.02464-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 677.Edström AML, Malm J, Frohm B, Martellini JA, Giwercman A, Mörgelin M, et al. The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins. J Immunol (2008) 181:3413–21. 10.4049/jimmunol.181.5.3413 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 678.Zhao H, Lee WH, Shen JH, Li H, Zhang Y. Identification of novel semenogelin I-derived antimicrobial peptide from liquefied human seminal plasma. Peptides (2008) 29:505–11. 10.1016/j.peptides.2008.01.009 [DOI] [PubMed] [Google Scholar]
- 679.Yenugu S, Hamil KG, Birse CE, Ruben SM, French FS, Hall SH. Antibacterial properties of the sperm-binding proteins and peptides of human epididymis 2 (HE2) family; salt sensitivity, structural dependence and their interaction with outer and cytoplasmic membranes of Escherichia coli. Biochem J (2003) 372:473–83. 10.1042/BJ20030225 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 680.Avellar MCW, Honda L, Hamil KG, Yenugu S, Grossman G, Petrusz P, et al. Differential expression and antibacterial activity of epididymis protein 2 isoforms in the male reproductive tract of human and rhesus monkey (Macaca mulatta). Biol Reprod (2004) 71:1453–60. 10.1095/biolreprod.104.031740 [DOI] [PubMed] [Google Scholar]
- 681.Sørensen OE, Gram L, Johnsen AH, Andersson E, Bangsbøll S, Tjabringa GS, et al. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem (2003) 278:28540–6. 10.1074/jbc.M301608200 [DOI] [PubMed] [Google Scholar]
- 682.Williams RJ. Biochemical Individuality. New York: John Wiley; (1956). [Google Scholar]
- 683.Ayres JS, Freitag N, Schneider DS. Identification of Drosophila mutants altering defense of and endurance to Listeria monocytogenes infection. Genetics (2008) 178:1807–15. 10.1534/genetics.107.083782 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 684.Schneider DS, Ayres JS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol (2008) 8:889–95. 10.1038/nri2432 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 685.Råberg L, Graham AL, Read AF. Decomposing health: tolerance and resistance to parasites in animals. Philos Trans R Soc Lond B Biol Sci (2009) 364:37–49. 10.1098/rstb.2008.0184 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 686.Ayres JS, Schneider DS. Tolerance of infections. Annu Rev Immunol (2012) 30:271–94. 10.1146/annurev-immunol-020711-075030 [DOI] [PubMed] [Google Scholar]
- 687.Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science (2012) 335:936–41. 10.1126/science.1214935 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 688.Råberg L. How to live with the enemy: understanding tolerance to parasites. PLoS Biol (2014) 12:e1001989. 10.1371/journal.pbio.1001989 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 689.Palaferri Schieber AM, Lee YM, Chang MW, Leblanc M, Collins B, Downes M, et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science (2015) 350:558–63. 10.1126/science.aac6468 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 690.Kogut MH, Arsenault RJ. Immunometabolic phenotype alterations associated with the induction of disease tolerance and persistent asymptomatic infection of Salmonella in the chicken intestine. Front Immunol (2017) 8:372. 10.3389/fimmu.2017.00372 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 691.Meunier I, Kaufmann E, Downey J, Divangahi M. Unravelling the networks dictating host resistance versus tolerance during pulmonary infections. Cell Tissue Res (2017) 367:525–36. 10.1007/s00441-017-2572-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 692.Longo VD, Finch CE. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science (2003) 299:1342–6. 10.1126/science.1077991 [DOI] [PubMed] [Google Scholar]
- 693.Gluckman P, Beedle A, Hanson M. Principles of Evolutionary Medicine. Oxford: Oxford University Press; (2009). [Google Scholar]
- 694.Rühli FJ, Henneberg M. New perspectives on evolutionary medicine: the relevance of microevolution for human health and disease. BMC Med (2013) 11:115. 10.1186/1741-7015-11-115 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 695.Svensson EI, Råberg L. Resistance and tolerance in animal enemy-victim coevolution. Trends Ecol Evol (2010) 25:267–74. 10.1016/j.tree.2009.12.005 [DOI] [PubMed] [Google Scholar]
- 696.Ayres JS. Cooperative microbial tolerance behaviors in host-microbiota mutualism. Cell (2016) 165:1323–31. 10.1016/j.cell.2016.05.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 697.Ayres JS. Microbes dress for success: tolerance or resistance? Trends Microbiol (2017) 25:1–3. 10.1016/j.tim.2016.11.006 [DOI] [PubMed] [Google Scholar]
- 698.Rangan KJ, Pedicord VA, Wang YC, Kim B, Lu Y, Shaham S, et al. A secreted bacterial peptidoglycan hydrolase enhances tolerance to enteric pathogens. Science (2016) 353:1434–7. 10.1126/science.aaf3552 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 699.Than NG, Balogh A, Romero R, Kárpáti É, Erez O, Szilágyi A, et al. Placental protein 13 (PP13) – a placental immunoregulatory galectin protecting pregnancy. Front Immunol (2014) 5:348. 10.3389/fimmu.2014.00348 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 700.Than NG, Sumegi B, Than GN, Berente Z, Bohn H. Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein. Placenta (1999) 20:703–10. 10.1053/plac.1999.0436 [DOI] [PubMed] [Google Scholar]
- 701.Visegrády B, Than NG, Kilár F, Sümegi B, Than GN, Bohn H. Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng (2001) 14:875–80. 10.1093/protein/14.11.875 [DOI] [PubMed] [Google Scholar]
- 702.Bohn H, Kraus W, Winckler W. Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med (1983) 4:343–50. [PubMed] [Google Scholar]
- 703.Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem (2004) 271:1065–78. 10.1111/j.1432-1033.2004.04004.x [DOI] [PubMed] [Google Scholar]
- 704.Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci U S A (2009) 106:9731–6. 10.1073/pnas.0903568106 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 705.Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 199:122.e121–122.e111. 10.1016/j.ajog.2008.01.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 706.Cowans NJ, Stamatopoulou A, Khalil A, Spencer K. PP13 as a marker of pre-eclampsia: a two platform comparison study. Placenta (2011) 32(Suppl):S37–41. 10.1016/j.placenta.2010.08.014 [DOI] [PubMed] [Google Scholar]
- 707.De Muro P, Capobianco G, Lepedda AJ, Nieddu G, Formato M, Tram NHQ, et al. Plasma PP13 and urinary GAGs/PGs as early markers of pre-eclampsia. Arch Gynecol Obstet (2016) 294:959–65. 10.1007/s00404-016-4111-0 [DOI] [PubMed] [Google Scholar]
- 708.Than NG, Abdul Rahman O, Magenheim R, Nagy B, Fule T, Hargitai B, et al. Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch (2008) 453:387–400. 10.1007/s00428-008-0658-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 709.Bruiners N, Bosman M, Postma A, Gebhardt S, Rebello G, Sammar M, et al. Promoter variant-98A-C of the LGALS13 gene and pre-eclampsia. Proceedings of the 8th World Congress of Perinatal Medicine. Florence: (2007). p. 371–4. [Google Scholar]
- 710.Than NG, Erez O, Wildman DE, Tarca AL, Edwin SS, Abbas A, et al. Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med (2008) 21:429–42. 10.1080/14767050802041961 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 711.Vasta GR. Roles of galectins in infection. Nat Rev Microbiol (2009) 7:424–38. 10.1038/nrmicro2146 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 712.Poltorak A, He XL, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282:2085–8. 10.1126/science.282.5396.2085 [DOI] [PubMed] [Google Scholar]
- 713.Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 162:3749–52. [PubMed] [Google Scholar]
- 714.Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest (2000) 105:497–504. 10.1172/JCI8541 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 715.Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem (1999) 274:17406–9. 10.1074/jbc.274.25.17406 [DOI] [PubMed] [Google Scholar]
- 716.Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, et al. The toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature (1999) 401:811–5. 10.1038/44605 [DOI] [PubMed] [Google Scholar]
- 717.Ishii KJ, Akira S. Toll-like receptors and sepsis. Curr Infect Dis Rep (2004) 6:361–6. 10.1007/s11908-004-0034-1 [DOI] [PubMed] [Google Scholar]
- 718.Zähringer U, Lindner B, Inamura S, Heine H, Alexander C. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology (2008) 213:205–24. 10.1016/j.imbio.2008.02.005 [DOI] [PubMed] [Google Scholar]
- 719.Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637–50. 10.1016/j.immuni.2011.05.006 [DOI] [PubMed] [Google Scholar]
- 720.Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 30:16–34. 10.3109/08830185.2010.529976 [DOI] [PubMed] [Google Scholar]
- 721.Oliveira-Nascimento L, Massari P, Wetzler LM. The role of TLR2 in infection and immunity. Front Immunol (2012) 3:79. 10.3389/fimmu.2012.00079 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 722.Alexander SPA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. The concise guide to pharmacology 2013/14: catalytic receptors. Br J Pharmacol (2013) 170:1676–705. 10.1111/bph.12449 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 723.Kumar S, Ingle H, Prasad DV, Kumar H. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol (2013) 39:229–46. 10.3109/1040841X.2012.706249 [DOI] [PubMed] [Google Scholar]
- 724.Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol (2014) 47:136–47. 10.1007/s12016-013-8402-y [DOI] [PubMed] [Google Scholar]
- 725.Jiménez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors – from microbial recognition to autoimmunity: a comprehensive review. Autoimmun Rev (2016) 15:1–8. 10.1016/j.autrev.2015.08.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 726.Mukherjee S, Karmakar S, Babu SP. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. Braz J Infect Dis (2016) 20:193–204. 10.1016/j.bjid.2015.10.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 727.Tinsley JH, Chiasson VL, Mahajan A, Young KJ, Mitchell BM. Toll-like receptor 3 activation during pregnancy elicits preeclampsia-like symptoms in rats. Am J Hypertens (2009) 22:1314–9. 10.1038/ajh.2009.185 [DOI] [PubMed] [Google Scholar]
- 728.Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124:783–801. 10.1016/j.cell.2006.02.015 [DOI] [PubMed] [Google Scholar]
- 729.Schroder K, Muruve DA, Tschopp J. Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome. Curr Biol (2009) 19:R262–5. 10.1016/j.cub.2009.02.011 [DOI] [PubMed] [Google Scholar]
- 730.Sauer JD, Witte CE, Zemansky J, Hanson B, Lauer P, Portnoy DA. Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe (2010) 7:412–9. 10.1016/j.chom.2010.04.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 731.Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev (2011) 243:99–108. 10.1111/j.1600-065X.2011.01051.x [DOI] [PubMed] [Google Scholar]
- 732.Konno H, Barber GN. The STING controlled cytosolic-DNA activated innate immune pathway and microbial disease. Microbes Infect (2014) 16:998–1001. 10.1016/j.micinf.2014.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 733.Paludan SR. Activation and regulation of DNA-driven immune responses. Microbiol Mol Biol Rev (2015) 79:225–41. 10.1128/MMBR.00061-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 734.Girling JE, Hedger MP. Toll-like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology. Immunol Cell Biol (2007) 85:481–9. 10.1038/sj.icb.7100086 [DOI] [PubMed] [Google Scholar]
- 735.van Rijn BB, Franx A, Steegers EAP, De Groot CJM, Bertina RM, Pasterkamp G, et al. Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome. PLoS One (2008) 3:e1865. 10.1371/journal.pone.0001865 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 736.Riley JK, Nelson DM. Toll-like receptors in pregnancy disorders and placental dysfunction. Clin Rev Allergy Immunol (2010) 39:185–93. 10.1007/s12016-009-8178-2 [DOI] [PubMed] [Google Scholar]
- 737.Pineda A, Verdin-Terán SL, Camacho A, Moreno-Fierros L. Expression of toll-like receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with preeclampsia. Arch Med Res (2011) 42:382–91. 10.1016/j.arcmed.2011.08.003 [DOI] [PubMed] [Google Scholar]
- 738.Panda B, Panda A, Ueda I, Abrahams VM, Norwitz ER, Stanic AK, et al. Dendritic cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias secondary to dysregulation of TLR receptors. J Reprod Immunol (2012) 94:210–5. 10.1016/j.jri.2012.01.008 [DOI] [PubMed] [Google Scholar]
- 739.Zhang L, Yang H. Expression and localization of TLR4 and its negative regulator tollip in the placenta of early-onset and late-onset preeclampsia. Hypertens Pregnancy (2012) 31:218–27. 10.3109/10641955.2011.642434 [DOI] [PubMed] [Google Scholar]
- 740.Amirchaghmaghi E, Taghavi SA, Shapouri F, Saeidi S, Rezaei A, Aflatoonian R. The role of toll like receptors in pregnancy. Int J Fertil Steril (2013) 7:147–54. [PMC free article] [PubMed] [Google Scholar]
- 741.Zhu Y, Wu M, Wu CY, Xia GQ. Role of progesterone in TLR4-MyD88-dependent signaling pathway in pre-eclampsia. J Huazhong Univ Sci Technolog Med Sci (2013) 33:730–4. 10.1007/s11596-013-1188-6 [DOI] [PubMed] [Google Scholar]
- 742.Koga K, Izumi G, Mor G, Fujii T, Osuga Y. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy complications. Am J Reprod Immunol (2014) 72:192–205. 10.1111/aji.12258 [DOI] [PubMed] [Google Scholar]
- 743.Xue PP, Zheng MM, Gong P, Lin CM, Zhou JJ, Li YJ, et al. Single administration of ultra-low-dose lipopolysaccharide in rat early pregnancy induces TLR4 activation in the placenta contributing to preeclampsia. PLoS One (2015) 10:e0124001. 10.1371/journal.pone.0124001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 744.Gong P, Liu M, Hong G, Li Y, Xue P, Zheng M, et al. Curcumin improves LPS-induced preeclampsia-like phenotype in rat by inhibiting the TLR4 signaling pathway. Placenta (2016) 41:45–52. 10.1016/j.placenta.2016.03.002 [DOI] [PubMed] [Google Scholar]
- 745.Kulikova GV, Nizyaeva NV, Nagovitsina MN, Lyapin VM, Loginova NS, Kan NE, et al. Specific features of TLR4 expression in structural elements of placenta in patients with preeclampsia. Bull Exp Biol Med (2016) 160:718–21. 10.1007/s10517-016-3259-8 [DOI] [PubMed] [Google Scholar]
- 746.Faas MM, Schuiling GA, Baller JF, Visscher CA, Bakker WW. A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol (1994) 171:158–64. 10.1016/0002-9378(94)90463-4 [DOI] [PubMed] [Google Scholar]
- 747.Fujita Y, Mihara T, Okazaki T, Shitanaka M, Kushino R, Ikeda C, et al. Toll-like receptors (TLR) 2 and 4 on human sperm recognize bacterial endotoxins and mediate apoptosis. Hum Reprod (2011) 26:2799–806. 10.1093/humrep/der234 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 748.Li N, Wang T, Han D. Structural, cellular and molecular aspects of immune privilege in the testis. Front Immunol (2012) 3:152. 10.3389/fimmu.2012.00152 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 749.Saeidi S, Shapouri F, Amirchaghmaghi E, Hoseinifar H, Sabbaghian M, Sadighi Gilani MA, et al. Sperm protection in the male reproductive tract by toll-like receptors. Andrologia (2014) 46:784–90. 10.1111/and.12149 [DOI] [PubMed] [Google Scholar]
- 750.Hagan S, Khurana N, Chandra S, Abdel-Mageed AB, Mondal D, Hellstrom WJ, et al. Differential expression of novel biomarkers (TLR-2, TLR-4, COX-2, and Nrf-2) of inflammation and oxidative stress in semen of leukocytospermia patients. Andrology (2015) 3:848–55. 10.1111/andr.12074 [DOI] [PubMed] [Google Scholar]
- 751.Kunjara S, Greenbaum AL, Wang DY, Caro HN, Mclean P, Redman CWG, et al. Inositol phosphoglycans and signal transduction systems in pregnancy in preeclampsia and diabetes: evidence for a significant regulatory role in preeclampsia at placental and systemic levels. Mol Genet Metab (2000) 69:144–58. 10.1006/mgme.2000.2964 [DOI] [PubMed] [Google Scholar]
- 752.Williams PJ, Gumaa K, Scioscia M, Redman CW, Rademacher TW. Inositol phosphoglycan P-type in preeclampsia: a novel marker? Hypertension (2007) 49:84–9. 10.1161/01.HYP.0000251301.12357.ba [DOI] [PubMed] [Google Scholar]
- 753.Scioscia M, Paine MA, Gumaa K, Rodeck CH, Rademacher TW. Release of inositol phosphoglycan P-type by the human placenta following insulin stimulus: a multiple comparison between preeclampsia, intrauterine growth restriction, and gestational hypertension. J Matern Fetal Neonatal Med (2008) 21:581–5. 10.1080/14767050802199934 [DOI] [PubMed] [Google Scholar]
- 754.Scioscia M, Gumaa K, Rademacher TW. The link between insulin resistance and preeclampsia: new perspectives. J Reprod Immunol (2009) 82:100–5. 10.1016/j.jri.2009.04.009 [DOI] [PubMed] [Google Scholar]
- 755.Scioscia M, Gumaa K, Selvaggi LE, Rodeck CH, Rademacher TW. Increased inositol phosphoglycan P-type in the second trimester in pregnant women with type 2 and gestational diabetes mellitus. J Perinat Med (2009) 37:469–71. 10.1515/JPM.2009.082 [DOI] [PubMed] [Google Scholar]
- 756.Paine MA, Scioscia M, Williams PJ, Gumaa K, Rodeck CH, Rademacher TW. Urinary inositol phosphoglycan P-type as a marker for prediction of preeclampsia and novel implications for the pathophysiology of this disorder. Hypertens Pregnancy (2010) 29:375–84. 10.3109/10641950903242667 [DOI] [PubMed] [Google Scholar]
- 757.Scioscia M, Williams PJ, Gumaa K, Fratelli N, Zorzi C, Rademacher TW. Inositol phosphoglycans and preeclampsia: from bench to bedside. J Reprod Immunol (2011) 89:173–7. 10.1016/j.jri.2011.03.001 [DOI] [PubMed] [Google Scholar]
- 758.Scioscia M, Robillard PY, Hall DR, Rademacher LH, Williams PJ, Rademacher TW. Inositol phosphoglycan P-type in infants of preeclamptic mothers. J Matern Fetal Neonatal Med (2012) 25:193–5. 10.3109/14767058.2011.557789 [DOI] [PubMed] [Google Scholar]
- 759.Scioscia M, Siwetz M, Fascilla F, Huppertz B. Placental expression of D-chiro-inositol phosphoglycans in preeclampsia. Placenta (2012) 33:882–4. 10.1016/j.placenta.2012.07.007 [DOI] [PubMed] [Google Scholar]
- 760.Scioscia M, Siwetz M, Campana C, Huppertz B. Differences in d-chiro-inositol-phosphoglycan expression between first and third trimester human placenta. Pregnancy Hypertens (2013) 3:1–2. 10.1016/j.preghy.2012.10.001 [DOI] [PubMed] [Google Scholar]
- 761.Scioscia M, Nigro M, Montagnani M. The putative metabolic role of d-chiro inositol phosphoglycan in human pregnancy and preeclampsia. J Reprod Immunol (2014) 101-102:140–7. 10.1016/j.jri.2013.05.006 [DOI] [PubMed] [Google Scholar]
- 762.Kunjara S, Mclean P, Rademacher L, Rademacher TW, Fascilla F, Bettocchi S, et al. Putative key role of inositol messengers in endothelial cells in preeclampsia. Int J Endocrinol (2016) 2016:7695648. 10.1155/2016/7695648 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 763.Pretorius E, Bester J, Kell DB. A bacterial component to Alzheimer-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis (2016) 53:1237–56. 10.3233/JAD-160318 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 764.Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, SIRS, and multiple organ dysfunction syndrome actually driven by a toxic prion/amyloid form of fibrin? Semin Thromb Hemost (2017). 10.1055/s-0037-1604108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 765.Pretorius E, Mbotwe S, Kell DB. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular comorbidities. Sci Rep (2017) 7:9680. 10.1038/s41598-017-09860-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 766.Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc Diabetol (2017) 16:141. 10.1186/s12933-017-0624-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 767.Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update (2008) 14:359–66. 10.1093/humupd/dmn013 [DOI] [PubMed] [Google Scholar]
- 768.Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost (2011) 37:141–5. 10.1055/s-0030-1270341 [DOI] [PubMed] [Google Scholar]
- 769.Chen Q, Guo F, Hensby-Bennett S, Stone P, Chamley L. Antiphospholipid antibodies prolong the activation of endothelial cells induced by necrotic trophoblastic debris: implications for the pathogenesis of preeclampsia. Placenta (2012) 33:810–5. 10.1016/j.placenta.2012.07.019 [DOI] [PubMed] [Google Scholar]
- 770.Lefkou E, Mamopoulos A, Fragakis N, Dagklis T, Vosnakis C, Nounopoulos E, et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension (2014) 63:e118–9. 10.1161/HYPERTENSIONAHA.114.03115 [DOI] [PubMed] [Google Scholar]
- 771.van Hoorn ME, Hague WM, Van Pampus MG, Bezemer D, De Vries JIP, Investigators F. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol (2016) 197:168–73. 10.1016/j.ejogrb.2015.12.011 [DOI] [PubMed] [Google Scholar]
- 772.Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis (2003) 62:388–93. 10.1136/ard.62.5.388 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 773.Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis (2006) 65:2–6. 10.1136/ard.2005.045443 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 774.Amin NM. Antiphospholipid syndromes in infectious diseases. Hematol Oncol Clin North Am (2008) 22:131–143, vii–viii. 10.1016/j.hoc.2007.10.001 [DOI] [PubMed] [Google Scholar]
- 775.Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev (2008) 7:272–7. 10.1016/j.autrev.2007.10.001 [DOI] [PubMed] [Google Scholar]
- 776.García-Carrasco M, Galarza-Maldonado C, Mendoza-Pinto C, Escarcega RO, Cervera R. Infections and the antiphospholipid syndrome. Clin Rev Allergy Immunol (2009) 36:104–8. 10.1007/s12016-008-8103-0 [DOI] [PubMed] [Google Scholar]
- 777.Zinger H, Sherer Y, Goddard G, Berkun Y, Barzilai O, Agmon-Levin N, et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus (2009) 18:1149–53. 10.1177/0961203309345738 [DOI] [PubMed] [Google Scholar]
- 778.Krone KA, Allen KL, Mccrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep (2010) 12:53–7. 10.1007/s11926-009-0075-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 779.Martínez-Zamora MA, Tassies D, Carmona F, Espinosa G, Cervera R, Reverter JC, et al. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies. J Reprod Immunol (2010) 86:133–40. 10.1016/j.jri.2010.05.002 [DOI] [PubMed] [Google Scholar]
- 780.Lockshin MD. Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy. Clin Lab Med (2013) 33:367–76. 10.1016/j.cll.2013.01.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 781.Lockshin MD. Pregnancy and antiphospholipid syndrome. Am J Reprod Immunol (2013) 69:585–7. 10.1111/aji.12071 [DOI] [PubMed] [Google Scholar]
- 782.Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther (2014) 16:209. 10.1186/ar4549 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 783.Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med (2014) 6:245ra292. 10.1126/scitranslmed.3008808 [DOI] [PubMed] [Google Scholar]
- 784.Jonas SM, Deserno TM, Buhimschi CS, Makin J, Choma MA, Buhimschi IA. Smartphone-based diagnostic for preeclampsia: an mHealth solution for administering the Congo Red Dot (CRD) test in settings with limited resources. J Am Med Inform Assoc (2016) 23:166–73. 10.1093/jamia/ocv015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 785.Kouza M, Banerji A, Kolinski A, Buhimschi IA, Kloczkowski A. Oligomerization of FVFLM peptides and their ability to inhibit beta amyloid peptides aggregation: consideration as a possible model. Phys Chem Chem Phys (2017) 19:2990–9. 10.1039/c6cp07145g [DOI] [PMC free article] [PubMed] [Google Scholar]
- 786.Clark EAS, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep (2007) 9:219–25. 10.1007/s11926-007-0035-9 [DOI] [PubMed] [Google Scholar]
- 787.Saccone G, Berghella V, Maruotti GM, Ghi T, Rizzo G, Simonazzi G, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol (2017) 216:525.e521–525.e512. 10.1016/j.ajog.2017.01.026 [DOI] [PubMed] [Google Scholar]
- 788.Horvath SE, Daum G. Lipids of mitochondria. Prog Lipid Res (2013) 52:590–614. 10.1016/j.plipres.2013.07.002 [DOI] [PubMed] [Google Scholar]
- 789.Mejia EM, Nguyen H, Hatch GM. Mammalian cardiolipin biosynthesis. Chem Phys Lipids (2014) 179:11–6. 10.1016/j.chemphyslip.2013.10.001 [DOI] [PubMed] [Google Scholar]
- 790.Ren M, Phoon CKL, Schlame M. Metabolism and function of mitochondrial cardiolipin. Prog Lipid Res (2014) 55:1–16. 10.1016/j.plipres.2014.04.001 [DOI] [PubMed] [Google Scholar]
- 791.Hatch GM. Cardiolipin: biosynthesis, remodeling and trafficking in the heart and mammalian cells (review). Int J Mol Med (1998) 1:33–41. [DOI] [PubMed] [Google Scholar]
- 792.Saini-Chohan HK, Holmes MG, Chicco AJ, Taylor WA, Moore RL, Mccune SA, et al. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res (2009) 50:1600–8. 10.1194/jlr.M800561-JLR200 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 793.Chaban Y, Boekema EJ, Dudkina NV. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta (2014) 1837:418–26. 10.1016/j.bbabio.2013.10.004 [DOI] [PubMed] [Google Scholar]
- 794.Mileykovskaya E, Dowhan W. Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes. Chem Phys Lipids (2014) 179:42–8. 10.1016/j.chemphyslip.2013.10.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 795.Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochim Biophys Acta (2014) 1837:408–17. 10.1016/j.bbabio.2013.10.006 [DOI] [PubMed] [Google Scholar]
- 796.Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Cardiolipin and mitochondrial function in health and disease. Antioxid Redox Signal (2014) 20:1925–53. 10.1089/ars.2013.5280 [DOI] [PubMed] [Google Scholar]
- 797.Dolinsky VW, Cole LK, Sparagna GC, Hatch GM. Cardiac mitochondrial energy metabolism in heart failure: role of cardiolipin and sirtuins. Biochim Biophys Acta (2016) 1861:1544–54. 10.1016/j.bbalip.2016.03.008 [DOI] [PubMed] [Google Scholar]
- 798.Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest (2002) 109:797–804. 10.1172/JCI12337 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 799.Harel M, Aron-Maor A, Sherer Y, Blank M, Shoenfeld Y. The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity. Immunobiology (2005) 210:743–7. 10.1016/j.imbio.2005.10.004 [DOI] [PubMed] [Google Scholar]
- 800.Cruz-Tapias P, Blank M, Anaya JM, Shoenfeld Y. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol (2012) 24:389–93. 10.1097/BOR.0b013e32835448b8 [DOI] [PubMed] [Google Scholar]
- 801.Ebringer A, Rashid T. Rheumatoid arthritis is caused by Proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed) (2009) 1:577–86. 10.2741/e56 [DOI] [PubMed] [Google Scholar]
- 802.Margulis L. Origin of Eukaryotic Cells. New Haven: Yale University Press; (1970). [Google Scholar]
- 803.Bullerwell CE, Gray MW. Evolution of the mitochondrial genome: protist connections to animals, fungi and plants. Curr Opin Microbiol (2004) 7:528–34. 10.1016/j.mib.2004.08.008 [DOI] [PubMed] [Google Scholar]
- 804.Williams KP, Sobral BW, Dickerman AW. A robust species tree for the alphaproteobacteria. J Bacteriol (2007) 189:4578–86. 10.1128/JB.00269-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 805.Gray MW. Mitochondrial evolution. Cold Spring Harb Perspect Biol (2012) 4:a011403. 10.1101/cshperspect.a011403 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 806.Burger G, Gray MW, Forget L, Lang BF. Strikingly bacteria-like and gene-rich mitochondrial genomes throughout jakobid protists. Genome Biol Evol (2013) 5:418–38. 10.1093/gbe/evt008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 807.Wang Z, Wu M. An integrated phylogenomic approach toward pinpointing the origin of mitochondria. Sci Rep (2015) 5:7949. 10.1038/srep07949 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 808.Ball SG, Bhattacharya D, Weber APM. Pathogen to powerhouse. Science (2016) 351:659–60. 10.1126/science.aad8864 [DOI] [PubMed] [Google Scholar]
- 809.John P, Whatley FR. Paracoccus denitrificans and the evolutionary origin of the mitochondrion. Nature (1975) 254:495–8. 10.1038/254495a0 [DOI] [PubMed] [Google Scholar]
- 810.Matsumoto K, Kusaka J, Nishibori A, Hara H. Lipid domains in bacterial membranes. Mol Microbiol (2006) 61:1110–7. 10.1111/j.1365-2958.2006.05317.x [DOI] [PubMed] [Google Scholar]
- 811.Epand RM, Epand RF. Domains in bacterial membranes and the action of antimicrobial agents. Mol Biosyst (2009) 5:580–7. 10.1039/b900278m [DOI] [PubMed] [Google Scholar]
- 812.Mileykovskaya E, Dowhan W. Cardiolipin membrane domains in prokaryotes and eukaryotes. Biochim Biophys Acta (2009) 1788:2084–91. 10.1016/j.bbamem.2009.04.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 813.Romantsov T, Guan Z, Wood JM. Cardiolipin and the osmotic stress responses of bacteria. Biochim Biophys Acta (2009) 1788:2092–100. 10.1016/j.bbamem.2009.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 814.Barák I, Muchová K. The role of lipid domains in bacterial cell processes. Int J Mol Sci (2013) 14:4050–65. 10.3390/ijms14024050 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 815.Mukamolova GV, Yanopolskaya ND, Votyakova TV, Popov VI, Kaprelyants AS, Kell DB. Biochemical changes accompanying the long-term starvation of Micrococcus luteus cells in spent growth medium. Arch Microbiol (1995) 163:373–9. 10.1007/BF00404211 [DOI] [Google Scholar]
- 816.Kell DB, Pretorius E. Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells. Metallomics (2014) 6:748–73. 10.1039/C3MT00347G [DOI] [PubMed] [Google Scholar]
- 817.Agmon-Levin N, Rosário C, Katz BS, Zandman-Goddard G, Meroni P, Cervera R, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus (2013) 22:1327–35. 10.1177/0961203313504633 [DOI] [PubMed] [Google Scholar]
- 818.Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 11:185. 10.1186/1741-7015-11-185 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 819.Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol (2004) 191:398–407. 10.1016/j.ajog.2004.04.025 [DOI] [PubMed] [Google Scholar]
- 820.Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol (2004) 60:659–66. 10.1007/s00228-004-0817-1 [DOI] [PubMed] [Google Scholar]
- 821.Riley EH, Fuentes-Afflick E, Jackson RA, Escobar GJ, Brawarsky P, Schreiber M, et al. Correlates of prescription drug use during pregnancy. J Womens Health (Larchmt) (2005) 14:401–9. 10.1089/jwh.2005.14.401 [DOI] [PubMed] [Google Scholar]
- 822.Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf (2011) 20:895–902. 10.1002/pds.2184 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 823.Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol (2011) 205:51.e51–8. 10.1016/j.ajog.2011.02.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 824.Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther (2012) 34(239–249):e232. 10.1016/j.clinthera.2011.11.025 [DOI] [PubMed] [Google Scholar]
- 825.Cea-Soriano L, Garcia Rodríguez LA, Fernández Cantero O, Hernández-Díaz S. Challenges of using primary care electronic medical records in the UK to study medications in pregnancy. Pharmacoepidemiol Drug Saf (2013) 22:977–85. 10.1002/pds.3472 [DOI] [PubMed] [Google Scholar]
- 826.Palmsten K, Hernández-Díaz S, Chambers CD, Mogun H, Lai S, Gilmer TP, et al. The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program. Obstet Gynecol (2015) 126:465–73. 10.1097/AOG.0000000000000982 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 827.Smolina K, Hanley GE, Mintzes B, Oberlander TF, Morgan S. Trends and determinants of prescription drug use during pregnancy and postpartum in British Columbia, 2002–2011: a population-based cohort study. PLoS One (2015) 10:e0128312. 10.1371/journal.pone.0128312 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 828.Valent F, Gongolo F, Deroma L, Zanier L. Prescription of systemic antibiotics during pregnancy in primary care in Friuli Venezia Giulia, Northeastern Italy. J Matern Fetal Neonatal Med (2015) 28:210–5. 10.3109/14767058.2014.906572 [DOI] [PubMed] [Google Scholar]
- 829.Heikkilä AM. Antibiotics in pregnancy – a prospective cohort study on the policy of antibiotic prescription. Ann Med (1993) 25:467–71. 10.3109/07853899309147314 [DOI] [PubMed] [Google Scholar]
- 830.Santos F, Oraichi D, Bérard A. Prevalence and predictors of anti-infective use during pregnancy. Pharmacoepidemiol Drug Saf (2010) 19:418–27. 10.1002/pds.1915 [DOI] [PubMed] [Google Scholar]
- 831.de Jonge L, Bos HJ, Van Langen IM, De Jong-Van Den Berg LTW, Bakker MK. Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study. Pharmacoepidemiol Drug Saf (2014) 23:60–8. 10.1002/pds.3492 [DOI] [PubMed] [Google Scholar]
- 832.Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, Mclaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy (2015) 35:1052–62. 10.1002/phar.1649 [DOI] [PubMed] [Google Scholar]
- 833.Calogero AE, Condorelli RA, Russo GI, Vignera S. Conservative nonhormonal options for the treatment of male infertility: antibiotics, anti-inflammatory drugs, and antioxidants. Biomed Res Int (2017) 2017:4650182. 10.1155/2017/4650182 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 834.Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter (2007) 12:89–102. 10.1111/j.1523-5378.2007.00478.x [DOI] [PubMed] [Google Scholar]
- 835.D’Elios MM, Czinn SJ. Immunity, inflammation, and vaccines for Helicobacter pylori. Helicobacter (2014) 19(Suppl 1):19–26. 10.1111/hel.12156 [DOI] [PubMed] [Google Scholar]
- 836.Sutton P, Chionh YT. Why can’t we make an effective vaccine against Helicobacter pylori? Expert Rev Vaccines (2013) 12:433–41. 10.1586/erv.13.20 [DOI] [PubMed] [Google Scholar]
- 837.Ng GZ, Chionh YT, Sutton P. Vaccine-mediated protection against Helicobacter pylori is not associated with increased salivary cytokine or mucin expression. Helicobacter (2014) 19:48–54. 10.1111/hel.12099 [DOI] [PubMed] [Google Scholar]
- 838.Grixti J, O’Hagan S, Day PJ, Kell DB. Enhancing drug efficacy and therapeutic index through cheminformatics-based selection of small molecule binary weapons that improve transporter-mediated targeting: a cytotoxicity system based on gemcitabine. Front Pharmacol (2017) 8:155. 10.3389/fphar.2017.00155 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 839.Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 100:7977–82. 10.1073/pnas.1337088100 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 840.Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 27:659–66. 10.1038/nbt.1549 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 841.Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genom (2009) 2:2. 10.1186/1755-8794-2-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 842.Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol (2010) 577:825–89. 10.1007/s00204-010-0577-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 843.Carey N. The Epigenetics Revolution. London: Icon Books; (2012). [Google Scholar]
- 844.Day J, Savani S, Krempley BD, Nguyen M, Kitlinska JB. Influence of paternal preconception exposures on their offspring: through epigenetics to phenotype. Am J Stem Cells (2016) 5:11–8. [PMC free article] [PubMed] [Google Scholar]
- 845.Abbasi J. The paternal epigenome makes its mark. JAMA (2017) 317:2049–51. 10.1001/jama.2017.1566 [DOI] [PubMed] [Google Scholar]
- 846.Agarwal A, Sekhon LH. The role of antioxidant therapy in the treatment of male infertility. Hum Fertil (2010) 13:217–25. 10.3109/14647273.2010.532279 [DOI] [PubMed] [Google Scholar]
- 847.Nakata K, Yamashita N, Noda Y, Ohsawa I. Stimulation of human damaged sperm motility with hydrogen molecule. Med Gas Res (2015) 5:2. 10.1186/s13618-014-0023-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 848.Halliwell B, Cheah IK, Drum CL. Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis. Biochem Biophys Res Commun (2016) 470:245–50. 10.1016/j.bbrc.2015.12.124 [DOI] [PubMed] [Google Scholar]
- 849.Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One (2010) 5:e13663. 10.1371/journal.pone.0013663 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 850.Bonney EA. Demystifying animal models of adverse pregnancy outcomes: touching bench and bedside. Am J Reprod Immunol (2013) 69:567–84. 10.1111/aji.12102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 851.LaMarca B, Amaral LM, Harmon AC, Cornelius DC, Faulkner JL, Cunningham MW., Jr Placental ischemia and resultant phenotype in animal models of preeclampsia. Curr Hypertens Rep (2016) 18:38. 10.1007/s11906-016-0633-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 852.Kenny LC, Broadhurst DI, Dunn W, Brown M, Francis-Mcintyre S, North RA, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension (2010) 56:741–9. 10.1161/HYPERTENSIONAHA.110.157297 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 853.Kell DB, Oliver SG. The metabolome 18 years on: a concept comes of age. Metabolomics (2016) 12:148. 10.1007/s11306-016-1108-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 854.Infectious Diseases Society of America. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 52(Suppl 5):S397–428. 10.1093/cid/cir153 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 855.Gelband H, Laxminarayan R. Tackling antimicrobial resistance at global and local scales. Trends Microbiol (2015) 23:524–6. 10.1016/j.tim.2015.06.005 [DOI] [PubMed] [Google Scholar]
- 856.Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science (2016) 353:874–5. 10.1126/science.aaf9286 [DOI] [PubMed] [Google Scholar]
- 857.Coates ARM, Hu Y. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D (2006) 7:133–51. 10.2165/00126839-200607030-00001 [DOI] [PubMed] [Google Scholar]
- 858.Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol (2011) 163:184–94. 10.1111/j.1476-5381.2011.01250.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 859.Hu Y, Liu A, Ortega-Muro F, Alameda-Martin L, Mitchison D, Coates A. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol (2015) 6:641. 10.3389/fmicb.2015.00641 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 860.Broxmeyer L. Parkinson’s: another look. Med Hypotheses (2002) 59:373–7. 10.1016/S0306-9877(02)00188-3 [DOI] [PubMed] [Google Scholar]
- 861.Shen CH, Chou CH, Liu FC, Lin TY, Huang WY, Wang YC, et al. Association between tuberculosis and Parkinson disease: a nationwide, population-based cohort study. Medicine (Baltimore) (2016) 95:e2883. 10.1097/MD.0000000000002883 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 862.Berstad K, Berstad JER. Parkinson’s disease; the hibernating spore hypothesis. Med Hypotheses (2017) 104:48–53. 10.1016/j.mehy.2017.05.022 [DOI] [PubMed] [Google Scholar]
- 863.Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv (2011) 66:497–506. 10.1097/OGX.0b013e3182331028 [DOI] [PubMed] [Google Scholar]
- 864.Chaiworapongsa T, Romero R, Whitten A, Tarca AL, Bhatti G, Draghici S, et al. Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med (2013) 41:485–504. 10.1515/jpm-2013-0082 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 865.Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol (2013) 209:544.e541–544.e512. 10.1016/j.ajog.2013.08.019 [DOI] [PubMed] [Google Scholar]
- 866.Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol (2014) 124:771–81. 10.1097/AOG.0000000000000472 [DOI] [PubMed] [Google Scholar]
- 867.Madazli R, Yuksel MA, Imamoglu M, Tuten A, Oncul M, Aydin B, et al. Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch Gynecol Obstet (2014) 290:53–7. 10.1007/s00404-014-3176-x [DOI] [PubMed] [Google Scholar]